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Abstract 
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Abstract 
Cyclic guanosine monophosphate (cGMP) is an important second messenger 
and plays a key role in the maintenance of cardio-vascular homeostasis. In the 
central nervous system cGMP signalling has been linked to long term potentia-
tion (LTP) in the hippocampus and the amygdala, hinting at its involvement in 
the processes of learning and memory formation. Despite the complexity of the 
systems cGMP is involved in, the standard methods for monitoring cGMP oscil-
lations still rely on destructive, ex vivo concentration determination in compet-
itive binding assays. First attempts have been made by several groups to de-
velop more sophisticated methods based on genetically encoded probes. How-
ever, these first generation tools show severe limitations, impeding their wide-
spread use in vivo. 
Here we systematically addressed these limitations in a methodical approach 
and developed a bright, genetically encoded FRET sensor for cGMP based on a 
cyan/yellow pair. Our sensor exhibits a large dynamic range, high selectivity and 
simple binding kinetics, outperforming established cGMP biosensors.  
Furthermore we developed single emission biosensors based on FRET of a red 
fluorescent protein to a dark acceptor, demonstrating the validity of this ap-
proach for cGMP sensors. This class of red fluorescent biosensors can harness 
more favourable imaging conditions in the red part of the visible spectrum, such 
as reduced scattering and auto fluorescence, while allowing the combination 
with other optogenetic tools.  
In the process of these efforts we established a generic pipeline for fast bio-
sensor prototyping and assessment, relying on modern assembly cloning meth-
ods in a harmonized vector system. Furthermore, we describe the construction 
of a low-cost automated screening set-up for directed evolution of genetically 
encoded biosensors and fluorescent proteins in bacteria. This screening set-up 
and the streamlined prototyping approach lower the entry hurdles in the field 
of biosensor development and are applicable for a wide variety of potential tar-
get molecules. Our pipeline allows other researchers to develop essential tools 
to elucidate the inner workings of cellular signalling circuits.  
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1 Introduction 
1.1 Fluorescent Proteins 
1.1.1 Physical Principles of Fluorescence 
The phenomena of fluorescence has been amply discussed by the literature (for 
review see Valeur and Berberan-Santos (2012)) and its relevant processes are 
best described by the Perrin–Jablonski diagram (see Figure 1.1). Energy of an 
electromagnetic wave is first absorbed by a chromophore. This energy is trans-
ferred to an electron, which is then excited from the ground state S0 to one of 
the vibrational levels of S1 or S2. These electrons then undergo a fast, internal 
conversion and fall to the lowest level of the excited state S1 in a non-radiative 
fashion. De-excitation can now occur through several processes, which stand in 
direct competition, and highly depend on the structure of the chromophore, its 
environment, and the relative position of its energy levels, namely: (1) Non-ra-
diative relaxation; energy of the excited state is lost from the system through 
vibration and contact with the solvent without the emission of a photon. (2) Inter 
system crossing; energy is transferred to the excited triplet state T1 and subse-
quently emitted through phosphorescence. (3) Fluorescence, the energy of the 
excited state is emitted as a photon. Eventually the excited electron returns to 
the ground state S0. 
The emitted light of fluorescence highly depends on the light which can be 
absorbed by the chromophore. Only photons, which match the energy difference 
between the ground state S0 and the excited states S1 and S2 and their 
vibrational levels can be absorbed. The fluorescence emission spectrum is red-
shifted in relation to the absorption spectrum, because part of the initially ab-
sorbed energy is removed from the system during internal conversion. Initially 
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excited electrons are lifted to unstable vibrational levels of S1 and S2 and sub-
sequently drop to the lowest level of S1, which is the only level from which fluo-
rescence emission occurs. Emitted photons carry only the energy difference be-
tween S1 and S0, but not of the initial drop during internal conversion.  
An important characteristic of a given chromophore is its quantum yield 𝛷. It 
is defined as the fraction of emitted photons to the number of absorbed  
photons. From an electron standpoint, it can be seen as the number of excited 
electrons returning to the ground state S0 by emission of a photon divided by 
the total of all de-excited electrons. Fluorescence competes with non-radiative 
de-excitation, usually achieved by molecular vibration or collision with solvent 
molecules. Chromophores, less able to vibrate due to being rigid or stabilized, 
therefore have higher quantum yields, because more energy has to be emitted 
through photons.  
In fluorescent proteins, typically π-electrons composing the conjugated  
system of the chromophore, are elevated to their excited state π*. In general, 
the extent of the conjugated π-system determines the required energy for the 
transition into the excited state; larger π-systems lower the difference between 
the energy levels and can therefore get excited by photons with longer wave-
lengths. 
 
Figure 1.1 Perrin-Jablonski diagram 
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1.1.2 Physical Principles of Förster Resonance Energy Transfer 
The theory behind Förster resonance energy transfer (FRET) was first laid 
down by the physical chemist Theodor Förster in 1946 and further developed in 
later works (Förster 1946, Förster 1948, Förster 1951). (for in depth review see 
Valeur and Berberan-Santos (2012)). 
FRET is a phenomenon in which energy from an excited donor chromophore 
is transferred non-radiatively to an acceptor chromophore in close vicinity, ex-
citing it in the process. FRET is a long-range dipole–dipole coupling; the  
excitation of the donor leads to a charge transfer within the donor chromo-
phore, which subsequently induces a charge transfer in the acceptor chromo-
phore, mimicking the excitation through a photon. This energy transfer is a non-
radiative relaxation from the perspective of the excited donor, because the ex-
cited electrons are transferred to the ground state S0, without the  
emission of a photon. In turn, the acceptor molecule gets excited through this 
process and can relax this excitation through fluorescence if its structure and 
environmental conditions are permissive.  
The efficiency of this energy transfer (𝛷𝑇) highly depends on the photo-phys-
ical properties of the involved chromophores, their distance, orientation and 
environment. 𝛷𝑇 is given as: 
 
 𝛷𝑇 =
1
1 + (𝑟 𝑅0⁄
)6
 (1.1) 
 
r is the distance between donor and acceptor  
R0 is the Förster radius for a specific pair of donor and acceptor 
 
Formula 1.1 reveals that the efficiency of transfer is highly dependent on the 
distance between chromophores, as it falls off with the inverse to the power of 
six of r. Typically this distance is in the range of 1–10 nm.  
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The Förster radius R0 is defined as the distance at which the efficiency of 
energy transfer ΦT is 50 %, for a specific pair of donor and acceptor chromo-
phore. It can be calculated as: 
 
 𝑅0 = (
9(𝑙𝑛10)𝜅2𝛷𝐷
0
128𝜋5𝑁𝐴𝑛
4
𝐽)
1
6⁄
 (1.2) 
 
𝜅2 is the orientation factor between donor and acceptor chromophore 
𝛷𝐷
0  is the quantum yield of the donor chromophore in the absence of the acceptor 
J is the spectral overlap between the emission spectrum of the donor and the excitation spectrum of the 
acceptor 
𝑁𝑎 is Avogadro’s constant 
n is the refractive index of the medium 
 
From formula 1.2 several important dependencies become apparent: (1) the 
orientation of the chromophores is quantified by the scalar factor 𝜅2. When the 
transitional dipole moments of the chromophores are orthogonal, 𝜅2 = 0. If they 
are parallel 𝜅2 becomes 1 and if they are collinear 𝜅2 = 4. In freely rotating chro-
mophores, 𝜅2 averages out to 2 3⁄ . This shows the dramatic effect the  
orientation of the chromophore can have; orthogonal transitional dipoles  
reduce the Förster radius to zero, consequently making FRET impossible. (2) The 
quantum yield of the donor chromophore 𝛷𝐷
0  is an important characteristic of 
the FRET pair. As with 𝜅2, low values for 𝛷𝐷
0  reduce the Förster radius and thus 
FRET efficiency for a given distance. 𝛷𝐷
0  is a measure of the amount of excited 
state energy that can be lost to vibrational relaxation and therefore does not 
take part in the dipole coupling. This means in turn, that care needs to be taken 
when picking a donor chromophore for a specific FRET pair, since low quantum 
yields result in reduced potential for FRET. (3) A further factor to  
consider in the choice of FRET partners is the spectral overlap J. It is the integral 
overlap of the donor emission spectrum and the acceptor excitation spectrum. 
Counterintuitively this suggests that a photon is emitted by the donor chromo-
phore and is then subsequently absorbed by the acceptor, but this is in fact not 
the case, since FRET is a non-radiative interaction. The spectral overlap is rather 
a measure of the compatibility of the energy levels of the excited state of the 
donor and the acceptor. Energy transition can only occur, if energy levels are 
matched, much like photon energy needs to match the difference between 
ground state and excited state.  
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The spectral overlap J is calculated by formula 1.3. 
 
 𝐽 = ∫ 𝐹𝜆(𝜆)𝜀(𝜆)𝜆4𝑑𝜆
∞
0
 (1.3) 
 
𝐹𝜆 is the normalized emission spectrum of the donor 
𝜀 is the absorption coefficient of the acceptor  
 
The spectral overlap integral of a given FRET pair depends not only on the shape 
of the excitation spectrum of the acceptor chromophore, but also on its extinc-
tion coefficient. Therefore, ε is an important factor to consider, when picking 
potential acceptors. Two fluorescent proteins may, for example, have very sim-
ilar excitation spectra, but very different extinction coefficients, making the flu-
orescent protein with the higher extinction coefficient more suitable as an ac-
ceptor. Taken together, to achieve large Förster radii, donors should display very 
high quantum yields and acceptors high extinction coefficients, while emission 
spectra of the donors should match the excitation spectrum of the acceptors. 
FRET efficiency can be indirectly measured by exciting the donor chromo-
phore and monitoring the emission of the donor and the emission of the  
acceptor. Since FRET decreases the emission of the donor and results in fluo-
rescence of the acceptor, the ratio of these two values approximates FRET effi-
ciency. As described above, the distance of the chromophores and their orien-
tation has a large influence on FRET. Therefore, the observed FRET ratio can be 
used to estimate both of these variables. Especially in intramolecular FRET, con-
formational changes in the molecule that harbors both donor and acceptor can 
be easily monitored. 
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1.1.3 The Green Fluorescent Protein 
The green fluorescent protein (GFP) was first described by Shimomura et al. 
(1962) and further characterized (Johnson et al. 1962) as a by-product in the ex-
traction procedure of the luminescent protein aequorin from the jellyfish Ae-
quorea Victoria. It was mentioned in a mere side note in the original publication. 
The gene, encoding aequoria GFP (avGFP), was cloned by Prasher et al. (1992) 
and subsequently demonstrated to be sufficient, to produce recombinant fluo-
rescent protein without co-factors or additional proteins by Chalfie et al. (1994), 
Inouye and Tsuji (1994). Since then, GFP and its engineered variants have be-
come some of the most important and versatile tools in cell biology and 
spawned a plethora of applications. For their contributions to this development, 
Osamu Shimomura, Martin Chalfie and Roger Y. Tsien were awarded the Nobel 
Prize for Chemistry in 2008 for the discovery, recombinant expression and engi-
neering of the green fluorescent protein, respectively. 
The 238 amino acids of GFP form a 11 stranded β-barrel tertiary structure with 
a central α-helix harboring the chromophore (Ormö et al. 1996, Yang et al. 1996) 
(see Figure 1.2).  
 
Figure 1.2 Structure of EGFP 
Crystal structure of EGFP (Arpino et al. 2012) A) top view B) side view C) topology map of EGFP  
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The chromophore itself is formed by an autocatalytic conversion of three 
amino acid side chains, namely Serine 65, Tyrosine 66 and Glycine 67. The for-
mation of the chromophore is depicted in Figure 1.3. First the amid-group of 
Gly67 performs a nucleophilic attack towards the carbonyl group of Ser65,  
cycling the backbone. An imidazolinone is then formed by eliminating a water 
molecule. Finally, the α–β bond of Tyr66 is dehydrogenated by molecular  
oxygen, creating a molecule of hydrogen peroxide in the process (Tsien 1998). 
The requirement of oxygen for this dehydrogenation is a limiting factor in the 
use of GFP in anaerobic organisms (Inouye and Tsuji 1994). This step  
introduces a conjugated double bond between the phenol group of tyrosine and 
the newly formed imidazolinone, joining their conjugated π-electron systems. 
This larger π-system gives rise to the photo-physical properties of GFP. The iso-
lated chromophore (a p-hydroxybenzyl ideneimidazolinone) is barely fluores-
cent in solution, but is stabilized within the protein structure by the surrounding 
scaffold, which prevents non-radiative relaxation of the excited state (Niwa et 
al. 1996).  
GFP shows a strong absorption band at 488 nm and a fluorescence emission 
maximum of 508 nm. The wild-type also exhibits a very strong absorption band 
at 397 nm, representing the protonated form of the tyrosine residue inside the 
chromophore.  
 
Figure 1.3 Chromophore formation in GFP  
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1.1.4 Engineered Fluorescent Proteins 
Since the first successful cloning of avGFP in 1992 (Prasher et al.) and subse-
quent expression in heterologous organisms, much effort was put into improv-
ing the photo-physical properties of the wild-type protein through mutagenesis. 
Substitutions of aromatic amino acids at the Tyr66 residue, for example, lead to 
blue shifted variants, while the introduction of aromatic residues at position 203 
promoted π-stacking with the chromophore, which in turn shifted the emission 
spectrum towards yellow emission (Tsien 1998). Besides color variants many 
other improvements were made, which addressed different problems of the 
wild-type protein. These improvements include: (1) increase in quantum effi-
ciency of fluorescence emission, (2) increase in absorption coefficient, (3) 
photo-stability, (4) folding efficiency, (5) pH-stability, (6) monomerization, and 
(7) decrease in cytotoxicity.  
The discovery of other fluorescent proteins in corals, homologue to GFP, 
which emit in the red part of the visible spectrum, by Matz et al. (1999) lead to 
an expansion of the color pallet. Since then, many GFP-like fluorescent proteins 
have been found in different anthozoas and even vertebrates (Shaner et al. 
2013). These new fluorescent proteins and GFP variants are the foundation of an 
ongoing engineering process taking places for the last 20 years. To date, many  
improvements have been made by various groups, leading to hundreds of  
variants of fluorescent proteins. Going into detail about all of them, or even just 
a fraction, is beyond the scope of this work. Instead, Table 1-1, provides a non-
inclusive list of some notable engineered fluorescent proteins and their photo-
physical properties.  
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Table 1-1 Fluorescent proteins and their photo-physical properties  
Protein 
 
λex 
[nm] 
λem 
[nm] 
ε 
[mM–1cm–1] 
Φ 
 
ε x Φ 
 
pKa 
 
Bleac
hing 
[s] 
Matu-
ration 
[min] 
Reference 
 
Blue Fluorescent Proteins 
Azurite 383 450 26.2 0.55 14.4 5.0 33  (Mena et al. 2006) 
EBFP2 383 448 32.0 0.56 18.0 4.5 55  (Ai et al. 2007) 
mKalama1 385 456 36.0 0.45 16.0 5.5   (Ai et al. 2007) 
mTagBFP2 399 454 50.6 0.64 32.4 2.7 53  (Subach et al. 2011) 
mTagBFP 402 457 52.0 0.63 32.8 2.7 34  (Subach et al. 2008) 
Cyan Fluorescent Proteins 
ECFP 433 475 32.5 0.4 13.0 4.7   (Heim et al. 1994) 
Cerulean 433 475 43.0 0.62 26.7 4.7 36  (Rizzo et al. 2004) 
mCerulean3 433 475 40.0 0.8 32.0 4.7   (Markwardt et al. 2011) 
SCFP3A 433 474 30.0 0.56 16.8 4.5   (Kremers et al. 2006) 
CyPet 435 477 35.0 0.51 17.8 5.02   (Nguyen and Daugherty 2005) 
mTurquoise 434 474 30.0 0.84 25.2    (Goedhart et al. 2010) 
mTurquoise2 434 474 30.0 0.93 27.9 3.1 90  (Goedhart et al. 2012) 
mTFP1 462 492 64.0 0.85 54.0 4.3   (Ai et al. 2006) 
monomeric Midoriishi-Cyan 470 496 22.2 0.7 15.5 7.0   (Karasawa et al. 2004) 
Aquamarine 430 474 26.0 0.89 23.1 3.3   (Erard et al. 2013) 
Green Fluorescent Proteins 
TurboGFP 482 502 70.0 0.53 37.1 5.2   (Evdokimov et al. 2006) 
TagGFP2 483 506 56.5 0.6 33.9 4.7   (Subach et al. 2008) 
mUKG 483 499 60.0 0.72 43.2 5.2   (Tsutsui et al. 2008) 
Superfolder GFP 485 510 83.3 0.65 54.1    (Pédelacq et al. 2006) 
Emerald 487 509 57.5 0.68 37.3 6.0 101  (Cubitt et al. 1999) 
EGFP 488 507 56.0 0.6 33.6 6.0 174 25 (Yang et al. 1996) 
Monomeric Azami Green 492 505 55.0 0.74 40.7 5.8   (Karasawa et al. 2003) 
mWasabi 493 509 70.0 0.8 56.0 6.0 93  (Ai et al. 2008) 
Clover 505 515 111.0 0.76 84.4 6.1 50 30 (Lam et al. 2012) 
mClover3 506 518 109.0 0.78 85.0 6.5 80  (Bajar et al. 2016) 
mNeonGreen 506 517 116.0 0.8 92.8 5.7 158 10 (Shaner et al. 2013) 
Yellow Fluorescent Proteins 
EYFP 513 527 83.4 0.61 50.9 6.9 60  (Ormö et al. 1996) 
Topaz 514 527 94.5 0.6 56.7    (Cubitt et al. 1999) 
Venus 515 528 92.2 0.57 52.5 6.0 15  (Nagai et al. 2002) 
SYFP2 515 527 101.0 0.68 68.7 6.0   (Kremers et al. 2006) 
Citrine 516 529 77.0 0.76 58.5 5.7 49  (Griesbeck et al. 2001) 
Ypet 517 530 104.0 0.77 80.1 5.6   (Nguyen and Daugherty 2005) 
mPapaya1 530 541 43.0 0.83 35.7 6.8   (Hoi et al. 2013) 
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Table 1-2 Fluorescent proteins and their photo-physical properties (continued) 
Protein 
 
λex 
[nm] 
λem 
[nm] 
ε 
[mM–1cm–1] 
Φ 
 
ε x Φ 
 
pKa 
 
Bleac
hing 
[s] 
Matu-
ration 
[min] 
Reference 
 
Orange Fluorescent Proteins 
Monomeric Kusabira-Orange 548 559 51.6 0.6 31.0 5.0   (Karasawa et al. 2004) 
tdTomato 554 581 138.0 0.69 95.2 4.7 70 60 (Shaner et al. 2004) 
mOrange 548 562 71.0 0.69 49.0 6.5 9 150 (Shaner et al. 2004) 
mOrange2 549 565 58.0 0.6 34.8 6.5   (Shaner et al. 2008) 
mKOκ 551 563 105.0 0.61 64.0 4.2   (Tsutsui et al. 2008) 
mKO2 551 565 63.8 0.62 39.6 5.5   (Sakaue-Sawano et al. 2008) 
Red Fluorescent Proteins 
TagRFP 555 584 100.0 0.48 49.0 3.8 48 100 (Merzlyak et al. 2007) 
TagRFP-T 555 584 81.0 0.41 33.2 4.6 337 100 (Shaner et al. 2008) 
mRuby 558 605 112.0 0.35 39.2 4.4   (Kredel et al. 2009) 
mRuby2 559 600 113.0 0.38 43.0 5.3 123 150 (Lam et al. 2012) 
mRuby3 558 592 128.0 0.45 58.0 4.8 349  (Bajar et al. 2016) 
mTangerine 568 585 38.0 0.3 11.4 5.7   (Shaner et al. 2004) 
mApple 568 592 75.0 0.49 36.7 6.5   (Shaner et al. 2008) 
mStrawberry 574 596 90.0 0.29 26.1 4.5 15 50 (Shaner et al. 2004) 
FusionRed 580 608 95.0 0.19 18.1 4.6 150 130 (Shemiakina et al. 2012) 
mCherry 587 610 72.0 0.22 15.8 4.5 96 40 (Shaner et al. 2004) 
mNectarine 558 578 58.0 0.45 26.1 6.9 11 30 (Johnson et al. 2009) 
Far Red Fluorescent Proteins 
mKate 588 635 45.0 0.33 14.9 6.0   (Shcherbo et al. 2007) 
mKate2 588 633 62.5 0.4 25.0 5.4 84 20 (Shcherbo et al. 2009) 
mLumin 587 621 70.0 0.46 32.2 4.7 166  (Chu et al. 2009) 
mPlum 590 649 41.0 0.1 4.1 4.5 53 100 (Wang et al. 2004) 
mRaspberry 598 625 86.0 0.15 12.9    (Wang et al. 2004) 
mNeptune 600 650 67.0 0.2 13.4 5.4 255 35 (Lin et al. 2009) 
mNeptune2.5 599 643 95.0 0.28 26.6 5.8 506 26 (Chu et al. 2014) 
eqFP650 592 650 65.0 0.24 15.6 5.7 190  (Shcherbo et al. 2010) 
eqFP670 605 670 70.0 0.06 4.2 4.5 1289  (Shcherbo et al. 2010) 
TagRFP657 611 657 34.0 0.1 3.4 5.0   (Morozova et al. 2010) 
TagRFP675 598 675 46.0 0.08 3.7 5.7  25 (Piatkevich et al. 2013) 
mCardinal 604 659 87.0 0.19 16.5 5.3 730 27 (Chu et al. 2014) 
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Table 1-2 Fluorescent proteins and their photo-physical properties (continued) 
Protein 
 
λex 
[nm] 
λem 
[nm] 
ε 
[mM–1cm–1] 
Φ 
 
ε x Φ 
 
pKa 
 
Bleac
hing 
[s] 
Matu-
ration 
[min] 
Reference 
 
Sapphire Fluorescent Proteins 
Sapphire 399 511 29.0 0.64 18.6    (Cubitt et al. 1999) 
T-Sapphire 399 511 44.0 0.6 26.4 4.9 25  (Zapata-Hommer and Griesbeck 
2003) 
mAmetrine 406 526 45.0 0.58 26.1  2.8  (Ai et al. 2008) 
Long Stokes Shift Fluorescent Proteins 
mKeima Red 440 620 14.4 0.24 3.5 6.5   (Kogure et al. 2006) 
mBeRFP 446 611 65.0 0.27 17.6 5.6   (Yang et al. 2013) 
LSS-mKate2 460 605 26.0 0.17 4.4 2.7   (Piatkevich et al. 2010) 
LSS-mKate1 463 624 31.2 0.08 2.5 3.2   (Piatkevich et al. 2010) 
LSSmOrange 437 572 52.0 0.45 23.4 5.7  138 (Shcherbakova et al. 2012) 
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1.1.5 Chromoproteins 
Chromoproteins are defined as compounds consisting of a protein and a pig-
ment, which is usually, but not always, bound as a co-factor (Fearon 1940). For 
the purpose of this work, a narrower definition of chromoproteins is used: Chro-
moproteins are a sub-class of the GFP-like protein family and possess a pig-
ment, which is formed through auto-catalysis from its poly-peptide chain. These 
proteins absorb strongly in the visible spectrum and are therefore intensely col-
ored. On the other hand, they exhibit very small quantum yields and conse-
quently little to no fluorescence. Synonymously, the term pocilloporin has been 
used for these proteins (Dove et al. 1995), referring to the family of corals this 
class of proteins had been first isolated from.  
Many chromoproteins were isolated from anthozoa species, specifically corals 
and sea anemones (Gurskaya et al. 2001, Labas et al. 2002, Shagin et al. 2004, 
Chan et al. 2006, Alieva et al. 2008). In these species chromoproteins function as 
a pigment and are the source of their coloration (Dove et al. 2001). Typically, 
they exist as dimers, tetramers or other higher order oligomers (Alieva et al. 
2008); which is detrimental to their use in biosensors, as these oligomers tend 
to aggregate and can lead to cell toxicity when recombinantly expressed (Shaner 
et al. 2005). Recently, a monomeric chromoprotein, Ultramarine, was engineered 
by Pettikiriarachchi et al. (2012) from the oligomeric precursor Rtms5, originating 
from the reef building coral Montipora efflorescens.  
In contrast, efforts were made to engineer fluorescent proteins with very low 
quantum yields (Ganesan et al. 2006, Murakoshi et al. 2008); which were used as 
dark acceptors for FRET sensors in fluorescent lifetime imaging (FLIM). FLIM uti-
lizes the fact, that the fluorescent lifetime of a donor fluorophore is altered by 
the presence of a suitable FRET acceptor. Since only the lifetime of the  
donor has to be monitored, the spectrum can be freed up by using a dark  
acceptor. However, these dark acceptors still retain some fluorescence, which 
can potentially interfere with other probes (Ganesan et al. 2006, Murakoshi et 
al. 2008).  
Pettikiriarachchi et al. (2012) demonstrated, that the engineered chromopro-
tein Ultramarine can be successfully used as a dark acceptor in a FRET pair, 
overcoming both the potential problems from oligomerization and retained flu-
orescence. This strategy seemed very promising and was therefore applied in 
the development of a FRET based cGMP sensor. Besides FLIM, such a FRET sensor 
can also be used in standard imaging as a single fluorophore biosensor, in which 
the brightness of a fluorescent protein is modulated by the presence of a ligand 
molecule.  
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1.2 Optogenetics 
 
“I suggest that neuroscientists should tell molecular biologists what their dif-
ficulties are, in the hope that this will stimulate the production of useful new 
biological tools” 
Francis Crick (1999) 
 
 
 
 
 
 
 
Optogenetics is the combination of genetic targeting of specific cells with op-
tical methods, which either monitor or control these cells with light (Miesenböck 
2009). The field of optogenetics originated from neuroscience to address the 
problem of analyzing complex neuronal circuits in the brain in a non-invasive 
manner. Due to their broad applicability, optogenetical methods are now 
spreading to the wider field of cell biology (Toettcher et al. 2011). 
In principle, the optogenetic approach incorporates the recombinant expres-
sion of engineered light sensitive proteins under the control of cell specific pro-
moters, to address a cell population of interest. These cell populations are then 
selectively probed and manipulated with light, which can be monitored and ap-
plied in a very spatially and temporally controlled manner. Broadly speaking, 
there are two types of optogenetic tools: actuators and reporters (Miesenböck 
2009).  
Optogenetic actuators are light sensitive proteins, which change the internal 
state of the cell expressing them upon illumination. These proteins were initially 
often light sensitive ion channels, which let ions pass after being activated by 
light, stimulating or inhibiting the host cell in the process (Nagel et al. 2005, 
Deisseroth 2015). To date, a wide variety of actuators is available, which stimu-
late processes as diverse as gene expression (Motta-Mena et al. 2014), second 
messenger synthesis (Stierl et al. 2011) and light activated  
degradation (Gasser et al. 2014). 
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1.2.1 Genetically Encoded Biosensors 
The main focus of this work is on reporters, the second type of optogenetic 
tools. Optogenetic reporters are engineered proteins, which are sensitive to an 
internal state of a cell and modulate a light signal according to changes in that 
particular state. Most often these reporters are modified fluorescent proteins, 
which are read out via fluorescent microscopy (Dugué et al. 2012). In general, 
genetically encoded biosensors consist of two types of domains: the sensor do-
main, which interacts with the molecule to detect and the reporter domain, a 
single or pair of fluorescent proteins, which translate this change into a  
detectable light signal (Tantama et al. 2012). The main advantage of these types 
of biosensors over other detection methods, like chemical dyes, is that they are 
self-contained within a single poly-peptide chain and can be genetically tar-
geted to specific cell populations and even compartments within cells (Mank 
and Griesbeck 2008). 
The development of these molecular probes is exemplified by genetically en-
coded calcium indicators (GECIs). GECIs were the first genetically encoded fluo-
rescent biosensors (Miyawaki et al. 1997) and have seen extensive engineering 
efforts over the last two decades to bring them to perfection (Mank and 
Griesbeck 2008, Rose et al. 2014, Miyawaki and Niino 2015). GECIs are biosensors, 
which bind intracellular calcium and modulate their fluorescence  
intensity according to the calcium concentration. Because changes of the  
internal calcium concentration can be directly linked to neuronal activity (Mank 
and Griesbeck 2008), sensors which can detect these changes were very im-
portant for neuroscience, likely encouraging  their early development and in-
tensive improvements. Besides calcium, sensors haven been developed for a 
wide range of inorganic and organic compounds: zinc (Hessels and Merkx 2014), 
chloride (Arosio and Ratto 2014), cyclic nucleotides (Nikolaev and Lohse 2009, 
Paramonov et al. 2015), glutamate (Liang et al. 2015), ATP (Tantama et al. 2013) 
and many more (Tantama et al. 2012, Miyawaki and Niino 2015). Also, biophysical 
and biochemical states can be probed by genetically encoded  
sensors; examples are: pH (Benčina 2013), temperature (Sakaguchi et al. 2015), 
redox potential (Chiu et al. 2014), membrane potential (Storace et al. 2015) and 
tension (Guo et al. 2014).  
Focusing on single chain fluorescent biosensors, i.e. sensors which are en-
coded by a single gene, they can be broadly categorized into two groups: single 
and dual emission fluorescent sensors (ratio metric sensors). Mechanisms, ad-
vantages and disadvantages of these types of sensors are discussed in the fol-
lowing sections. 
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1.2.1.1 Single Emission Fluorescent Biosensors 
Single fluorophore sensors modulate the emission of a fluorescent protein 
according to a change of an internal state of a cell (e.g. concentration of an an-
alyte). This modulation can be achieved by different means: (1) utilizing the in-
nate environment sensitivity of certain fluorescent proteins, (2) inserting sensor 
domains into the β-barrel of a fluorescent protein, thus exposing and destabi-
lizing its chromophore and (3) using dark acceptors in FRET sensors. 
The fluorescence emission of Tyr66 based chromophores, such as GFP and 
YFP, is inherently sensitive to changes in their environment, because the  
hydroxyl group of tyrosine can be protonated, which changes the π-system of 
the chromophore, blue-shifting its absorption spectrum and quenching its  
fluorescence (Bizzarri et al. 2009). This property has been used in the past as the 
basis for fluorescent biosensors, which can detect environmental changes, such 
as changes in pH (Sankaranarayanan et al. 2000) or chloride concentration 
(Grimley et al. 2013). However, this strategy only works for very specific mole-
cules and states and is therefore often not applicable.  
This environment sensitivity can be enhanced by directly exposing the chro-
mophore to the solvent. Usually, the chromophore is efficiently shielded by the 
strands of the β-barrel. By opening up the β-barrel directly at the chromophore 
position and inserting a sensor domain, exposure to the solvent and thus fluo-
rescence intensity can be modulated. Baird et al. (1999) discovered that fluores-
cent proteins can tolerate the insertion of sensor domains into the β-barrel. The 
authors inserted the calcium binding protein calmodulin in between residue 144 
and 145 of EYFP, resulting in the calcium sensor camgaroo1.  
This strategy was further refined with the use of circular permutated fluores-
cent proteins. In circular permutated fluorescent proteins, the DNA encoding the 
fluorescent protein is split inside the sequence encoding a β-strand or a loop 
and the two resulting DNA strands are then swapped in their order,  
fusing the native N-term with a short linker to the native C-term (Baird et al. 
1999). This results in a fluorescent protein, which has a similar overall structure 
to the wild-type FP, with the exception of having its new N- and C-term very 
close together and in a different position. If these new termini are located close 
to the chromophore, even small changes in their relative location can lead to 
exposure of the chromophore to the solvent. This strategy was successfully im-
plemented by Nakai et al. (2001) to create a calcium sensor, by fusing the cal-
cium binding protein calmodulin and the M13 peptide to an at position 144–149 
circular permutated version of GFP, transforming calcium binding of the calmod-
ulin domain into modulation of fluorescence emission. This calcium sensor, 
named G-CaMP, was the basis for a whole family of single fluorophore GECIs 
(GCaMP2 (Tallini et al. 2006), GCaMP3 (Tian et al. 2009), GCaMP5 (Akerboom et al. 
2012), G-CaMP6/7/8 (Ohkura et al. 2012), GCaMP6s/m/f (Chen et al. 2013)). Similar 
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approaches were employed to produce single fluorophore biosensors for cGMP 
(Nausch et al. 2008).  
Another strategy for single emission biosensors was demonstrated by 
Pettikiriarachchi et al. (2012). Here the authors showed that the fluorescence 
intensity of a fluorescent protein can be modulated by the presence of a chro-
moprotein, which acts as a dark acceptor in FRET (see 3.3.4). This strategy will be 
further explored in this work.  
The advantage of single emission fluorescent biosensors is the simplicity of 
the imaging procedure, since only a single fluorescent protein has to be moni-
tored (Miyawaki and Niino 2015), which also allows to collect more light from the 
whole emission spectrum. Furthermore, they are more readily combined with 
either optogenetic actuators or other fluorescent biosensors, because of their 
smaller spectral bandwidth. On the other side, there are several disadvantages 
of this type of sensor (Rose et al. 2014): the intensity of emission is not only 
modulated by the presence of an analyte, but also depends on  
concentration of the fluorescent probe. This complicates the interpretation of 
results, when biosensor expression levels vary between cells, or when cells 
move in and out of the focal plane. Furthermore, sensors which are dark in the 
basal state are difficult to locate in the tissue, which makes long term experi-
ments with several revisits of the same region more challenging.  
1.2.1.2 Dual Emission Fluorescent Biosensors 
In general, there are two types of dual emission fluorescent biosensors:  
(1) single emission biosensors, which are fused to a reference fluorescent pro-
tein, (2) FRET based biosensors with two fluorescent proteins. The focus of this 
work is on unimolecular FRET based biosensors, i.e. sensors which encode two 
fluorescent proteins within the same polypeptide chain. 
In FRET based biosensors the emission of two fluorescent proteins is modu-
lated through the binding of a ligand to a sensor domain. This binding event 
causes a conformational change within the molecule, rearranging the orienta-
tion and distance of the fluorophores (Miyawaki et al. 1997). This in turn has an 
impact on the FRET efficiency, as the distance and orientation of the transition 
moments within the chromophores is a major factor in FRET efficiency (see 1.1.2). 
FRET efficiency can be estimated by exciting the donor fluorophore and moni-
toring donor and acceptor emission. The ratio between these two intensities 
then allows inference of ligand concentration. 
The main advantage of these types of sensors is that measurements are ratio-
metric and therefore, in principle, independent of sensor concentration 
(Tantama et al. 2012). This means that variations in sensor concentration which 
are caused by differences in expression levels over time or in between cells can 
be accounted and adjusted for. Furthermore, artefacts introduced by movement 
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of specimen or cells, shifting in and out of the focal plane and therefore chang-
ing the brightness of fluorophores, can also be corrected, as only the ratio of 
emission is related to ligand concentration, but not the intensity itself (Mues et 
al. 2013). Furthermore, FRET sensors are always visible when recombinantly ex-
pressed, because at least one fluorescent protein will emit, making long term 
experiments with multiple revisits of the same cells easier, as cells are always 
sufficiently labeled (Rose et al. 2014).  
This comes at the cost of more complex imaging set-ups, as two fluorescent 
proteins have to be monitored simultaneously (Tantama et al. 2012). Further-
more, because of their larger spectral footprint, as they are consisting of two 
fluorescent proteins, they typically occupy a larger part of the visible spectrum 
than single emission sensors, making it more difficult to accommodate other 
optogenetic tools.  
 
Figure 1.4 Model of FRET-based biosensor 
A) Two fluorescent proteins (FP I and FP II) are fused via a sensor domain (SD). In the unbound 
state the donor FP transfers energy to the acceptor FP. Upon ligand binding a conformational 
change within the molecule occurs, rearranging the chromophores and reducing FRET effi-
ciency. B) Emission spectra of FRET based biosensors in ligand-bound and ligand-free state 
with indicated imaging windows for fluorescence microscopy  
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1.3 cGMP 
1.3.1 cGMP, a Cellular Secondary Messenger 
Cyclic guanosine–3’,5’–monophosphate (cGMP) is a secondary messenger in 
cellular signaling. It is formed through the activity of guanylate cyclases, cata-
lyzing the conversion of the nucleotide GTP into a cyclic phosphodiester and 
releasing inorganic pyrophosphate (PPi) (Figure 1.5 A). PPi in turn is degraded 
into two phosphates through the activity of pyrophosphatase, driving the  
cyclization of cGMP by removing one of the products, rendering this reaction 
irreversible (Yang and Wensel 1992). 
 
Figure 1.5 Enzyme reactions involved in cGMP generation and degradation 
There are two major classes of guanylate cyclases: membrane-bound partic-
ulate guanylate cyclases (pCG) and soluble guanylate cyclases (sGC). They  
represent two distinct signaling pathways, through which cGMP is generated.  
pCGs are homo-dimeric transmembrane receptors, which are typically  
activated by extracellular ligands (Kuhn 2009). These ligands are peptide  
hormones called natriuretic peptides. They bind to the extracellular receptor 
domain and cause an intramolecular rotation, which is transduced into the  
cytoplasm, leading to the synthesis of cGMP in the cyclase domain (Misono et 
al. 2005). There are seven pCG receptors in mammals (CG-A to CG-F) and five 
natriuretic peptides have been identified as their ligands (ANP, BNP, CNP, guan-
ylin, uroguanylin) so far (Kuhn 2009).  
sGC are hetero-dimeric receptors in the cytosol, consisting of an α and β sub-
unit. They are activated by nitric oxide (NO), which is generated by nitric oxide 
synthases from L-arginine and can freely diffuse through membranes, enabling 
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cell-signaling (Derbyshire and Marletta 2009). Nitric oxide synthases and soluble 
guanylate cyclases form the NO/cGMP signaling pathway.  
The downstream targets of cGMP signaling are cGMP dependent protein ki-
nases (cGK), cGMP gated ion channels (CNG) and, to an extent, phosphodiester-
ases (PDE). In mammals, there are three isoforms of cGKs (cGKIα, cGKIβ and 
cGKII).These are serine/threonine kinases, which phosphorylate their respective 
targets, typically activating them in the process (Hofmann et al. 2009, 
Schlossmann and Desch 2009). CNGs, on the other hand, are ion channels, which 
are modulated by the binding of cGMP, subsequently changing the membrane 
potential or increasing the intracellular Ca2+ concentration (Biel and Michalakis 
2009).  
Phosphodiesterases degrade cyclic nucleotides into their monophosphate 
counterparts and therefore regulate the cGMP signal (Figure 1.5 B). There are 21 
PDE genes in the human genome, grouped into 11 families (Conti and Beavo 
2007). Besides degrading cyclic nucleotides, some PDEs are also allosterically 
regulated by them. These allosterically regulated PDEs are often bi-specific for 
cAMP and cGMP, allowing cross-talk between the two signaling pathways 
(Kleppisch 2009).  
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1.3.2 Physiological Functions of cGMP Signaling 
cGMP signaling plays an important role in maintaining cardiovascular home-
ostasis. In particular, the action of the neurotic peptide (NP)/NO/cGMP pathway 
counterbalances the renin/angiotensin/aldosterone system (RAA) in the regu-
lation of blood pressure. Under high cardiac load arterial natriuretic  
peptide (ANP) and B-type natriuretic peptide (BNP) are secreted into the blood-
stream by the heart (Boerrigter et al. 2009). ANP and BNP then bind to the re-
ceptor GC-A and stimulate cGMP synthesis (Kuhn 2003). There are several hypo-
tensive effects of cGMP stimulation: smooth muscle relaxation leads to vascular 
dilation; blood volume is reduced through increased renal blood flow and in-
creased excretion of sodium and water (Kuhn 2009). By virtue of these effects 
the cGMP signaling pathway is pharmacologically addressed to treat cardiac dis-
eases and hypertension. This was traditionally done through NO donors (stimu-
lating sGC) like nitroglycerin (Brunton 1867) and more recently through artificial 
natriuretic peptides and phosphodiesterase inhibitors, all of which elevate in-
tracellular cGMP concentration (Boerrigter et al. 2009). The introduction of the 
PDE5 inhibitor sildenafil (Viagra®) furthermore revealed the role of the cGMP 
signaling pathway in erectile dysfunction (Sandner et al. 2009). Besides this, 
cGMP signaling is involved in processes as diverse as bone growth and remod-
eling (Tsuji and Kunieda 2005), platelet aggregation (Walter and Gambaryan 
2009) and sperm motility (Miraglia et al. 2011), demonstrating its ubiquitous im-
portance. 
Furthermore, cGMP plays a key role as a second messenger in the central 
nervous system and is therefore of great interest as a target molecule for opto-
genetic investigation. Nitric oxide (NO)/cGMP signaling has been implicated in 
synaptic long term potentiation (LTP) in the hippocampus and the amygdala and 
in synaptic long term depression (LTD) in the cerebellum (for review see 
Kleppisch and Feil (2009)). 
In neurons in the hippocampus and amygdala N-methyl-D-aspartate (NMDA) 
receptor mediated calcium influx activates the Ca2+/calmodulin-regulated neu-
ronal NO synthase (nNOS), which in turn generates NO (see Figure 1.6 A). The 
gaseous NO can freely diffuse through membranes and permeates retrograde 
into the presynapse. There it stimulates soluble guanylate cyclases (sGC), which 
synthesize cGMP. The downstream targets for this cGMP signal are cGMP de-
pendent protein kinases (cGK), cyclic nucleotide gated ion channels (CNG) and 
hyperpolarization-activated cyclic nucleotide gated ion channels (HCN). In the 
hippocampus, it is hypothesized that cGKI localizes to the presynaptic mem-
brane and then phosphorylates various target proteins. This modulates vesicle 
clustering and eventually leads to an increased glutamate release. The exact 
mechanism for this process and the resulting LTP is still not clear and subject 
for further studies. CGKI knock outs in mice showed reduced LTP in the amyg-
dala, which lead to impaired long-term fear memory in behavioral experiments, 
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linking this form of synaptic plasticity to learning and memory formation (Paul 
et al. 2007). 
Conversely, in synapses between parallel fibers and purkinje neurons in the 
cerebellum synaptic plasticity is evoked through long term depression (LTD)(see 
Figure 1.6 B). This is process is mediated, in contrast to the hippocampus and 
the amygdala, through an anterograde NO signal. Nitric oxide is generated in the 
presynapse, crosses the synaptic cleft where it stimulates cGMP synthesis by 
sGCs. LTD is believed to be caused by cGKI which may trigger increased AMPA 
receptor internalization. LTD in the cerebellum was suggested to play a role in 
motor learning (Ito 2001).  
 
Figure 1.6 Current models of NO/cGMP signaling in synaptic plasticity 
A) LTP through retrograde NO signaling in the amygdala and hippocampus B) LTD through  
anterograde NO signaling in the cerebellum 
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1.3.3 Optogenetic Tools for cGMP 
The standard methods used for studying cGMP currently, rely on biochemical 
measurements of cGMP concentrations in either crude or purified cell extract. 
These methods utilize competitive binding of cGMP and a labeled cGMP  
analogue to a cGMP binding site (RIA, ELISA). Schmidt (2009) provides an excel-
lent overview of all established assay types. While these assays are very sensi-
tive to even femtomolar concentrations of cGMP, they all suffer from the same 
drawback: they all require cell extract as starting material, which leads to poor 
special and temporal resolution of the acquired measurements, since the tissue 
that is being observed is destroyed in the process (Nikolaev and Lohse 2009). 
cGMP signaling on the other hand is, as described above, very complex and dy-
namic and has been shown to be compartmentalized inside the cell 
(Fischmeister et al. 2006). Therefore, more sophisticated methods, that allow in 
vivo monitoring of cGMP oscillations in living tissue or even animals, have to be 
developed.  
1.3.3.1 Genetically encoded Biosensors for cGMP 
Several groups have developed genetically encoded biosensors (reviewed by 
Gorshkov and Zhang (2014)), to monitor cGMP concentrations in vivo. Table 1-2 
contains a list of the best cGMP sensors to date and their properties. Most of 
the current sensors are FRET-based and utilize cGMP binding domains from  
either cGKI or PDE5A. 
The first three in that collection (CGY-Del1, Cygnet 2.1 and cGES-DE5) can be 
seen as the first generation of cGMP sensors; which were developed independ-
ent of each other (Sato et al. 2000, Honda et al. 2001) or with a different binding 
domain (Nikolaev et al. 2006). This first generation, while an important step in 
the development, also exemplifies several limitations for their use for live cell 
imaging. CGY-Del1 for example displays poor selectivity between cGMP and 
cAMP. Cygnet 2.1 on the other hand was reported to exhibit very slow  
kinetics (Nikolaev et al. 2006). Both CGY-Del1 and Cygnet 2.1 use a large part of 
cGKIα, with only minor truncations of the N-terminus, resulting in a very large 
fusion protein. Since the catalytic domain of cGKIα is also retained, there might 
be potential for unwanted cross-reactivity of the sensor itself, causing artefacts 
in the observed specimen through phosphorylation. Furthermore, all three of 
these sensors have a very limited dynamic range, which impedes their useful-
ness in in vivo applications. Adding to that, the fluorescent proteins used in 
these sensors are very dim in comparison to more modern variants. Especially 
ECFP, with low quantum yield (0.4) and extinction coefficient (32.5 mM-1cm-1), 
is not only very dim but also limits the Förster radius and therefore potentially 
the dynamic range. 
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Table 1-2 cGMP sensors and their properties 
Name Type Binding Do-
main 
ΔR/R EC50  
cGMP 
EC50 
cAMP 
selec-
tivity 
FPs Reference 
ratio metric sensors       
CGY-Del1 FRET cGKIαΔ1-47 ~10 % 20.0 nM 152.3 nM 7.6 ECFP / YFP 10C 
Q69K 
(Sato et 
al. 2000) 
Cygnet 2.1 FRET cGKIαΔ1-77 ~30 % 1.7 µM >1 mM >600 ECFP / Citrine (Honda et 
al. 2001) 
cGES-DE5 FRET PDE5A GAF-A ~16 % 1.5 µM 630 µM 420 ECFP / EYFP (Nikolaev 
et al. 
2006) 
Red cGES-
DE5 
FRET PDE5A GAF-A ~20 % 40 nM - - T-sapphireΔC11 
dimer2 (DsRed) 
(Niino et 
al. 2009) 
cGi500 FRET cGKI CNB-A 
CNB-B 
77 % 470 nM - - CFP W1B / YFP 
10C 
(Russwur
m et al. 
2007) 
GFP2-
GAFa-Rluc 
BRET PDE5A GAF-A ~30 % 30 nM - - Rluc / GFP2 (Biswas et 
al. 2008) 
Single fluorophore sensors ΔF/F      
Cygnus FRET PDE5A GAF-A ~9 % 1 µM 400 µM 400 mTagBFP 
sREACh 
(Niino et 
al. 2010) 
δ-FlincG Single 
FP 
cGKIαΔ1-77 175 % 170 nM 48 µM 280 cpEGFP145 (Nausch 
et al. 
2008) 
 
Red cGES-DE5, cGi500 and to an extent GFP2-GAFa-Rluc and Cygnus are the 
second generation of cGMP sensors, which were engineered to overcome some 
of the described problems of the first generation. Specifically Russwurm et al. 
(2007) demonstrated a very methodical approach in sensor engineering, reduc-
ing the sensor domain to just CNB-A and CNB-B of cGKIα, while retaining good 
affinity and fair dynamic range. Red cGES-DE5 on the other hand was optimized 
to work in unison with a second FRET-indicator (Niino et al. 2009), shifting its 
spectral footprint dramatically to accommodate a CFP/YFP pair. This engineer-
ing effort also improved affinity and to a lesser extent the dynamic range. Still 
the problem of dim fluorescent proteins persists for both sensors. T-sapphire 
is, in terms of brightness (𝜀=44.0 mM-1cm-1, 𝛷=0.6, 𝜀 ∗ 𝛷=26.4), a slight improve-
ment over ECFP (𝜀=32.5 mM-1cm-1, 𝛷=0.4, 𝜀 ∗ 𝛷=13), but it can only be effectively 
excited in the near UV, which limits its applicability. Dimer2 on the other hand 
is dimmer (𝜀=60 mM-1cm-1, 𝛷=0.69, 𝜀 ∗ 𝛷=41.4) than all of the YFP variants used 
in the first generation and is also, as the name suggests, a dimer (Campbell et 
al. 2002), which could potentially lead to aggregation and other artefacts.  
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GFP2-GAFa-Rluc is an interesting twist on PDE5A based FRET sensors. Here the 
authors (Biswas et al. 2008) placed the GAF-A domain from PDE5A between an 
engineered version of GFP and the Renilla luciferase (Rluc), using a  
bioluminescent protein as the donor for resonance energy transfer (BRET). BRET 
has some advantages over FRET (Xu et al. 2003): since the sensor is the source 
of the light, no background florescence is induced through excitation light, re-
ducing noise in the sample considerably. Furthermore bleaching of the chromo-
phore and phototoxicity through intense excitation can be avoided. The down-
sides of BRET sensors on the other hand are, that bioluminescence is very dim 
and therefore requires very sensitive instruments and long exposure times. Be-
sides that, luciferase requires a substrate (coelenterazine), which has to be ex-
ternally supplied.(Xu et al. 2003) This puts conceptual limitations to BRET imag-
ing, especially for in vivo applications.  
Cygnus is an engineered version of cGES-DE5 (Niino et al. 2010), which  
replaces the CFP/YFP pair of the original with mTagBFP and the dark acceptor 
sREACh, creating a FRET based single fluorophore sensor, as demonstrated by 
Murakoshi et al. (2008) before. While this sensor demonstrates the feasibility of 
this approach for cGMP, the sensor itself has a very poor dynamic range and is 
thus only of limited use.  
δ-FlincG is a single fluorophore cGMP sensor (Nausch et al. 2008), based on 
the first GCaMP (Nakai et al. 2001). While the maximal intensity change reported 
by Nausch et al. (2008) compares very well to other cGMP sensors, Bhargava et 
al. (2013) casted serious doubt on the accuracy of these findings. According to 
Bhargava et al. (2013) the sensors of the FlincG family were very pH-sensitive, a 
feature inherited from the first generation GCamP sensors, thus causing arte-
facts in their initial characterization. Furthermore, the group reported problems 
with the genetic stability of the published sensor construct and uncertainty 
about its identity. Besides that, it is not unreasonable to assume that δ-FlincG 
inherited other problems from GCaMP1, namely its dimness and fast bleaching 
rate (Mank and Griesbeck 2008).  
Of the described sensors only cGi500 and Red cGES-DE5 found wider adaption 
so far, with transgenic mice being generated by Thunemann et al. (2013) and 
Götz et al. (2014).  
Taken together cGMP imaging is still in its infancy and many problems with 
the pioneer sensors have to be overcome before they compare to their highly 
engineered counterparts used in Ca2+ imaging, like Twitch2B (Thestrup et al. 
2014) and GCaMP6s (Chen et al. 2013). In this work, cGi500 was chosen as a base 
framework for further development, because of its relatively high dynamic range 
and large knowledgebase provided by Russwurm et al. (2007). 
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1.3.3.2 Genetically encoded Stimulators of cGMP Generation 
More recently, the optogenetic toolbox for studying cGMP was enriched by the 
development of genetically encoded, light activated guanylate cyclases. Specif-
ically, Ryu et al. (2010) mutated the light activated adenylate cyclase BlaC from 
the filamentous bacterium Beggiatoa sp., to use GTP as educt instead of ATP, 
yielding a light activated guanylate cyclase, denoted as BlgC. Kim et al. (2015) 
improved on this initial work, leading to the BlgC variant EROS, which was suc-
cessfully used to treat erectile dysfunction in rats through optogenetic stimula-
tion. 
Furthermore a study by Gao et al. (2015) isolated a membrane bound light 
activated guanylate cyclase from the aquatic fungus Blastocladiella emersonii 
and established it as an optogenetic tool (BeCyclOp). The authors of the study 
demonstrated major improvements over EROS, with a 50 x higher production of 
cGMP and significantly less cAMP production after light stimulation.  
With the availability of optogenetic activators and reporters for the cGMP 
pathway, the foundation has been laid for studying complex neurobiological 
questions through optical means, once these tools ripen to maturity.  
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1.4 Aims 
The overarching aim of this study is to develop genetically encoded fluores-
cent biosensors for cGMP with improved characteristics, to make them suitable 
for a variety of in vivo imaging applications. The outlined key issues of first and 
second generation cGMP sensors will be addressed, with a focus on brighter 
fluorophores, larger dynamic range and higher cGMP selectivity. The base con-
structs for this process will be cGi500, the cGMP sensor with the best overall 
characteristics to date. Building on the insights gained from a host of recent 
structural studies, cGMP binding domains will be optimized for simpler binding 
kinetics and higher selectivity. Lessons learned from the development of genet-
ically encoded calcium sensors will be generalized and transferred to cGMP sen-
sors. Specifically, an important objective is the transfer of the development pro-
cedure into E. coli, to simplify the process in order to be able to implement 
changes more quickly and to eventually employ directed evolution approaches 
such as bacterial plate screening (Litzlbauer et al. 2015). In addition, cGMP sen-
sors with red shifted spectral characteristics will be explored, in order to har-
ness more favorable imaging conditions within the red part of the visible spec-
trum. In connection to that, it is the aim to assess the viability of a single emis-
sion cGMP biosensor based on a red fluorescent protein which is quenched by 
a chromoprotein through FRET. 
In pursuit of the main goal, a secondary aim is to streamline the general bio-
sensor development pipeline, to make this process quicker and more adaptable. 
A further objective in this spirit is the construction of an automated screening 
system for high throughput directed evolution approaches.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Table 2-1 Chemicals 
Name Vendor Abbreviation Catalogue # 
2-Propanol (Isopropanol) Sigma Aldrich  33539 
Acetic acid Sigma Aldrich  33209 
Adenosine 3′,5′-cyclic monophos-
phate sodium salt monohydrate 
Sigma Aldrich cAMP A6885 
Agar-Agar Carl Roth  2266.2 
Agarose, high electroendosmosis Biomol  1280.1 
Ampicillin sodium salt Carl Roth Amp K029.5 
D(+) Saccharose Carl Roth  4621.1 
Dimethylsufloxid Sigma Aldrich DMSO D8418 
di-Sodium hydrogen phosphate Merck Na2HPO4 106580 
Ethanol Sigma Aldrich EtOH 32205 
Ethidium bromide solution 1 % Carl Roth EtBr 2218.2 
Ethylenediaminetetraacetic acid Merck EDTA 108418 
Glycerol 86 % Carl Roth  4043.1 
Guanosine 3′,5′-cyclic monophos-
phate sodium salt 
Sigma Aldrich cGMP G6129 
Imidazole Merck  104716 
Isopropyl β-D-1-thiogalactopyra-
noside 
Carl Roth IPTG 2316.4 
Kanamycin sulphate Carl Roth Kan T832.1 
L-(+)-arabinose Sigma Aldrich  A91906 
Leupeptin Sigma Aldrich Leu L0649 
Magnesium chloride Merck MgCl2 105833 
Orange G (C.I. 16230) Carl Roth  318.1 
Pepstatin A Sigma Aldrich Pep A P5318 
Phenylmethanesulfonyl fluoride Sigma Aldrich PMSF P7626 
Polyethylene glycol 3000 Sigma Aldrich PEG 81227 
Polypropylene glycol P2000 Sigma Aldrich PPG 81380 
Potassium dihydrogen phosphate Carl Roth KH2PO4 P018.2 
Sodium chloride Merck NaCl 106404 
Streptomycin sulfate salt Sigma Aldrich Strep S6501 
Tetracycline hydrochloride Carl Roth Tet 237.1 
Tris(hydroxymethyl)aminomethane Carl Roth Tris 2449.1 
Tryptone Carl Roth  8952.2 
Yeast Extract Carl Roth  2363.2 
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2.1.2 Enzymes, Kits and Standards 
Table 2-3 Enzymes, kits and standards 
Name Vendor Catalogue # 
1 kb DNA Ladder New England Biolabs N3232L 
100 bp DNA Ladder New England Biolabs N3231L 
Antarctic Phosphatase New England Biolabs M0289L 
BamHI-HF® New England Biolabs R3136L 
Deoxyribonuclease I (DNase I) Sigma-Aldrich D5025-150KU 
DpnI New England Biolabs R0176L 
EcoRI-HF® New England Biolabs R3101L 
EcoRV-HF® New England Biolabs R3195L 
Herculase II Fusion DNA Polymerase Agilent 600679 
Lysozyme from chicken egg white Sigma-Aldrich L6876 
Nickel-IDA Agarose Jena Bioscience AC-310-500 
NucleoSpin® Gel and PCR Clean-up MACHEREY-NAGEL 740609.25 
NucleoSpin® Plasmid EasyPure MACHEREY-NAGEL 740727.25 
PureYield™ Plasmid Midiprep System Promega A2495 
Ribonuclease A (RNase A) Sigma-Aldrich R5503 
SphI-HF® New England Biolabs R3182L 
T4 DNA Ligase New England Biolabs M0202L 
T4 DNA Ligase Reaction Buffer New England Biolabs B0202S 
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2.1.3 Devices and Appliances 
Table 2-4 List of devices 
Device type Name Vendor 
CCD Camera CoolSNAP-HQ Visitron Systems GmbH 
Centrifuge RC-5B Sorval 
Centrifuge 3K30 SIGMA 
Fluorescence spectropho-
tometer 
Cary Eclipse Varian 
Gel documentation GelDoc 200 Videosystem BIO RAD 
Micro-centrifuge Centrifuge 5415 D Eppendorf 
Plate reader Infinite® M200 PRO Tecan 
Power supply for electro-
phoresis 
E143 Consort 
Power supply for screen-
ing system 
BT-305 BASETech 
Stereo-fluorescence-mi-
croscope 
Leica M205 FA Leica Microsystems 
Thermocycler T3000 Analytic Jena AG 
Thermocycler FlexCycler2 Analytic Jena AG 
Ultra-sonic water bath ONOREX SUPER RK 510 Bandelin 
UV-Vis spectrometer NanoDrop 1000 spectrom-
eter 
Thermo Scientific 
 
2.1.4 Strains and Plasmids 
Table 2-5 Strains and plasmids 
Name Details Source 
E. coli XL1 blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)] 
Invitrogen 
E. coli Bl21 (DE3) gold E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) 
endA Hte 
Invitrogen 
E. coli PPY F– endA1 recA1 galE15 galK16 nupG rpsLΔlacX74 
Φ80lacZΔM15 araD139Δ(ara,leu)7697 mcrA Δ(mrr-
hsdRMS-mcrBC) cynX::[araC pBAD- redα EM7- redβ 
Tn5-gam]λ– 
(Zhang et 
al. 2012) 
Plasmids   
pcDNA3  Invitrogen 
pRSET-B  Invitrogen 
pSinRep5  Invitrogen 
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2.1.5 Buffers 
Table 2-6 Buffer composition 
Buffer Component Concentration Notes 
50 x TAE Tris base 2 M  
 Acetic acid 1 M  
 EDTA 50 mM  
1 x TAE Tris base 40 mM  
 Acetic acid 20 mM  
 EDTA 1 mM  
10 x Orange G EDTA 10 mM  
DNA loading dye Tris 100 mM pH 7.5 
 Glycerol  50 % (v/v)  
 Orange G 1 % (w/v)  
2xYT Tryptone 16 g/L autoclave 
liquid medium Yeast extract 10 g/L  
 NaCl 5 g/L (85.5 mM) pH 7 
LB (Lennox) Tryptone 10 g/L autoclave 
liquid medium Yeast extract 5 g/L  
 NaCl 5 g/L (85.5 mM) pH 7 
LB (Lennox) Tryptone 10 g/L autoclave 
solid medium Yeast extract 5 g/L  
 NaCl 5 g/L (85.5 mM)  
 Agar-Agar 10 g/L pH 7 
YTS Yeast extract 5 g/L autoclave 
solid medium Tryptone 10 g/L  
 D(+) Saccharose 100 g/L  
 Agar-Agar 10 g/L pH 7 
Autoinduction D-(+)-glucose 1.25 % (w/v) sterile filter 
additive Glycerol  15 % (v/v)  
 Lactose 5 % (w/v)  
Protein Resuspen-
sion Buffer I 
Na2HPO4 20 mM  
NaCl 300 mM  
 Imidazole 20 mM pH 7.8 (HCl) 
Protein Resuspen-
sion Buffer I 
Na2HPO4 20 mM  
NaCl 300 mM  
 Imidazole 55 mM pH 7.8 (HCl) 
Protein Elution 
Buffer 
Na2HPO4 20 mM  
NaCl 300 mM  
 Imidazole 250 mM pH 7.8 (HCl) 
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Table 2-6 Buffer composition (continued) 
Buffer Component Concentration Notes 
PBS NaCl 137 mM autoclave 
 KCl 2.7 mM  
 Na2HPO4 10 mM  
 KH2PO4 2 mM pH 7.4 
TSS Trypton 10 g/L sterile filter 
 Yeast Extract 5 g/L  
 NaCl 5 g/L (85.5 mM)  
 PEG 100 g/L  
 DMSO 5 % (v/v)  
 MgCl2 50 mM pH 6.5 
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2.2 Methods 
2.2.1 Working with DNA 
2.2.1.1 Polymerase Chain Reaction 
“I was sagging as I walked out to my little silver Honda Civic, which never failed 
to start. Neither Fred, empty Becks bottles, nor the sweet smell of the dawn of the 
age of PCR could replace Jenny [girlfriend, who broke up with him]. I was 
lonesome.” 
        Kary B. Mullis (1993) 
 
Since the invention of the polymerase chain reaction (PCR) by Kary B. Mullis 
in 1983 it has become one of the most important and versatile tools in molecular 
biology and warranted him the Nobel Prize for Chemistry in 1993.  
In brief, template DNA strands are cyclically heated and cooled in a thermo-
cycler, melting and re-hybridizing them with complementary DNA. During this 
process two primers (short oligonucleotides) bind the start and the end of a 
desired DNA section and a thermostable polymerase elongates the primers, 
copying the template DNA. In each cycle both DNA strands are copied and can 
serve as templates in the next cycle, enabling a doubling of DNA strands with 
every cycle. This exponential reaction can relatively quickly produce large quan-
tities of linear dsDNA starting from very few molecules of template DNA.  
In this work PCR was used for several purposes: (1) to amplify DNA for con-
struction of recombinant plasmids, (2) to introduce synthetic sequences into 
amplified DNA, (3) to fuse separate pieces of linear DNA, (4) to generate DNA 
libraries, and (5) to verify the length of resulting products from cloning.  
To guarantee the integrity of DNA sequences during amplification a polymer-
ase with proofreading capability was used. The enzyme of choice was  
Herculase II Fusion DNA Polymerase (Agilent), with an advertised error rate of  
1 in 777000 bp and an elongation rate of 30 s/kbp. Reaction conditions were cho-
sen according to the guidelines provided by the vendor. A typical PCR mix, with 
a reaction volume of 50 µL, is shown in Table 2-7. Components were pipetted in 
depicted order into a 0.2 mL reaction tube and carefully mixed. Primers were 
HPSF purified, custom synthesized oligonucleotides from Eurofins  
Genomics. Lyophilized oligonucleotides were resolubilized in autoclaved dH2O 
to a stock concentration of 100 µM. Stocks were diluted 10 fold to obtain a 10 µM 
working solution. Both stock and working solutions were stored at – 20 °C. In 
case of problems with amplification of GC-rich targets, the PCR mix was aug-
mented with up to 8 % (v/v) DMSO.   
Materials and Methods – Working with DNA 
53 
 
Table 2-7 Composition of standard PCR with Herculase II Fusion Polymerase 
Compound Concentration Volume Final Concentra-
tion 
dH2O, autoclaved   35 µL  
5 x Herculase II re-
action buffer 
5 x 10 µL 1 x 
Primer 1 10 µM 1 µL 0.2 µM 
Primer 2 10 µM 1 µL 0.2 µM 
dNTP mix  25 mM (each dNTP) 1 µL 500 µM (each 
dNTP) 
Template DNA 1–400 ng/µL 1 µL 0.02–8 ng/µL 
Herculase II Fusion 
DNA Polymerase 
 1 µL  
 Finale Volume: 50 µL  
 
PCRs were performed in the thermocyclers T3000 or FlexCycler2 from Analytic 
Jena AG. A standard PCR temperature program is depicted in Table 2-8. Two  
parameters of this basic program were adjusted to the specific requirements of 
each individual reaction: (1) elongation time, according to the length of the  
expected product, and (2) annealing temperature, according to the specific pri-
mer set in use. 
 
Table 2-8 Temperature program for PCRs with Herculase II Fusion Polymerase 
Step Temperature [°C ] Time [s] Cycles 
Denaturation 98 120 Initial 
Denaturation 98 20 
30x 
Annealing 65 20 
Elongation 72 
30 per 1 kbp of 
product 
Elongation 72 180 Final 
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Annealing temperatures for the use of Herculase II Fusion polymerase can be 
calculated, according to the vendor, as the melting temperature of the primers 
–5 °C. Because most often complex primers with long non-complementary 5’-
overhangs were used, the utility of these calculations is limited. An annealing 
temperature of 65°C was found to work for most primer sets. Annealing 
temperatures were optimized using a thermocycler with gradient option. These 
cyclers enable PCRs with different annealing temperatures, but otherwise 
identical parameters, to be performed in parallel within the same machine. In 
general annealing temperatures were either: (1) lowered, if little or no PCR 
product was observed, to facilitate better binding of the primers to the 
template, or (2) increased to reduce unspecific primer binding, if additional, 
unwanted PCR products were observed. 
Introduction of short synthetic DNA Sequences 
DNA polymerases are used in PCR to catalyze the extension of the template-
bound primer at the 3’-end of the oligonucleotide. Depending on the sequence, 
18–21 nucleotides are sufficient to specifically bind the template DNA within the 
operating temperature range of polymerases. Since only the 3’-end has to bind 
to the template DNA to achieve successful elongation, the 5’-end of a primer can 
be non-complementary to the template strand. This property can be used to 
introduce synthetic nucleotide sequences at the ends of PCR amplified linear 
DNA. As long as there are a sufficient number of complementary base pairs at 
the 3’-end of the primer, the 5’-“overhang” can be relatively long and is mainly 
limited by the synthesis length a supplier is able to deliver (~100 bp). In this 
work, this property was used to introduce a variety of different synthetic se-
quences to amplified DNA: (1) recognition sites for restriction endonucleases to 
facilitate classical cloning, (2) homology regions to facilitate SLiCE cloning, (3) 
functional genetic elements (e.g. promoters, RBS, Kozak-consensus sequence), 
(5) randomized sequences to generate DNA libraries and (6) short purification 
tags (e.g. His-tag) to enable purification of recombinant proteins.  
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Overlap extension PCR 
Overlap extension PCR (OE-PCR) was first introduced by Higuchi et al. (1988), 
mainly as a method for site directed mutagenesis. In the context of this work it 
was used to fuse two smaller linear DNA fragments sequence specific (e.g. to 
generate fusion proteins).  
The fusion was achieved by a two-step process: First the two fragments were 
amplified separately with standard PCR, as described above. During these PCRs 
homologue regions were introduced at the end of the first fragment and at the 
start of the second fragment through the use of primers with 5’ overhangs. Typ-
ically, primers consisted of 21 base pairs for primer binding and 21 base pairs 
overhang. This generated two DNA fragments, which had a common overlap se-
quence of 42 base pairs. These two fragments were then purified as described 
in 2.2.1.3 and used as template for the second step. The fragments were equimo-
lar combined into a reaction as shown in Table 2-9 and a PCR was performed 
using the program in Table 2-8. The two primers, which were used in this reac-
tion, are complementary to the 5’- end of the first template and the 3’- end of 
the second template. These primers were functionalized through 5’- overhangs 
for subsequent cloning steps. In the initial cycles of the PCR two different hy-
bridization products were formed. Of these two possible products, only one has 
the necessary 3’- OH groups, which are required for successful extension with 
DNA polymerases. These extended strands were amplified in subsequent PCR 
cycles, as they incorporated complementary regions for both primers. In prac-
tice it was found, that OE-PCRs often show 3 distinct bands: the high running 
fusion product and the lower running templates. Therefore OE-PCR products 
were always gel purified as described in 2.2.1.3, by cutting the desired band out 
of the agarose gel. Resulting purified products were then inserted into vector 
DNA by means of classical (see 2.2.1.6) or SliCE cloning (see 2.2.1.7). 
 
Table 2-9 Composition of OE-PCR with Herculase II Fusion Polymerase 
Compound Concentration Volume Final Concentra-
tion 
ddH2O, autoclaved   34 µL  
5 x Herculase II re-
action buffer 
5 x 10 µL 1 x 
Primer 1 10 µM 1 µL 0.2 µM 
Primer 2 10 µM 1 µL 0.2 µM 
dNTP mix  25 mM (each dNTP) 1 µL 500 µM (each 
dNTP) 
Template 1 10 – 100 ng/µL 1 µL 0.2 – 2 ng/µL 
Template 2 10 – 100 ng/µL 1 µL 0.2 – 2 ng/µL 
Herculase II Fusion 
DNA Polymerase 
 1 µL  
 Finale Volume: 50 µL  
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Colony PCR 
Colony PCR is a fast and cost effective high throughput method, to assess 
whether recombinant DNA fragments were successfully integrated into target 
vectors. If target vectors are kept constant, as it was often the case in this work, 
parallelization of the cloning process is easily achieved. This allowed the verifi-
cation of several dozen prototype biosensors at once.  
In brief, potentially positive E. coli clones were tested for successful integra-
tion of the transgenic fragment by amplification of the integration site, using 
primers that are complementary to regions on the plasmid. Material from the 
colony, instead of purified plasmid DNA, was used as a template. This is what 
sets colony PCR apart from other means of verification (e.g. restriction digest of 
purified plasmid). As it can be performed with colonies harvested directly from 
agar selection plates after the cloning step. There is no requisite for another 
overnight growth cycle to produce plasmid DNA in a small liquid culture. Even 
though purified plasmid DNA is required eventually, clones can be tested right 
away and only positive candidates are subsequently inoculated for plasmid pu-
rification, thus cutting down costs for plasmid preparation kits.  
The detail protocol was as follows: Primers for the colony PCR were designed, 
that two possible products can be observed, a short product, if there was no 
integration and a long product if integration was successful. Typically, priming 
sites were chosen ~150 bp up- and downstream from the targeted  
integration site, yielding a 300 bp product for empty vectors and an x + 300 bp 
product for positive clones (x = insert length).  
After successful transformation of E. coli with a cloning mix, colonies were ob-
served on selective agar plates after overnight incubation. Colonies were picked 
using sterile pipette tips and streaked on selective agar plates into a grid pat-
tern that allowed later identification of individual clones. Right after streaking, 
the pipette tip was briefly transferred into 10 µL of PCR mix in 0.2 mL reaction 
tubes, carrying small amounts of bacteria over into the mix. The key factor in 
this process was, to minimize the amount of material used. Since  
bacterial colonies contain a huge variety of biological compounds, there are 
many potential PCR inhibiting factors (e.g. proteases) present. Because of this 
and the fact that PCR can amplify miniscule amounts DNA, counterintuitively, 
colony PCR worked best with very small colonies, since only small amounts of 
bacterial material were present to begin with. Selective plates with streaked-
out colonies were incubated at 37°C. 
Table 2-10 depicts a standard reaction mix for a colony PCR. The volume of 
the reaction is reduced to 10 µL in comparison to the standard PCR, because 
only a small amount of product is needed for subsequent analysis, further  
reducing the cost of this method. Several colonies were tested in parallel, war-
ranting the production and subsequent distribution of a larger scale master mix. 
The temperature program used was the one shown in Table 2-8 with  
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appropriate annealing temperatures for the primer sets used and extension 
times for the products expected.  
After the PCR program, products were analyzed by agarose gel electrophoresis 
as described in 2.2.1.2. Positive clones were then inoculated from the back-up 
selective agar plate into 2 mL selective liquid LB medium in 14 mL culture tubes, 
in the evening of the same day they were streaked out – even if growth on the 
plates was not yet visible. Back-up plates and culture tubes were incubated 
overnight at 37°C, the latter with vigorous agitation.  
Lastly, colony PCR is only a rough verification method and was used as such, 
since it can only detect correct length (within the boundaries of gel electropho-
resis resolution), but not sequence identity. Final verification was always 
achieved through sequencing.  
 
Table 2-10 Composition of colony PCR mix with Herculase II Fusion Polymerase 
Compound Concentration Volume Final Concentra-
tion 
ddH2O, autoclaved   7.4 µL  
5 x Herculase II re-
action buffer 
5 x 2 µL 1 x 
Primer 1 10 µM 0.2 µL 0.2 µM 
Primer 2 10 µM 0.2 µL 0.2 µM 
dNTP mix  25 mM (each dNTP) 0.1 µL 250 µM (each 
dNTP) 
Herculase II Fusion 
DNA Polymerase 
 0.1 µL  
 Finale Volume: 10 µL  
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2.2.1.2 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the standard method to separate polynucleo-
tides according to their length, which allows identification and isolation of spe-
cific polynucleotides after subsequent visualization of the separated  
specimen. Detailed description of this method can be found in Green and 
Sambrook (2012). In the context of this work agarose gel electrophoresis was 
used for the separation, analysis and isolation of DNA, linear and circular, be-
tween 100 bp and 15 kbp in length.  
In the buffer conditions (1 x TAE, pH 8.0) used for gel electrophoresis DNA is 
negatively charged, due to the deprotonation of phosphate groups inside the 
DNA backbone. Placed into an electric field in a liquid environment, this nega-
tive charge accelerates the DNA strands and they move towards the anode. This 
movement is the basis of separation in gel electrophoresis, which is a type of 
chromatography. The mobile phase (DNA) interacts physically with a stationary 
phase (polymerized agarose gel), which leads to a separation of  
different types of molecules according to their physical properties. Specifically, 
polymerized agarose is a hydrocolloid gel, which forms pores, through which 
DNA strands move. Since larger DNA molecules present a larger surface, they 
interact stronger with the pores of the gel and therefor move slower than 
smaller DNA molecules. The electric mobility of a DNA molecule in such a gel 
depends linearly on the logarithm of its length. In time, different DNA molecules 
separate according to their size, with smaller DNA fragments being closer to the 
anode than larger ones.  
Besides separation, DNA molecules also have to be visualized to allow any 
kind of analysis. To make DNA visible, ethidium bromide is incorporated into the 
gel. Ethidium bromide (EtBr) is an organic compound with a conjugated  
π- system, which acts a chromophore, absorbing in aqueous solutions strongly 
at 210 nm and 285 nm. EtBr intercalates with DNA, inserting itself between the 
DNA bases through van der Waals interactions. The planar molecules lie parallel 
to the planes of the DNA bases and are sandwiched between them. They are 
stabilized from above and below, which fixes the chromophore in place, allowing 
for less molecular movement. This causes an increase in the fluorescent quan-
tum yield, because absorbed electromagnetic energy has fewer opportunities to 
leave the molecule through molecular movement and is therefore  
re-emitted as photons. This emission lies in the visible part of the spectrum with 
its peak at around 610 nm and can be either imaged with a camera or seen with 
the naked eye. The quantum yield of DNA bound EtBr is ~20-30 times higher than 
the free solution, making the DNA complex clearly visible over the background 
when excited with UV light (Green and Sambrook 2012).  
Agarose gel electrophoresis was used for two purposes: (1) for analysis of DNA 
(PCR products, plasmids, restriction maps) and (2) the preparation of linear DNA 
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(linearized plasmids and PCR products for cloning). Custom made horizontal gel 
chambers with mobile trays and combs of different well-width were used (4mm 
for analytical gels, 12 mm for preparative gels). 1 % (w/v) agarose gels were 
made by suspending 0.5 g Agarose in 50 mL 1 x TAE buffer. The agarose suspen-
sion was melted by heating it in the microwave for 2 min at 800 W. The molten 
agarose was poured into a gel-tray and 2.5 µL of a 1 % (w/v) ethidium bromide 
solution were added (end concentration 0.5 µg/mL) and thoroughly mixed. The 
agarose gel was left to solidify for 30 min at room temperature, while a comb 
displaced part of the gel to create wells, in which the DNA could be pipetted in. 
The solidified gel was placed into the gel chamber and flooded with 1 x TAE 
buffer. Samples were mixed 1:6 with loading dye, which provides density to the 
sample, so it can sink into the pockets easily. Besides that, the loading dye gives 
a visual indication of: (1) the sample in the pocket and (2) the progress of the 
electrophoresis, since the dye molecules move through the gel at comparable 
rates to DNA. To estimate the molecular weight of gel-bands, at least one lane 
was loaded with either 1 kb or 100 bp DNA Ladder (New England Biolabs). Gels 
were run at 70 V–120 V and 50 mA for 30 min–1 h, depending on desired resolu-
tion and available time (higher voltage being faster, but with poorer resolution 
and potential for melting gels).  
For analytical gel electrophoresis, gels were imaged, using a GelDoc 2000 (BI-
ORAD) unit. Preparative gels were imaged using the UV table of the same unit, 
but in a slightly different manner. Gründemann and Schömig (1996) pointed out 
that DNA is severely damaged by the use of UV tables in preparative Gel extrac-
tion. The half-life of DNA, which is still functional in subsequent cloning steps, 
on a UV table is around 3–6 s, rendering 99 % of DNA useless after only a 45 s 
exposure. To prevent UV damage, preparative gels were cut “blind”. This was 
achieved by slicing a thin strip of the gel, containing the marker-lane and a small 
fraction of the lane with the DNA to purify. This thin strip was examined by eye 
on the UV-table and the band of interest was located and marked with a scalpel. 
Subsequently the strip was re-aligned with the non-exposed part of the gel and 
the band was cut out with the help of the marking; thus avoiding UV exposure 
altogether. The isolated gel-bands were then further processed as described in 
2.2.1.3. 
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2.2.1.3 Purification of PCR Products and linear DNA 
In this work purification of PCR products and linear DNA was mainly  
performed to isolate specific linear DNA fragments for subsequent use in the 
production of recombinant plasmids. To ensure good yields for subsequent en-
zyme reactions, high concentration of input DNA was prioritized. Empirically, it 
was found, that losses in gel purification were around 70–85 % of input  
material, while PCR clean-ups usually only retained 15–20 %. Therefore, PCRs 
were usually first analyzed via gel electrophoresis, as explained in the previous 
section. This analysis was used to determine if gel purification was necessary or 
if PCR clean-up would be sufficient. Gel purifications were only performed 
if major unspecific side-products were observed.  
For the purification process of both methods the Nucleospin® Gel and PCR 
Clean-up kit was used according to the manufactures instructions. This kit is 
based on the following principle: DNA fragments are exposed to high salt buff-
ers, containing chaotropic salts (such as guanidinium hydrochloride or guani-
dinium thiocyanate). These conditions destroy the hydrate shell around the DNA 
molecules and expose their negatively charged backbone phosphates. These are 
then able to bind negatively charged oxygen ions of the silica membrane, 
through the forming of cation bridges with the help of sodium ions. The mem-
brane bound DNA is washed under high salt and ethanolic conditions, to remove 
enzymes, buffer components, nucleotides and primers (this is achieved because 
binding strength increases with the length of the DNA molecule, allowing the 
adjustment of conditions to a certain cut-off length). After that, the bound DNA 
is re-hydrated under low salt conditions, releasing the molecules from the mem-
brane.  
Specifically, PCR reactions were mixed 1:2 (v/v) with NTI buffer (high salt, cha-
otropic buffer). Cut-out gel bands, in turn, were weighted and mixed 1:2 (w/v) 
with NTI buffer, and agitated on a shaker (IKA-VIBRAX-VXR, 1,600 rpm), until the gel 
block was completely dissolved. Subsequent steps were performed similarly for 
both purification methods. DNA in high salt NTI buffer was transferred to the 
provided silica membrane columns and centrifuged (RT, 11,000 x g, 1 min) to fa-
cilitate binding to the membrane. The flow-through was discarded. Afterwards, 
columns were washed by application of 700 µL of Wash Buffer NT3 (high salt, 
80 % ethanol) and centrifugation (RT, 11,000 x g, 1 min). Again, the flow-through 
was discarded. To remove residual ethanol, the columns were centrifuged again 
(RT, 11,000 x g, 2 min) and subsequently transferred to sterile Eppendorf reac-
tion tubes. 50 µL of Elution Buffer NE (low salt, 5 mM Tris/HCl, pH 8.5) were ap-
plied to re-solubilize the DNA. Elution was achieved through an additional cen-
trifugation step (RT, 11,000 x g, 1 min).  
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2.2.1.4 Determination of DNA Concentration and Purity 
DNA concentration and purity was determined through UV absorption spec-
troscopy. DNA exhibits a strong absorption maximum at 260 nm, which enables 
the correlation of the OD260 nm to the DNA concentration. Furthermore, the ab-
sorption at 230 nm and 280 nm was measured to determine the concentration 
of potential contaminants within the DNA preparation. Proteins have a strong 
absorption at 280 nm, from the π-systems of the aromatic amino acids (trypto-
phan, phenylalanine and tyrosine). Chaotropic salts, containing guanidinium 
ions, phenolates and thiocyanates, which are all commonly found in DNA prep-
aration protocols on the other hand, exhibit strong absorption at around 
230 nm. Therefore the ratios of OD260 nm:OD280 nm and OD260 nm:OD230 nm were used to 
assess whether these contaminants were present, with a OD260 nm:OD280 nm ratio of 
~1.8 being considered pure of proteins and a OD260 nm:OD230 nm ratio of 1.8–2 being 
considered pure of substances absorbing at 230 nm. In practice OD260 nm:OD230 nm 
ratios observed in DNA samples, purified with the Nucleospin® Gel and PCR 
Clean-up kit, were much lower than these values. This indicates the presence of 
residual guanidinium thiocyanate, which according to the manufacturer, does 
not influence subsequent enzyme reactions in the typically observed concen-
tration range. 
UV absorption measurements were performed using either a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific), or a NanoQuant Plate™ in com-
bination with an Infinite® M200 PRO microplate reader (Tecan), according to the 
instructions provided by the respective manufacturer.  
2.2.1.5 Restriction Digest of DNA 
Restriction endonucleases (restriction enzymes) are enzymes, which recog-
nize specific, often palindromic sequences in double stranded DNA. These mo-
tifs are typically between 4–8 bp long, determining the frequency, with which 
they are found in a random DNA sequence. After binding to their respective 
recognition site, these enzymes catalyze the cleavage of both DNA strands. De-
pending on the enzyme in question, different types of “ends” result from this 
reaction: (1) “blunt ends”, in which both strands are cut at the same position, 
and (2) “sticky ends”, in which DNA strands are cut in a staggered fashion, pro-
ducing either 5’- or 3’-overhangs. This property of restriction enzymes has made 
them an invaluable tool in molecular biology; acting as a pair of sequence spe-
cific molecular scissors. Within the context of the work, restriction enzymes were 
used for several purposes: (1) to generate specific “sticky ends” for directional 
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“classic”-cloning, (2) to linearize circular plasmids for SLiCE cloning, (3) to inac-
tivate plasmid DNA, which served as template in PCRs and (3) to verify the iden-
tity of plasmid DNA through digestion patterns. 
For directional cloning two restriction enzymes with different recognition mo-
tifs and “sticky ends”, which were also present in the MCS of the target vector, 
were selected. Inserts were either cut-out from existing vectors with the same 
recognition sites, or amplified via PCR using primers with synthetic  
5’-overhangs, as described in 2.2.1.1, and then cut. Typically, these overhangs 
consisted of the recognition site, a 5’-spacer of 3–5 bps, to facilitate efficient 
cleavage, and occasionally 1–2 bps between the recognition site and the priming 
site, to adjust for potential frameshifts. Plasmids and PCR products were first 
purified as described in 2.2.3.3 and 2.2.1.3 and then digested with restriction en-
zymes according to the instructions provided by the manufacturer. After diges-
tion, linear DNA was again purified, using either gel extraction, if e.g. a fragment 
with a resolvable size-difference was cut-out of a vector, or PCR clean-up, if no 
visible difference between digested and undigested species can be achieved 
through electrophoresis.  
Restriction enzymes were ordered from NEB, focusing on the use of HF®  
Restriction Endonucleases, which are engineered to operate within the same 
buffer conditions and exhibit less unspecific binding. A standard reaction mix 
for a double restriction digest is depicted in Table 2-11. Digests were incubated 
for 1–3 h at the appropriate temperature (typically 37 °C). If buffer conditions for 
two enzymes varied, digests were performed sequentially, starting with the en-
zyme requiring lower salt concentrations, topping-up the buffer after the first 
digest and continuing with the second enzyme.  
 
Table 2-11 Reaction mix for double restriction digest with NEB HF®-enzymes  
Compound Concentration Volume Final Concentration 
DNA 10–200 ng/µL 40 µL 0.2–4 ng/µL 
H2O  3 µL  
CutSmart® Buffer 10 x 5 µL 1 x 
Enzyme A 20,000 U/mL 1 µL 0.4 U/µL 
Enzyme B 20,000 U/mL 1 µL 0.4 U/µL 
 Finale Volume: 50 µL  
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As “classic” cloning through “sticky”-end hybridization was only rarely per-
formed in favor of modern assembly cloning (see 2.2.1.7), restriction digest was 
mainly used to linearize plasmids for these techniques. To avoid re-ligation of 
linearized plasmids through complementary base-pairing of “sticky”-ends, a 
single blunt-cutting enzyme was selected for these tasks. 
Some restriction endonucleases depend on specific methylation patterns 
within their recognition site. This property originates from their initial purpose 
in microorganisms as defense mechanisms against foreign DNA. Restriction en-
donucleases distinguish host DNA from foreign DNA, by specific methylation 
patterns, which can only be found in foreign DNA. Methylation only occurs if 
methyltransferases are present, as is the case for plasmid DNA produced in 
E. coli cultures, but not for regular PCRs. This can be used to selectively cut DNA 
of bacterial origin in mixtures were both PCR products and plasmids are  
present. Since the templates for PCRs in this work were often plasmids using the 
same backbone as the newly constructed plasmids, these templates could pro-
duce false positive colonies after being carried through from the PCR to the 
eventual transformation into chemical competent E. coli. To avoid false positive 
clones through this process, a restriction digest with DpnI was performed rou-
tinely after each PCR, whose products were used in subsequent constructions of 
new plasmids. This digest was performed by simply adding 1 µL of DpnI to a fin-
ished PCR reaction and incubating it at 37 °C for 2 h, without changing  
buffers. DpnI is a restriction enzyme with a four base pair recognition site (GATC), 
which can only cut in the presence of a methylated adenine. Its short recognition 
site assures that it is very frequently found within a random DNA sequence (sta-
tistically every 44bps = 256 bps). Therefor potentially contaminating template-
plasmids are frequently cut into smaller linear pieces and thus rendered non-
functional.  
Furthermore, restriction digests were performed in order to verify the identity 
of plasmids. Typically, a frequently cutting enzyme (4 bp recognition site) was 
used to digest plasmid DNA. Afterwards an analytical gel electrophoresis was 
performed and the resulting pattern of observed gel bands was compared to 
simulated, digests of the expected sequence in silico. 
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2.2.1.6 Ligation and Dephosphorylation of DNA 
Ligation 
If restriction endonucleases are the scissors of molecular biology, then DNA 
ligases are the glue stick, which puts cut DNA strands back together. In the con-
text of this work, T4 DNA ligase (NEB) was used, an enzyme which catalyzes the 
formation of phosphodiester bonds from 5’ phosphate and 3’ hydroxyl groups 
in the backbone of DNA strands. This reaction, which requires energy in form of 
ATP, is the reversal of a restriction digest. T4 DNA ligase was used to insert re-
combinant DNA into linearized plasmids. Vector and insert DNA were first cut 
with two different restriction enzymes, as described in 2.2.1.5, producing two dif-
ferent overhanging “sticky”-ends on each linear fragment. Overhanging ends of 
the vector and insert could then hybridize through complementary base pairing 
and therefore allow directional specificity. This hybridization was then fixed 
through the use of T4 DNA ligase, which forms covalent bonds between the vec-
tor- and insert-DNA, resulting in a functional circular plasmid. Ligations were 
performed according to the instructions provided by the vendor. Vector- and 
insert-DNA were supplied in a molecular ratio of 1:5 into ligation reactions. A 
standard ligation reaction-mix is depicted in Table 2-12. T4 Ligase Reaction 
Buffer was initially aliquoted into 4 µL lots, and then stored at –20 °C, to prevent 
ATP degradation through repeated freeze thaw cycles and contamination (ali-
quots were only defrosted once and then discarded). Ligations were incubated 
for 1 h at 16 °C and subsequently transformed into chemically competent E. coli 
XL1 Blue (see 2.2.3.4). 
 
Table 2-12 Reaction mix for ligation with T4 DNA Ligase 
Compound Concentration Volume Final Concentration 
Insert DNA 5 x µM 4 µL 2 x µM 
Vector DNA 1 x µM 4 µL 0.4 x µM 
T4 DNA Ligase Re-
action Buffer 
10 x 1 µL 1 x 
T4 DNA Ligase 400,000 U/mL 1 µL 40 U/µL 
 Finale Volume: 10 µL  
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Dephosphorylation 
The ligation of one linear vector and one linear insert molecule produces only 
one circular plasmid and therefore decreases entropy. The intramolecular cir-
cularization of linear vector DNA competes with the desired insertion of  
recombinant DNA into the linear vector and is thermodynamically favored,  
because no entropy is lost due to reduction of the number of resulting mole-
cules. This circularization can occur through complementary base pairing if only 
one restriction enzyme was used, or even through non-complementary base 
pairing if two different restriction enzymes were used. The circularization of vec-
tor DNA leads to false positive colonies in the cloning process. To prevent circu-
larization, linearized vector DNA was treated with Antarctic Phosphatase (NEB), 
an enzyme which catalyzes the dephosphorylation at the 5’-end of DNA strands. 
Since these 5’ phosphate groups are required for ligation, vector DNA cannot 
circularize. In contrast, ligation of linear insert DNA with dephosphorylated lin-
ear vector DNA can still occur, because the insert DNA provides two phosphates 
at the 5’-ends. Instead of four covalent bonds between the four single strands, 
only two are formed, leading to a circular plasmid with two nicks. These nicked 
plasmids are still functional and will be repaired inside E. coli after transfor-
mation. Dephosphorylation was performed right after the restriction digest of 
vector DNA, without prior clean-up (reaction mix as shown in Table 2-13). The 
enzyme reaction was incubated for 30 min at 37 °C and subsequently purified as 
described in 2.2.1.3. 
 
Table 2-13 Reaction mix for desphosphorylation with Antarctic Phosphatase 
Compound Concentration Volume Final Concentration 
Vector restriction 
digest 
 44 µL  
Antarctic Phospha-
tase reaction 
buffer 
10 x 5 µL 1 x 
Antarctic Phospha-
tase 
5,000 U/mL 1 µL 0.1 U/µL 
 Finale Volume: 50 µL  
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Introduction of synthetic DNA through Ligation 
Besides regular cloning, ligations were also used to introduce short 
 synthetic DNA sequences into plasmid DNA. Instead of ligating linear pieces of 
DNA, which were cut with restriction enzymes, long PCR products are circularized 
into a functional plasmid. Products of standard PCRs cannot be circularized, be-
cause the 5’-ends of primers usually lack the required phosphate groups. In or-
der to facilitate this ligation, functionalized oligonucleotides, which are phos-
phorylated at the 5’-end, were used. A PCR with phosphorylated primers was 
performed, which amplified the whole plasmid. The 5’overhangs of these phos-
phorylated primers were used to incorporate new synthetic sequence infor-
mation (see 2.2.1.1). PCR products were purified as described in 2.2.1.3, and cir-
cularized through intramolecular ligation using standard reaction mix and con-
ditions and subsequently transformed into chemically competent E. coli XL1 
Blue. 
2.2.1.7 SLiCE Cloning 
In recent years several new cloning technics have been developed, which use 
different approaches from traditional cloning with restriction enzymes (Valla 
and Lale (2014)). These new cloning techniques simplify cloning in many ways 
and overcome limitations traditional cloning poses. One of these new tech-
niques, i.e. SLiCE cloning, was published by Zhang et al. (2012). SLiCE cloning (ac-
ronym for seamless ligation cloning extract) is a DNA assembly method, which 
relies on in vitro recombination of short homologue sequences at the ends of 
linear DNA. This method was adapted and extensively used throughout this 
work.  
Specifically, a crude cell-extract is prepared from an engineered E. coli strain. 
This cell-extract contains the enzymes which catalyze the in vitro recombination. 
The production of this crude cell-extract is very simple, cheap and results in 
large quantities of active enzyme mix, which is a big advantage, because there 
is no need for commercial enzymes. The cloning procedure itself is  
performed by the introduction of short homology regions through PCR, which 
are shared between the insert (or several inserts) and the vector DNA and sub-
sequent recombination of these homology regions into a functional circular 
plasmid. Through this method up to seven inserts can be cloned into a target 
vector at the same time, in a directional and specific manner. This recombina-
tion is independent of the sequence of the homology region. Both of these prop-
erties are big advantages over traditional cloning. The ability to clone several 
inserts at the same time, with high efficiency, allows for quick cloning of fusion 
proteins, which is at the core of this work. The sequence independence is also 
important, as there is no longer a need for specific restriction sites that would 
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pose a problem specifically in large vectors, or the engineering of fusion pro-
teins, as certain parts of the protein coding sequence are fixed by the  
requirement for restriction site sequences. 
Seamless Ligation Cloning Extract 
In detail, the protocol of Zhang et al. (2014), was adapted in the following way. 
An overnight culture of E. coli PPY was inoculated from a single colony into 5 mL 
of 2xYT liquid medium supplemented with 10 µg/mL streptomycin in sterile 
14 mL round bottom culture tubes. Overnight cultures were agitated (220 rpm) 
at 37 °C in a round shaker incubator. On the next day a 200 mL main culture 
(2xYT medium, 10 µg/mL streptomycin) was inoculated with the overnight cul-
ture in a baffled Erlenmeyer-flask. The culture was incubated at 37 °C in a round 
shaker (220 rpm). Growth was monitored as described in 2.2.3.2 until an OD600 nm 
of 5–5.5 was reached. Protein production was induced by addition of 1.1 mL of a 
36 % (w/v) L-(+)-arabinose solution (final concentration 0.2 % (w/v)). After in-
duction, the culture was incubated for 2 h at 37 °C and strong agitation 
(220 rpm), to facilitate protein production. After this, cells were harvested 
through centrifugation (5,000 x g, 20 min, 4 °C), the supernatant was discarded. 
To produce the cell extract from the cell-pellet, an adapted version of the large-
scale protein purification was performed (see 2.2.2.2). First cells were re-sus-
pended in 2.5 mL Protein Resuspension Buffer I and transferred to a 50 mL Fal-
con tube. To prevent proteases from digesting the active components of the en-
zyme extract, the cell suspension was supplemented with a cocktail of protease 
inhibitors (4 mM PMSF, 20 µg/mL Pepstatin A, 4 µg/mL Leupeptin; end concen-
tration) and thoroughly vortexed. To break open E. coli cells, several physical 
and enzymatic steps were performed. First, the cell suspension was frozen solid 
at –80 °C and subsequently thawed again. This produces ice crystals within the 
cells, which rupture the cell-wall and membrane. After this step, the cell sus-
pension was kept on ice, to reduce potential degradation. Next, 1 mg of lyophi-
lized Lysozyme powder was added to the suspension, thoroughly vortexed and 
incubated for 30 min on ice. Lysozyme is an enzyme that catalyzes the hydrolysis 
of peptidoglycan in the bacterial cell wall. 50 µL of a 1 mg/mL RNAse solution 
was added (end concentration 20 µg/mL). Then, the suspension was incubated 
for 30 min in an ultrasound water bath. The ultrasonic agitation facilitates the 
physical rupture of already damaged cell-walls and membranes. After this step, 
the cell lysate was cleared through centrifugation (20,000 x g, 30 min, 4 °C). The 
supernatant was decanted, supplemented with glycerol to a final concentration 
of 50 % (v/v) and incubated at 4 °C overnight to facilitate protein folding. The 
supernatant was subsequently aliquoted into 100 µL lots, shock frozen in liquid 
nitrogen and stored at –80 °C. One batch contained between 4,000 and 6,000 
reactions.   
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In vitro Recombination with SLiCE 
The enzyme extract facilitates the recombination of short homology regions 
at the ends of linear DNA. These homology regions were introduced as described 
in 2.2.1.1 through 5’-overhangs on primers during PCR. Typically, 21 bp were 
added at the end of each insert, which were either homologue to the ends of 
the vector or to the next insert in line. This leads to homology regions of 21 bp 
between the vector and insert and 42 bp between multiple insert. In this work, 
up to 4 inserts were successfully cloned into a vector in this manner. PCR prod-
ucts were digested with DpnI, as described in 2.2.1.5, to inactivate potentially 
contaminating template plasmids. Vectors were either linearized through a sin-
gle restriction digest (typically a “blunt” cutter), or through amplification with 
PCR. If PCR was used, it was also possible to introduce 21 bp  
regions, which are homologous to the insert(s). Linearized vector and insert DNA 
were purified (see 2.2.1.3) and DNA concentration was determined (see 2.2.1.4). A 
recombination reaction mix is shown in Table 2-14. Vector and insert DNA were 
supplied in a molar ratio of 1:5, respectively (for vector and two  
inserts the ratio was 1:5:5, etc.). Since the suggested reaction buffer of Zhang et 
al. (2014) was very similar to T4 Ligase reaction Buffer, this buffer was used, 
mainly for convenience. Recombination reactions were incubated for 15 min at 
37 °C and subsequently transformed in chemically competent E. coli XL1 Blue. 
 
Table 2-14 SLiCE reaction mix 
Compound Concentration Volume Final Concentration 
Insert DNA 5 x µM 4 µL 2 x µM 
Vector DNA 1 x µM 4 µL 0.4 x µM 
T4 DNA Ligase Re-
action Buffer 
10 x 1 µL 1 x 
SLiCE  1 µL  
 Finale Volume: 10 µL  
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2.2.2 Working with Proteins 
2.2.2.1 Overexpression of recombinant Proteins in E. coli 
In order to analyze the performance and biophysical properties of a  
constructed biosensor, it was overexpressed in E. coli and then purified. Biosen-
sors were cloned in two different derivatives of the expression vector pRSET B 
(Thermo Fisher Scientific), deemed pRSET SL II and pRSET SL III. Both vectors are 
based on the same backbone and are only different in the length of their His-
tags (6 x His and 10 x His respectively). The overexpression of recombinant pro-
tein is achieved by making use of the inducible lac/T7 system. The transcription 
of the target gene is driven by the strong T7 promoter which is located down-
stream of the biosensor coding sequence on the vector. The T7 promoter is rec-
ognized by T7 RNA polymerase. In this work E. coli Bl21 (DE3) was used as an 
expression strain which harbors a copy of T7 RNA polymerase under the control 
of the lacUV5 promoter in its genome. This promoter is part of the lac operon, 
which metabolically controls the expression of genes involved in lactose catab-
olism. It is activated by the presence of lactose (or compounds structurally sim-
ilar to lactose) and therefore chemically inducible. Isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) is a lactose analogue, which can bind and release the lac re-
pressor, but cannot be catabolized by E. coli and is therefore often used to in-
duce protein expression. IPTG induction requires fairly precise timing and there-
fore constant, close monitoring of the culture to achieve optimal expression. 
Early induction leads to reduced cell density, because most energy is devoted 
to protein expression, and late induction to poor protein expression, because 
nutrients have already been spent on cell division. However, a study by Studier 
(2005) suggested the use of a more sophisticated method for metabolic control 
of induction of protein expression. The lac operon is actually antagonistically 
controlled by glucose and lactose. The presence of glucose inhibits protein ex-
pression even if lactose is present. Thus, a mixture of glucose and lactose can 
be used as a timer, which automatically induces protein expression. At first the 
presence of glucose inhibits the expression of recombinant protein under the 
control of the lac operon, allowing the culture to reach sufficient density. As 
glucose is depleted by the growing culture, the presence of lactose finally in-
duces the production of T7 RNA polymerase, starting high rates of protein ex-
pression. In addition, glycerol is added to supply the culture with an additional 
energy source. This so-called auto induction medium was found to be very ef-
fective in the overexpression of biosensors.   
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In detail, the following procedure was performed, adapting the suggested 
protocol by Studier (2005). Chemically competent E. coli BL21 (DE3) were trans-
formed with purified plasmid preparations of either pRSET SLII or pRSET SLIII, 
containing the biosensor of interest, as described in 2.2.3.4. Cells were immedi-
ately transferred to baffled 250 mL Erlenmeyer flasks containing 50 mL LB me-
dium supplemented with 0.05 % (w/v) D-(+)-glucose, 0.2 % (w/v) lactose, 0.6 % 
glycerol and 100 µg/mL ampicillin. Furthermore, polypropylene glycol (PPG) was 
added to an end concentration of 0.1 % (v/v). PPG is used as an anti-foaming 
agent, as it does not readily mix with water, and exhibits phase separation, 
which prevents foam from occurring during continues shaking. Flasks were in-
cubated for 72 h at room temperature under vigorous agitation (220 rpm) in a 
round shaker incubator. Owing to the fact that biosensors expressed in the con-
text of this work always incorporated fluorescent proteins or chromoproteins, 
success of protein production was visually assessable by the color of either the 
suspension culture or the harvested cell pellet. 
2.2.2.2 Purification of His-tagged Proteins 
Proteins were expressed using the vectors pRSET SLII and pRSET SLIII (see 
3.1.3), which add His-tags of different lengths (6 x His, 10 x His respectively) to 
the N-terminus of recombinant proteins. The basic protocol for extraction and 
purification of these differently tagged proteins was the same, using slightly ad-
justed buffer conditions for 10 x His-tagged proteins, denoted in square brack-
ets. In principle, E. coli cells are lysed through various physical and enzymatic 
methods and the soluble fraction is collected through centrifugation. His-tagged 
recombinant proteins are then purified through metal-ion affinity chromatog-
raphy. This chromatography is based on the coordination of multiple histidine 
side chains to Ni2+-ions, which are immobilized through chelating agents on aga-
rose beads. Elution of the stationary phase is achieved through competition with 
high concentrations of imidazole that similarly binds to Ni2+-ions.  
In detail, overexpression cultures were harvested by centrifugation in 50 mL 
Falcon tubes (5,000 x g, 10 min, 4 °C), discarding the supernatant. Cell pellets 
were then re-suspended in 10 mL Protein Resuspension Buffer I [Protein Resus-
pension Buffer II], supplemented with a protease inhibitor cocktail (4 mM PMSF, 
20 µg/mL Pepstatin A, 4 µg/mL Leupeptin; end concentration) to prevent pro-
tein degradation by proteases released through cell disintegration. The cell sus-
pension was frozen solid at –80 °C to promote cell-rupture through the for-
mation of ice crystals. Suspensions were then defrosted and supplemented with 
1 mg of lyophilized chicken lysozyme. Lysozyme catalyzes the hydrolysis of 1,4-
beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine res-
idues of peptidoglycan within the bacterial cell wall, further weakening the 
structural integrity of the cells. Furthermore, 5 µg/mL DNAse and 10 µg/mL 
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RNAse were added to degrade nucleic acids, which are released from lysed cells 
and which otherwise create a sludge. The enzymatic degradation of the cell wall 
was promoted by incubating the suspension at 37 °C for 30 min. Afterwards Fal-
con tubes were transferred to an ultrasonic water bath (cooled by crushed ice 
to prevent heat induced protein denaturation) and sonicated for 30 min. To re-
move insoluble cell-debris, the suspension was centrifuged (20,000 x g, 30 min, 
4 °C) and the supernatant was collected in 15 mL Falcon tubes. 120 µL of a 
6 % (v/v) Nickel-IDA agarose bead suspension (Jena Bioscience) were added to 
the clarified lysate. This suspension was then incubated for 2 h under constant 
weak agitation on a rotator, to promote binding of His-tagged proteins to Ni2+ 
ions present in the agarose resin. Subsequently, the bead suspension was trans-
ferred to 1 mL polypropylene columns (Qiagen) that retained beads with bound 
protein. Beads were washed by passing 10 mL Protein Resuspension Buffer I 
[Protein Resuspension Buffer II] through the column. His-tagged proteins were 
eluted from the resin by addition of 600 µL of Protein Elution Buffer. The eluate 
was collected in 1.5 mL Eppendorf reaction tubes and incubated at 4 °C over-
night, to promote protein folding and maturation. The purified protein solution 
was either used immediately in subsequent experiments or frozen at –80 °C for 
long term storage. 
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2.2.2.3 Dialysis of Protein Solutions 
To free proteins from salts and other buffer components, which are incom-
patible with subsequent methods, they were dialyzed after elution. Dialysis is 
achieved by separating the high salt protein solution from a low salt dialysis 
solution by a semi-permeable cellulose membrane, which allows small mole-
cules to pass but retains larger molecules. The salt ions then diffuse along their 
concentration gradient through the membrane into the low salt dialysis solu-
tion. This process reduces the salt concentration in the protein solution, while 
the protein concentration remains constant.  
Specifically, a custom dialysis device was assembled: A 8 mm hole was drilled 
into the center of the lid of an 1.5 mL Eppendorf reaction tube, using an 8 mm 
wood drill bit and a cordless drill. These reaction tubes were then sterilized by 
autoclaving. As dialysis membrane ZelluTrans (Carl Roth) dialysis tubing with a 
molecular weight cut off of 8,000–10,000 Da was used. Dialysis tubing was cut 
into 2 cm single walled squares and then soaked in dialysis buffer (typically PBS) 
to revitalize the cellulose membranes. 400 µL eluted protein solution were 
transferred into reaction tubes with holes. The revitalized dialysis membranes 
were then placed over the opening of the reaction tube. Then the lid was closed 
in a manner that traps the cellulose membrane between the rim of the lid and 
the reaction tube. This covered the hole in the reaction tube with a single layer 
of membrane, allowing the protein solution to get in contact with dialysis solu-
tion through the lid. Dialysis devices assembled in such a way were then placed 
up-side down in a floating device and were then transferred into a beaker glass 
containing 500 mL PBS. Care was taken, that the protein solution was completely 
in contact with the cellulose membrane and that no air bubbles were trapped 
between the dialysis solution and the bottom of the membrane. The dialysis 
solution was stirred by a magnetic stirring device and incubated at 4 °C. Typi-
cally three dialysis steps were undertaken to increase difference in the salt gra-
dient. For each step dialysis solution was replaced with fresh buffer and was 
incubated for 2 h, with one of the steps requiring overnight incubation.  
This method is very cost effective and allows for parallel dialysis of several 
dozen samples.  
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2.2.2.4 Mass Spectrometry 
Mass spectrometry methods were adapted from Hornburg et al. (2014) and 
performed in close collaboration with Daniel Hornburg from the Department of 
Proteomics and Signal Transduction of the Max Planck Institute for Biochemis-
try.  
Sample Preparation 
His-tagged proteins were purified via metal ion affinity chromatography as 
described in 2.2.2.2 and subsequently dialyzed against PBS (see 2.2.2.3). To 
800 µL of purified protein solution 100 µL of 6 M guanidinium chloride (GuHCl) 
solution (final concentration 0.67 M) and 9 µL of 1 M dithiothreitol (DTT) (final 
concentration 10 mM) were added and thoroughly mixed. The sample was then 
incubated at 95 °C for 10 min in a thermos shaker at 190 rpm. The proteins within 
the sample were denatured by heat and the effect of GuHCl, a chaotropic salt, 
making their polypeptide chains more accessible to the later proteolytic digest. 
DTT on the other hand is a reducing agent, which was used to break disulfide 
bonds. Samples were then sonicated for 5 min, to re-solubilize any precipitate 
and then incubated for 25 min at room temperature. Reduced cysteine residues 
were then alkylated by adding 100 µL 0.5 M iodoacetamide (IAA) to a final con-
centration of 50 mM. The reaction was incubated for 45 min at room tempera-
ture in the dark and then stopped with the addition of 100 µL of a urea/thiourea 
(6 M/2 M) solution. Samples were centrifuged (16,000 x g, 5 min, RT) to pellet in-
soluble components and the supernatant was transferred into a new reaction 
tube. Denatured proteins were then digested by adding 4 µL of a Lys-C solution 
(0.5 µg/µL) and 4 µL of a Trypsin solution (0.5 µg/µL). Lys-C and Trypsin are pro-
teases with very specific digestion patterns, always cleaving after either lysine 
or after arginine and lysine, respectively. This property allows the prediction of 
resulting peptides and therefore their expected masses when the protein se-
quence is known. The proteolytic digest was aided by the addition of 100 µL ac-
etonitrile to make the proteins more ”fluffy” ([sic] Hornburg, 2015) and then in-
cubated for 4 h at room temperature. Finally, samples were desalted on C18 
Stage Tips (Rappsilber et al. 2007).  
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LC-MS/MS 
Peptide mixtures ware separated using an EasynLC 1,000 HPLC system 
(Thermo Scientific) with columns (75 µm inner diameter, 20 cm length) packed 
in-house with 1.9 µm C18 particles. Samples were loaded in buffer A (0.5 % for-
mic acid) and separated in an 85 min gradient from 2 % to 60 % buffer B (80 % 
acetonitrile, 0.5 %formic acid) with a flow rate of 250 nl/min and a column tem-
perature of 40 °C. After separation, peptides were directly ionized by a nano-
electrospray source, coupling the liquid chromatography (LC) directly to the 
mass spectrometer (MS). The mass spectrometer was a quadrupole Orbitrap  
(Q Exactive, Thermo Fisher Scientific,(Scheltema et al. 2014)) which was operated 
in data dependent mode. The survey scan range was between 300 and 1650 m/z, 
with a resolution of 60,000 at m/z 200. The 10 most abundant isotope patterns 
with a charge ≥2 were fragmented and further analyzed. Fragmentation was 
achieved by high-energy collision dissociation (normalized collision energy 25, 
isolation window 1.4 Th, resolution 15,000 at m/z 200). Repeated sequencing was 
limited by setting the dynamic exclusion of sequenced peptides to 20 s. Ion in-
jection times and ion target value thresholds were 20 ms and 3 x 106 for survey 
scans and 50 ms and 105 for MS/MS scans, respectively. Data acquisition was 
performed using Xcalibur software (Thermo Scientific).  
Data Analysis and Statistics 
MS raw files were analyzed with MaxQuant software (v 1.5.2.22) (Cox and Mann 
2008), using Andromeda (Cox et al. 2011) to search MS/MS spectra against a Uni-
Prot FASTA database of E. coli K12 proteins (UP000000625, 18.7.2015) and added 
sequences for the proteins of interest and common contaminants. Trypsin was 
used for enzyme specificity and N-terminal cleavage after proline and up to two 
miscleavages were allowed. The minimum peptide length was set to seven 
amino acids. N-terminal acetylation, methionine oxidation and deamidation of 
asparagine and glutamine were set as variable modifications, while carbami-
domethylation was set as a fixed modification. The cutoff for the false discovery 
rate (FDR) was 1 % at the peptide and at the protein level. 4.5 ppm and 20 ppm 
mass deviation was allowed for the initial precursor mass and the fragment 
mass, respectively. The cutoff score for MS/MS spectra was 17. At least one 
unique peptide was required to identify a protein and homologous proteins 
which could not be discriminated were grouped.  
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2.2.2.5 Fluorescence Measurements 
Fluorescence measurements were either performed in a Varian Cary Eclipse 
spectrophotometer or a Tecan Infinite® M200 PRO plate reader. 
For spectrophotometer measurements, 20 µL of a purified protein solution 
were added to 970 µL PBS and thoroughly mixed in a 10 mm quartz cuvette. 
Emission- and excitation spectra were recorded using slow scanning speed and 
1 nm steps. The photomultiplier voltage was adjusted to individual proteins and 
optimized so that spectral peaks fell into a window between 200 a.u. and 
600 a.u. The excitation and emission slit width was usually kept at 5 nm, and 
only increased for very low concentrated or very dim fluorescent proteins. Lig-
ands for biosensors were added in a volume of 10 µL (e.g. 100 mM cGMP for cGMP 
sensors) and thoroughly mixed. Mixing of protein solutions was found to be a 
very crucial step, which can introduce errors into subsequent measurements. 
On the one hand, concentrated protein solutions have to be thoroughly mixed 
to avoid uneven distribution; on the other hand, it was found that recombinant 
protein binds to plastic pipette tips and even glass Pasteur pipettes and is 
therefore removed with each mixing step, leading to lower fluorescence inten-
sities. To mitigate this problem, protein solutions were initially thoroughly 
mixed through pipetting with a 1 mL Eppendorf pipette. After recording of spec-
tra and addition of ligand solutions, samples were mixed through prolonged 
shaking of cuvettes containing them. Measurements were either performed at 
room temperature or in a special cuvette holder connected to a temperature 
controlled water bath, to measure at elevated temperatures (e.g. 30 °C or 37 °C).  
Plate reader fluorescence measurements were conducted in black, flat bot-
tom 96 well plates (Brandt). Typically, 4 µL of purified protein solution were di-
luted in 196 µL PBS. Gain and z-height were optimized for one well, using the 
software integrated optimization function, and applied to all wells which were 
measured. 
Spectra of FRET based biosensors were normalized to the isosbestic point. 
The FRET ratio (R) was calculated according to equation 8.4 for peak emissions. 
The dynamic range of FRET based sensors was calculated as ∆𝑅 𝑅⁄ , given by 
equation 8.5, with R0 and R1 being the FRET ratio before and after addition of the 
maximum concentration of ligand molecule, respectively.  
 
 𝑅 =
𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟[𝐸𝑚𝑚𝑎𝑥]
𝐷𝑜𝑛𝑜𝑟[𝐸𝑚𝑚𝑎𝑥]
 (8.4) 
 
 ∆𝑅 𝑅⁄ =  
(𝑅0 − 𝑅1)
𝑅1
 × 100 % (8.5) 
The dynamic range of single fluorophore sensors, on the other hand, was 
characterized by ∆𝐹 𝐹⁄ , as given by equation 8.6, F0 and F1 being the fluorescence 
Materials and Methods – Working with Proteins 
76 
at the emission maximum before and after addition of the maximum concentra-
tion of ligand molecule, respectively. 
 
 ∆𝐹 𝐹⁄ =
𝐹1 − 𝐹0
𝐹0
× 100 % (8.6) 
 
It should be noted, that  ∆𝑅 𝑅⁄  and ∆𝐹 𝐹⁄  as measures of the dynamic range of 
fluorescent biosensors, although of similar nature, are not directly comparable, 
with ∆𝑅 𝑅⁄  being a ratio of ratios, while ∆𝐹 𝐹⁄  only being a simple ratio. 
2.2.2.6 Determination of Biosensor Kd 
The apparent Kd of cGMP biosensors to cGMP and cAMP was determined 
through titration. Two solutions of equal biosensor concentration were pre-
pared, which contained either no cyclic nucleotide (cNMP0) or the maximum con-
centration of cyclic nucleotide (cNMPmax) used in the titration (1 mM cGMP, 
10 mM cAMP). 200 µL of cNMPmax solution were added to the first well in a row of 
a 96 well plate, all subsequent wells in that row were filled with 150 µL of cNMP0 
solution. A serial dilution was performed, by transferring 50 µL from each well 
to its consecutive one, thoroughly mixing after each step and discarding pipette 
tips after each transfer. The concentration series achieved through this process 
spans six orders of magnitude, and was found to be sufficient to cover all ob-
served Kds. Fluorescence spectra of each well were recorded using a fluores-
cence plate reader (Tecan). Spectra of FRET-based biosensors were normalized 
to the isosbestic point and FRET ratios were calculated for each well according 
to equation 8.4. FRET ratios were plotted against the decadic logarithm of the 
cyclic nucleotide concentration, using the graphing software Origin 8. Plotted 
values were fitted sigmoidal, using a dose-response curve with a variable Hill 
slope. The apparent Kd was equated to the EC50 of the fitted dose-response 
curve.  
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2.2.3 Working with Bacteria 
2.2.3.1 Culture and Strain Maintenance 
E. coli strains were cultivated in complex liquid and solid media, containing 
antibiotics; typically, LB with 100 µg/mL ampicillin. Single perfectly round colo-
nies on solid media were assumed to be all ancestors of a single bacterium and 
therefore genetically identical. To purify genetically mixed bacteria  
cultures, aliquots of these cultures were streaked onto selective plates using 
sterile inoculation needles, in a manner which diluted them until only single 
colonies were visible.  
Cryo-conservation of Bacteria 
To preserve strains for longer periods of time, cryo-stocks were established. 
A single colony of the strain to preserve was used to inoculate a 2 mL overnight 
culture (LB, with strain appropriate antibiotics) and incubated at 37 °C. 350 µL 
of sterile 30 % (v/v) glycerol solution were added to 850 µL of freshly grown cul-
ture (end concentration 8.75 %) in a 1.5 mL Eppendorf reaction tube and thor-
oughly mixed. Glycerol forms strong hydrogen bonds with water molecules and 
therefore interferes with the formation of ice crystals, because the water crystal 
lattice is disturbed. The cell suspension was shock frozen in  
liquid nitrogen, to further prevent ice crystals from forming, and then stored at 
 –80 °C. 
To revitalize a cryo-stock, a small portion of the stock was scratched of its 
surface with a sterile inoculation needle, without defrosting the rest of the 
stock, and used to inoculate fresh cultures.  
2.2.3.2 Monitoring Growth 
Bacterial growth was monitored photometrically, by measuring the optical 
density at 600 nm. Light is scattered on the interfaces of bacterial membranes. 
This scattering can be used, to an extent, as a measure of cell density. 
To eliminate absorption of media components, growth medium was used as a 
reference and subsequently subtracted from further measurements. 1 mL cell 
suspension was transferred into a 1 mL plastic cuvette and the OD600 nm was de-
termined. The relationship between OD and cell density was assumed to be lin-
ear, in a value range from 0.1–0.5. If observed values exceeded this range, sus-
pensions were diluted with growth medium and OD values were multiplied with 
the dilution factor.   
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2.2.3.3 Plasmid Isolation and Purification 
Plasmids were isolated using the NucleoSpin® Plasmid QuickPure kit from Ma-
cherey-Nagel for small scale isolation (“mini-prep”) and the PureYield™ Plasmid 
Midiprep System for large scale isolation (“midi-prep”) according to the instruc-
tions provided by the manufacturers. The basic principle is as  
follows: E. coli cells are first lysed through an alkaline/SDS containing buffer. 
Then chromosomal DNA and proteins are denatured and precipitated, leaving 
plasmid DNA in solution. Precipitated components are separated through  
centrifugation. Subsequently plasmid DNA is bound to silica membranes, as de-
scribed in in 2.2.1.3, washed and eluted. 
Mini-prep 
2 mL LB cultures with appropriate antibiotic were grown at 37 °C overnight 
into a dense cell suspension. Cells were pelleted through centrifugation 
(11,000 x g, 1 min, RT) in 2 mL Eppendorf reaction tubes. The supernatant was 
discarded and cell-pellets were suspended in 250 µL buffer A1. Lysis was initi-
ated by the addition of 250 µL lysis buffer A2, containing SDS and sodium  
hydroxide. Proteins and chromosomal DNA were precipitated by adding 350 µL 
A3 buffer. The lysate was clarified through centrifugation (11,000 x g, 5 min, RT) 
and the resulting supernatant was transferred to the provided silica columns. 
The solution was passed through the column with a further centrifugation step 
(11,000 x g, 1 min, RT), discarding the flow through. The silica bound plasmid DNA 
was washed, by adding 450 µL buffer AQ, containing 80 % ethanol, and centri-
fuging (11,000 x g, 3 min, RT). Plasmid DNA was then eluded from the membrane 
by applying 50 µL elution buffer AE, incubating for 1 min and centrifuging once 
more (11,000 x g, 1 min, RT). Purified plasmid DNA was frozen at 
 –20 °C for long term storage. 
Midi-prep 
200 mL LB cultures with appropriate antibiotic were grown overnight at 37 °C 
in 500 mL baffled Erlenmeyer flasks in a round shaker-incubator (220 rpm). Cells 
were harvested by centrifugation (5,000 x g, 10 min, 4 °C) and the supernatant 
was decanted. Cell pellets were resuspended in 6 mL Cell Resuspension Solution 
(CRA). To initialize lysis, 6 mL Cell Lysis Solution (CLA) were added, containing 
1 % SDS and 200 mM NaOH, carefully mixed by slowly shaking the container and 
incubated for 3 min at room temperature. The lysate was neutralized by adding 
10 mL Neutralization Solution (NSB) and mixed by shaking. This step precipi-
tated cellular proteins and chromosomal DNA. The lysate was then clarified by 
centrifugation (15,000 x g, 15 min, RT). A column stack of a PureYield™ Binding 
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Column on the bottom and a PureYield™ Clearing Column on the top was as-
sembled on a vacuum manifold. The supernatant of the centrifugation was 
transferred to the Clearing Column and vacuum was applied to the manifold 
until the solution passed both the Clearing and the Binding Column. The Clearing 
Column filtered remaining precipitate from the supernatant and passed the 
clarified lysate onto the Binding Column, where plasmid DNA was retained. After 
this step the Clearing Column was discarded. E. coli endotoxins were removed 
by washing the bound plasmid DNA by passing 5 mL Endotoxin Removal Wash, 
containing 40 % isopropanol, through the Binding Column, while applying 
 vacuum. 20 mL Column Wash, containing 60 % ethanol, were passed through 
the Binding Column by applying vacuum, to remove salts and other impurities. 
The binding membrane was dried, by applying vacuum to the Binding Column 
for 1 min. The Binding Column was then removed from the vacuum manifold. 
Excess Column Wash buffer was carefully dried off with a paper towel and the 
column was then placed on an assembled Eluator™ Vacuum Elution Device, con-
taining a 1.5 mL Eppendorf reaction tube. 600 µL of 70 °C warm Nuclease-Free 
Water were transferred onto the binding membrane inside the Binding Column 
and incubated for 2 min, to elute the plasmid DNA from the membrane. Vacuum 
was then applied to pass the DNA solution into the 1.5 mL Eppendorf reaction 
tube. Purified plasmid DNA was frozen at –20 °C for long term storage. 
2.2.3.4 Transformation of E. coli 
Plasmid DNA was introduced into E. coli via chemical transformation. Chemi-
cal transformation is based on preparing cell suspensions, which contain a high 
concentration of Ca2+ ions, the so called “competent” cells. These competent 
cells are then incubated with DNA and later exposed to elevated temperatures 
(heat shock), to promote DNA uptake. Although it is hypothesized, that the pres-
ence Ca2+ ions (1) generates pores in the bacterial membranes and  
(2) masks the charge of the DNA backbone, the exact mechanism of transfor-
mation remains still at large (Green and Sambrook 2012).  
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Production of chemically competent E. coli  
The protocol used in the context of this work is an adapted version of the one 
published by Chung et al. (1989).  
Specifically, a pre-culture was established by inoculating 10 mL LB medium 
(containing 10 µg/mL tetracycline) with cells from a cryo-stock in a 100 mL  
Erlenmeyer flask and incubating it overnight at 37 °C under constant shaking 
(220 rpm). On the next day, a 300 mL main culture (pre-warmed LB medium with-
out antibiotics, 37 °C, 1 L Erlenmeyer flask) was inoculated with the entire vol-
ume of the pre-culture. The culture was incubated under constant agitation 
(220 rpm) at 37 °C until it reached an OD600 nm of 0.5. Next, the flask with the  
culture was incubated on wet ice for 10 min. Cells were harvested by centrifuga-
tion (1,000 x g, 15 min, 4 °C) and the supernatant was discarded. Pellets were 
carefully re-suspended in 30 mL ice-cold TSS buffer and 7.5 mL ice-cold 86 % 
(v/v) glycerol were added (end concentration ~15 %). The cell suspension was 
aliquoted into 50 µL portions in 1.5 mL Eppendorf reaction tubes and shock fro-
zen in liquid nitrogen. Competent cells were stored at –80 °C. 
Transformation of chemically competent E. coli 
For transformation, an aliquot of chemically competent cells was defrosted 
on wet ice. 1 µL of DNA solution (e.g. isolated plasmids, SLiCE ligations, etc.) was 
added to the cell suspension and incubated between 5 min–45 min. The incuba-
tion period was chosen according to the needed transformation-efficiency, 
short incubation for propagation of established plasmids and longer incubation 
for complex cloning steps. Next, the cell suspension was “heat-shocked” for 42 s 
at 42 °C in a water bath. The cell suspension was then cooled for 2 min on wet 
ice. Most plasmids used in this work, contained the β-lactamase gene (bla) as a 
resistance marker and were used in combination with liquid or solid media con-
taining ampicillin as selecting agent. Ampicillin inhibits the synthesis of pepti-
doglycan and therefore prevents cell division, as no additional cell-wall can be 
made, while other cell processes remain intact (translation, protein synthesis). 
Because of this, in contrast to other antibiotics, resistance against ampicillin can 
be acquired by E. coli while already exposed to the selection agent. Thus, cells 
transformed with plasmids containing the bla cassette were either plated on 
selective agar plates or transferred into selective liquid media right away. If 
other selection markers were used, cells were transferred into 1 mL non-selec-
tive SOC medium and incubated for 1 h at 37 °C, to express the resistance-me-
diating proteins, before they were exposed to selective media. 
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2.2.3.5 Counter-selection using sacB 
Empirically, it was determined, that the main source of false positive colonies 
from SLiCE cloning (as described in 2.2.1.7) was un-cut target vector, which was 
co-purified after the linearization and carried through all subsequent steps and 
then successfully transformed E. coli cells. To minimize this background, a coun-
ter selection gene (sacB) was established in vectors, which were frequently used 
(see 3.1.2). SacB encodes the levansucrase from B. subtilis and catalyzes the hy-
drolysis of sucrose and subsequent synthesis of levans, which are high molecu-
lar weight fructose polymers (Pelicic et al. 1996). Expression of sacB in E. coli is 
lethal, if exposed to 10 % sucrose in media containing low NaCl concentrations 
(Gay et al. 1985, Blomfield et al. 1991).  
E. coli cells, which were transformed with vectors containing sacB as counter-
selection marker, were plated on YTS-agar (0.5 % (w/v) yeast extract, 1 % (w/v) 
tryptone, 10 % (w/v) D-(+)-sucrose, 1 % (w/v) agar-agar) with the appropriate an-
tibiotic to select for the presence of the newly assembled plasmid.  
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3 Results 
3.1 Vector System for Biosensor Development 
The biosensor development approach applied in this work required a lot of 
complex cloning, especially in the prototyping stage, in which different sensor 
and reporter domains were assembled and tested (see 3.3). Furthermore, pro-
totype sensors were evaluated according to their performance in vitro, in cell 
culture and in brain slices. Therefore, it was necessary to be able to quickly and 
efficiently subclone candidate sensors into vectors, which can facilitate expres-
sion in these conditions. Having to rely on the availability of restriction sites was 
often an obstacle in the past for several reasons: (1) Suitable restriction sites, 
which were used in the assembly of the FRET sensor, were not available for sub-
cloning anymore. (2) Restriction sites which were used within the coding se-
quence of a sensor were fixed sequences, which in turn were translated into 
fixed amino acids. As FRET sensors are assembled from fluorescent proteins and 
sensor domains, these fixed sequences were often located in the critical linker 
region between domains, which then were not available for linker diversifica-
tion. (3) Planning the assembly of prototype sensors from multiple parts from 
various sources, became very complex and therefore time consuming, which re-
duced the number of potential sensors that could be made and tested. (4) Sub-
cloning, while usually trivial, also became challenging because critical re-
striction sites were often already in use or appeared by chance naturally in the 
sequence. This was especially problematic in large viral vectors, as they usually 
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only have very limited multiple cloning sites for related reasons. Besides that, 
“classic” cloning can typically only facilitate direction selective insertion of one 
DNA fragment at a time efficiently, requiring multiple steps to assemble a com-
plete biosensor from multiple parts. It was therefore desirable to establish an 
efficient cloning strategy, which allows sequence independent fast assembly of 
prototype sensors and their subsequent subcloning into a variety of vectors for 
further characterization. 
Zhang et al. (2012) demonstrated a very efficient novel cloning method, which 
relies on in vitro homologous recombination and can facilitate the direction se-
lective assembly of up to seven DNA fragments into a target vector. This ap-
proach simplified sensor construction considerably and was therefore the 
method of choice to achieve the stated goals. Specifically, sensors could be as-
sembled from multiple parts in a one-step procedure in a sequence independ-
ent manner.  
  
Results – Vector System for Biosensor Development 
84 
3.1.1 Harmonization of Vectors for quick Transfer 
SLiCE cloning relies on in vitro recombination of 15–50 bp homologous regions 
at the ends of linear DNA (Zhang et al. 2012). This process is independent of the 
sequence itself, as long as consecutive DNA fragments exhibit the same se-
quence in the overlaps. In order to quickly subclone potential sensor candidates 
it was useful to generate a series of vectors which share the same homologous 
regions. Sensor constructs then could simply be amplified by priming form the 
constant homologous region, using standard primers and PCR conditions, gen-
erating the homologous regions required for subcloning in the process (see Fig-
ure 3.1 C). This step could be parallelized easily, as PCRs were standardized in-
dependent of the actual architecture of the sensor. This approach also had the 
advantage, that primers, which introduced vector-facing homologous ends, 
could be reused, as fluorescent proteins often share N-and C-terminal ends. 
This made it possible to turn sensor assembly into a modular system with reus-
able parts, enabling combinatorial cloning and quick exchange of individual 
components. 
Three different vectors for very specific tasks were designed: (1) a small bac-
terial expression vector for cloning and recombinant expression in E. coli, (2) an 
eukaryotic expression vector for the transfection of cultured cells and (3) a large 
viral vector for transduction of brain slices. These three vectors were con-
structed based on pRSET B (Invitrogen), pcDNA3 (Invitrogen) and pSinRep5 (Invi-
trogen) respectively. The resulting harmonized vectors were named pRSET SL, 
pcDNA3 SL and pSinRep5 SL (SL stands for SLiCE). Since homologous regions 
would be shared in all three of those vectors, these sequences had to be de-
signed very carefully to fulfill multiple tasks in different backgrounds. pRSET B, 
a small pUC based expression vector for E. coli, encodes a 34 amino acid N-ter-
minal fusion tag upstream of the multiple cloning site (MCS). This fusion tag 
contains the 6 x Histidine sequence for protein purification, a transcript stabi-
lizing sequence from gene 10 of the T7 phage, the Xpress™ epitope and an en-
terokinase recognition site, to enable the removal of this peptide from ex-
pressed protein. Since translation starts at the N-terminal fusion tag, no start 
codon is required when transferring genes of interest into the MCS of pRSET B. 
In pcDNA3 and pSinRep5 on the other hand, no such leader peptides are present 
and translation starts from the start codon provided by the gene of interest. 
Therefore, the upstream homologous region for the vector system was designed 
in such a way, that it could encode the leader peptide of pRSET B and also pro-
vide a valid translation start. Figure 3.1 A depicts both the up- and downstream 
homologous region of pRSET SL and pcDNA3 SL. The upstream homologous re-
gion partially encoded the pRSET leader peptide, which was only expressed in 
pRSET SL. Furthermore, it contained the Kozak-consensus sequence and a start 
codon, which served as a translation start in pcDNA3 SL and pSinRep5 SL; in 
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pRSET SL this sequence was translated into Ala-Thr-Met and part of the N-ter-
minal fusion peptide. The 33 bp downstream homologous  
region was adapted from the downstream region of pcDNA3 and contained all 
three possible stop codons, providing translation termination for various organ-
isms. To be able to linearize these vectors efficiently, an EcoRV restriction site 
was placed between the homologous regions in pRSET SL and pcDNA3 SL. The 
6 bp recognition site was omitted during the SLiCE reaction and not integrated 
into resulting constructs. EcoRV was chosen, because it leaves “blunt” ends, re-
ducing the possibility of hybridization of overhangs after the restriction digest. 
Furthermore, the restriction sites BamHI and EcoRI were retained, to allow com-
patibility with restriction cloning. 
 
Figure 3.1 Harmonized vector system for biosensor development 
A) Sequence of the homologous regions in pRSET SL and pcDNA3 SL B) SLiCE cloning with vector 
system: pRSET SL is linearized with EcoRV, PCR introduces overhangs in sensor fragments, one-
step assembly in SLiCE reaction C) Subcloning of sensor prototypes into pcDNA3 SL and 
pSinRep5 SL with SLiCE reaction  
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The vectors pRSET SL and pcDNA3 SL were generated by amplifying pSRSET B 
and pcDNA3 with 5’ phosphorylated primers containing the 5’ overhangs, which 
introduced the synthetic sequence of the homologous regions (primer 3 and 4 
for pRSET B and primer 5 and 6 pcDNA3, see Table 2-2). The resulting PCR prod-
ucts were circularized by ligation and sequence identity was confirmed by 
Sanger sequencing (sequence of pRSET SL under 6.1.1 and pcDNA3 SL under 
6.1.4).  
In the viral vector pSinRep5 SL, the homologous regions were shortened to 
21 bp on either side, to minimize the impact of these foreign sequences on viral 
expression. Besides that, EcoRV was replaced with SwaI, as two EcoRV recogni-
tion sites were already present in this vector. To generate pSinRep5 SL, the 
counter selection cassette of pRSET SL II (see 3.1.2) was amplified with  
primers 7 and 8 (See Table 2-2) and inserted via SLiCE cloning into SphI linear-
ized pSinRep5, omitting its MCS. The resulting plasmid was sequenced to con-
firm successful integration (for sequence of pSinRep5 SL see 6.1.6).  
These three vectors and their iterations were very successfully applied 
throughout this work and proofed to be very reliable tools. In brief, a typical 
usage scenario was as follows (See Figure 3.1 B): pRSET SL was produced in large 
quantities in E. coli, isolated through “midi-prep”, then linearized with EcoRV 
and purified. The linearized vector was produced in large batches and stored 
until needed. For sensor prototyping, two fluorescent proteins and a sensor do-
main were amplified from template, introducing homologous ends via 5’ over-
hangs on primers. PCR products were purified and subsequently  
assembled with the linearized vector in a SLiCE reaction and transformed in 
E. coli. To confirm successful assembly, colony PCR was performed with primers 
1 and 2 (see Table 2-2) and positive clones were inoculated for small scale plas-
mid purification. Isolated plasmids were then partially sequenced to demon-
strate correct assembly. This protocol could be easily parallelized and per-
formed for several dozen different sensor constructs at the same time.  
Typically, this procedure took only 2.5 days from amplification of sensor frag-
ment to fully assembled plasmid, enabling many rounds of prototyping in rela-
tively short time spans. Following successful cloning, sensor prototypes were 
expressed in E. coli and characterized in vitro.  
Subcloning followed a similar strategy (see Figure 3.1 C). Characterized sen-
sors were amplified from pRSET SL using primers 9 and 10, then assembled in a 
SLiCE reaction with linearized vector pcDNA3 SL or pSinRep5 SL and subse-
quently confirmed via colony PCR and sequencing.  
  
Results – Vector System for Biosensor Development 
87 
 
3.1.2 Counter Selection 
While the in 3.1.1 described vector system was very efficient in combination 
with SLiCE cloning, occasionally there was a considerable amount of false posi-
tive colonies. It was observed, that most false positive colonies harbored empty 
vector. Furthermore, the number of these “background” colonies increased 
when linearized vector was used, which was produced in large scale midi-preps. 
Therefore, it was suspected, that this background was the result of incompletely 
digested plasmid DNA, which was retained throughout the purification process. 
In support of this, there was no difference in length between the digested and 
undigested vectors and thus gel separation could be ineffective. To overcome 
this problem and reduce the number of false positive colonies, which had to be 
tested after cloning, a two layered strategy was employed to eliminate false 
positive colonies transformed by un-cut vector DNA.  
Scholz et al. (2013) demonstrated a counter selection strategy for removing 
background from parental vector DNA, by constitutively expressing the toxic 
ccdB gene from the same plasmid. A similar strategy was utilized to eliminate 
background from un-cut vector. Instead of ccdB, the sacB gene of bacillus sub-
tilis was chosen as a counter selection gene. SacB encodes a levansucrase which 
catalyzes the hydrolysis of sucrose and subsequent synthesis of levans, high 
molecular weight fructose polymers (Pelicic et al. 1996). Expression of sacB in 
E. coli is lethal if exposed to 10 % sucrose in media containing low NaCl concen-
trations (Gay et al. 1985, Blomfield et al. 1991). This had the advantage of a con-
ditional counter selection, meaning plasmids encoding sacB could be propa-
gated normally under standard conditions and only became lethal in sucrose 
containing media. SacB was constitutively expressed under the control of the 
lppp-5 promoter and placed between the up- and downstream homologous re-
gions of the vectors described above (Figure 3.2). The lppp-5 promoter is an op-
timized version of the promoter of the E. coli outer membrane lipoprotein 
(OmpA), a very strong constitutive promoter (Inouye and Inouye 1985).  
 
Figure 3.2 Counter selection with sacB in pRSET SL II 
Incomplete linearization of pRSET SL II with EcoRV leads to 3 distinct gel bands, which could be 
selectively isolated through gel purification  
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The counter selection gene was flanked by two EcoRV (SwaI for pSinRep5)  
restriction sites. Digestion with EcoRV linearized the vectors much like their ear-
lier iterations, removing the fragment encoding sacB in the process. The result-
ing vector fragments were identical to linearized vectors described in 3.1.1. 
This enabled the reduction of background on two levels: During gel purifica-
tion, completely digested vector DNA displayed a clear gel shift towards undi-
gested or partially digested vector and could therefore be effectively isolated 
from these species (See Figure 3.2). Furthermore, the background was reduced 
by plating transformed E. coli on YTS agar, containing 10 % (w/v) sucrose, after 
SLiCE reactions. Bacteria which were transformed with un-cut plasmid DNA, 
which was carried through purification steps, were then unable to produce col-
onies.  
This counter section strategy was developed in close collaboration with  
Tobias Kruse, who kindly provided the plasmid, encoding sacB. The counter se-
lection cassette was amplified with primers 11 and 12 (See Table 2-2),  
purified and then assembled in a SLiCE reaction with linearized pRSET SL and 
pcDNA3 SL vectors, resulting in the plasmids pRSET SL II (see 6.1.2 for sequence) 
and pcDNA3 SL II (see 6.1.5 for sequence). To assess the effectivity of the counter 
section 270 ng of undigested pRSET SL II plasmid were transformed into E. coli 
XL1 Blue and plated either on selective LB agar plates or selective YTS agar 
plates. After overnight incubation at 37 °C LB agar plates displayed dense bac-
terial lawns, while YTS plates were empty. While these were relative extreme 
conditions, with very high concentrations of undigested vector, it demonstrated 
that this counter selection strategy is very effective even under adverse condi-
tions.  
The strategy of using SLiCE with harmonized vectors and sacB counter selec-
tion proofed to be very reliable and was used extensively throughout this work. 
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3.1.3 Improvement of His-tag Purification  
During biosensor development prototype sensors were purified via metal ion 
affinity chromatography, in order to assess their biophysical properties. Sensor 
candidates were assembled in pRSET SL II, which introduced a 6 x His-tag at the 
N-terminus, mediating affinity towards immobilized nickel ions on agarose 
beads. The purification protocol had to fulfill two very important criteria: the 
procedure had to be as simple as possible in order to allow high throughput 
processing; and the purity of protein preparations had to be sufficient, to allow 
biophysical characterization assays. The purification was performed using 
Nickel-IDA Agarose bead suspensions (Jena Bioscience) in combination with 
gravity flow columns (Qiagen), closely following the guidelines provided by the 
manufacturers.  
In order to assess the performance of this purification procedure, mKOK, an 
orange fluorescent protein (Tsutsui et al. 2008), was cloned into pRSET SL II in a 
SLiCE reaction, using primers 15 and 16 to amplify the insert from template, and 
purified as described in 2.2.2.2. Then, the identity and quantity of proteins within 
the preparation was determined via a mass spectrometry based quantitative 
shotgun proteomics approach. Mass spectrometry and analysis of proteomics 
data were performed in close collaboration with Daniel Hornburg from the De-
partment of Proteomics and Signal Transduction at the Max Planck Institute for 
Biochemistry. Figure 3.3 displays the composition of a standard purification of 
mKOK, as determined by mass spectrometry.  
 
Figure 3.3 Composition of His-tag purified protein preparations of mKOK 
yfbG – E. coli formyl transferase 
crp – E. coli cAMP receptor protein 
hfq – E. coli host factor-I, RNA-binding protein, phage Qβ replication 
rpsO – E. coli regulatory ribosomal protein 
fur – E. coli ferric uptake regulator 
glmS – E. coli Glucosamine-6-phosphat synthase 
adhP – E. coli alcohol dehydrogenase, propanol-preferring  
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In total, 429 individual proteins were identified in the sample. Due to the loga-
rithmic abundance distribution, only the eight most abundant proteins ac-
counted for more than 1 % of the total protein amount. Critically, the target pro-
tein mKOK constituted only 46 % of the sample. 
The seven main co-purified proteins (yfbG, crp, hfq, rspO, fur, glmS and adhP) 
together accounted for 43 % and the remaining 421 identified proteins for 11 %. 
All seven main co-purified proteins were identified as E. coli proteins, which are 
common byproducts in metal ion chromatography of recombinantly expressed 
His-tagged proteins (Bolanos-Garcia and Davies 2006). 
These proteins were enriched through the purification procedure, because 
they display surface clusters of histidine residues, competing with His-tagged 
proteins for nickel binding sites (Bolanos-Garcia and Davies 2006). While  
purity of fluorescent biosensors in purified protein preparation is important for 
the determination of the extinction coefficient (Tsien 1998), it was in general not 
considered to be a major concern for the determination other biophysical and 
photo-physical characteristics, as these sensors will be used in a cellular envi-
ronment in the presence of thousands of other proteins, and therefore have to 
function regardless. However, the presence of the cAMP receptor protein of 
E. coli (crp) was identified as potential problem specifically for the development 
of biosensor for cGMP. Crp is a transcription regulator protein within E. coli, 
which is activated by cAMP binding (Busby and Ebright 1999). Because of its nat-
ural affinity to cAMP and its relative high abundance (~9 %) as a contaminant in 
purified protein samples, we concluded, that the presence of crp might interfere 
with determination of cAMP and cGMP binding constants and therefore should 
be ideally eliminated from samples. The structure of crp (Passner and Steitz 
1997) revealed a N-terminal motive containing four histidine residues in close 
proximity, mimicking a His-tag, which is most likely the reason for its binding to 
metal ions. While these contaminants could be removed through other addi-
tional chromatographic separations like gel filtration, keeping sample prepara-
tion as streamlined as possible was highly prioritized. Therefore, the goal was 
set to adjust the parameters of the standard protocol for metal ion chromatog-
raphy in order to remove crp as a contaminant and increase the overall purity 
of target protein.  
In essence, in metal ion chromatography, histidine residues of His-tagged 
proteins bind non-covalently to immobilized nickel ions (Green and Sambrook 
2012). Contaminant proteins, which naturally contain exposed histidine clusters, 
compete with recombinant protein for these binding sites (Bolanos-Garcia and 
Davies 2006). Imidazole, essentially the isolated side chain of histidine, is used 
to displace bound protein from these binding sites, to elute it from the column 
material. It was hypothesized, that there is a delicate equilibrium, between (1) 
the available binding sites in the nickel resin, (2) the affinity of His-tagged re-
combinant proteins, (3) the affinity of histidine rich contaminant proteins and 
(4) the concentration of imidazole in binding buffers, which could be shifted in 
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favor of the binding of recombinant protein. Three strategies were considered 
to shift this equilibrium. First, the binding affinity of His-tagged proteins could 
be increased by lengthening the His-tag, providing more potential binding sites 
for nickel. Second, increasing the concentration of imidazole in the binding 
buffer could displace contaminants with lower metal ion affinity, therefore re-
ducing their binding to the resin. Lastly, if more binding sites than recombinant 
proteins are available, remaining binding sites will be filled by contaminant pro-
teins, therefore column material has to be loaded in excess of His-tagged pro-
tein. Since recombinant protein was finite from a given culture volume, protein 
excess could be achieved by reducing the amount of column material instead of 
increasing the amount of protein. 
In order to increase the affinity to nickel resin of recombinant protein, the 
6 x His-tag of pRSET SL II was lengthened to ten histidine residues. The vector 
pRSET SL II was amplified with the primers 13 and 14, introducing a 10 x His-tag 
and a 20 bp region at one end of the linear product, which was homologous to 
the other end. The PCR product was circularized in a SLiCE reaction and se-
quence identity was confirmed by Sanger sequencing with primers 1 and 2. The 
resulting vector was named pRSET SL III (annotated sequence under 6.1.3). The 
orange fluorescent protein mKOK was inserted into this new vector via SLiCE 
cloning, using primers 15 and 16 to amplify the insert from template. To  
compare binding affinity between 6 x His-tagged and 10 x His-tagged protein, 
mKOK with both tags was expressed in E. coli and isolated as described in 2.2.2.2, 
using resuspension buffer with 20 mM imidazole. Clarified lysate was incubated 
with 300 µL Nickel-IDA Agarose slurry bead resin and then loaded onto gravity 
flow columns. Proteins were eluted from the column material using a step  
gradient with increasing concentrations of imidazole (1 mL per step) and eluates 
were fractionated. The concentration of fluorescent protein of each fraction was 
determined as measured by total fluorescence of the sample, calibrated against 
a standard curve. Figure 3.4 A depicts the amount of eluted protein after each 
step as a percentage of the total eluted protein. These results showed clearly, 
that the affinity of 10 x His-tagged mKOK towards the nickel was greatly in-
creased compared with 6 x His-tagged mKOK. While 50 % of the protein with the 
6 x His-tag had eluted already at 66 mM imidazole, the 10 x His-tagged protein 
reached 50 % elution at around 130 mM imidazole. Therefore, not only the affin-
ity towards the raisin was increased, but also relatively high concentrations of 
imidazole could be used in the binding and wash buffer, as only a small fraction 
of 10 x His-tagged protein eluted at elevated concentrations, making more strin-
gent washing conditions possible.  
Next, the volume of column material was evaluated, to estimate at which point 
binding sites were saturated with recombinant protein. To that end, 10 x His-
tagged mKOK was expressed in a 600 mL culture, yielding 60 mL  
clarified bacterial lysate. The Imidazole concentrations in the binding and wash 
buffer were elevated to 40 mM.  
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Figure 3.4 Optimization of binding conditions for His-tagged proteins 
A) Relative concentration of eluted 6 x His and 10 x His-tagged mKOK in imidazole step gradient 
fractions B) Relative yield of 10 x His-tagged mKOK as a function of bead suspension volume 
Six aliquots of 10 mL clarified lysate were incubated with decreasing volume 
of Nickel-IDA agarose bead suspension (300 µL, 150 µL, 75 µL, 37.5 µL, 18.75 µL, 
9.375 µL), loaded onto gravity flow columns and subsequently washed with 
10 mL wash buffer. Proteins were eluted with 1 mL Protein Elution Buffer and the 
concentration of fluorescent protein was determined, as measured by total flu-
orescence. Protein yields were set in relation to the bead volume, as seen in 
Figure 3.4 B. This experiment clearly demonstrated that binding sites in the col-
umn material were not saturated using 300 µL material, leaving room for con-
taminant proteins to bind. In fact, the total protein yield using 300 µL and 150 µL 
bead volume, showed no difference. Maximum yield per volume of beads was 
only reached at 75 µL under these conditions. Reducing the column material vol-
ume below 75 µL, reduced the yield again, possibly because with such small 
bead volumes losses due to retention on container walls are getting more sig-
nificant.  
These preliminary results outlined the parameter space, in which the protocol 
for purification of 10 x His-tagged proteins could be optimized. Specifically, the 
concentration of imidazole was considered in a range between 20 mM and 
90 mM and the volume of Nickel-IDA agarose beads in a range between 20 µL 
and 150 µL.  
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Classical “one factor at a time” optimizations have the disadvantage that non-
linear dependencies of variables cannot be discovered and usually many indi-
vidual experiments have to be performed in order to find optimal conditions 
(Hibbert 2012). Because biological experiments are often very complex and re-
quire multi parameter optimization, the Design of Experiments (DoE) approach 
recently gained traction in the life science community (Hibbert 2012). DoE is a 
statistical method in which multiple parameters are varied at a time and then 
empirically modelled by linear, higher order functions and multiplicities in or-
der to discover dependencies between variables. To optimize the protocol for 
10 x His purification, DoE was employed, using the software tool MODDE 10 
(Umetrics). Two parameters were optimized: imidazole concentration in Protein 
Resuspension Buffer (used for binding and washing) and volume of Nickel-IDA 
agarose column material, using protein purity, as measured by mass spectrom-
etry, and yield, as estimated by total fluoresce, as performance read outs. For 
optimization, a central composite design for response surface modelling (RSM) 
was chosen. The range for each of the two factors were: 20 mM–90 mM, with a 
center point of 55 mM, for the imidazole concentration and 20 µL–150 µL, with a 
center point of 95 µL, for the volume of Nickle-IDA agarose bead suspension. In 
total 11 experiments were performed, combining minimum and maximum levels 
of each factor and a triplicate of the center point for estimation of robustness. 
Figure 3.5 A depicts the response surface of the DoE model with respect to purity. 
The optimum in this model was between 55 mM and 80 mM imidazole and be-
tween 80 µL and 150 µL bead suspension, displaying a purity > 99 %. When the 
yield was taken into account, the optimum range shrank considerably, as can be 
seen in Figure 3.5 B.  
 
Figure 3.5 DoE results for 10 x His-tag purification protocol 
A) Surface plot imidazole vs. Nickle-IDA bead volume with respect to protein purity. B) Sweet 
spot analysis: surface plots imidazole vs. Nickle-IDA bead volume for protein purity (yellow) 
and protein yield (red), 2 dimensional projections onto the base plane include conditions with 
purity > 0.99 and yield > 400 a.u. (green intersection) 
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From this analysis the optimal conditions were determined to be 55 mM  
imidazole concentration and 120 µL Nickel-IDA agarose bead suspension. Addi-
tionally, when looking more closely into the data of the individual experiments 
it became apparent that, even though depleted by a factor of ~300 compared to 
the standard 6 x His-tag purification, the cAMP receptor protein was still present 
within samples with low imidazole concentrations (20 mM). In samples with im-
idazole > 20 mM crp was not detected, underlining the validity of the assump-
tions initially made.  
In conclusion, it can be said, that the purification protocol was improved very 
successfully, with adjustments of critical parameters and the switch to an elon-
gated His-tag. Biosensors now could be purified with purities >99 %, while keep-
ing the purification procedure simple and therefore more useful for high 
throughput applications. Furthermore, the most critical contamination for the 
development of biosensors detecting cyclic nucleotides was completely  
removed, accomplishing another important goal of this project. While these re-
sults were very encouraging, it needs pointing out, that the equilibrium  
between the individual compounds (His-tagged recombinant proteins, histidine 
rich contaminant proteins, imidazole and binding sites in Nickel-IDA  
agarose beads) is fragile and high expression yields of recombinant proteins are 
needed to push the it into the right direction.  
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3.2 Automated Set-up for Biosensor Screening 
To refine biosensors it is often necessary to employ directed evolution and 
large scale screening techniques. These methods introduce variation into a 
given prototype sensor construct through mutagenesis, to create large libraries 
of different sensor variants. These libraries are then screened for improvements 
in performance and promising candidate variants are selected and further char-
acterized. We recently demonstrated a technique for screening large libraries of 
biosensors in E. coli(Litzlbauer et al. 2015) colonies (Litzlbauer et al. 2015). In 
brief, biosensors were diversified through various PCR based methods in vitro 
(error prone PCR, introduction of degenerated linkers), cloned into expression 
vectors and transformed into competent E. coli, which are streaked onto selec-
tive agar plates. Each colony represented one variant, with each plate contain-
ing between 800–1,000 colonies. These colonies were then transferred to blot-
ting paper and imaged with a custom-build wide field fluorescence imaging set-
up, to assess performance of individual sensors. This assessment was carried 
out by monitoring the read-out variable of the biosensor (FRET ratio, fluores-
cence intensity) over time, while first applying permeation agents and then the 
analyte of interest with the help of a spray gun. Changes in the read-out variable 
were recorded and analyzed by custom software tools. The best performing var-
iants were highlighted on a picture of the particular plate and later hand-picked 
for further characterization. This procedure enables high throughput screening 
of thousands of sensor variants. However, the main bottleneck of this method 
is the requirement for hand-picking colonies. This labor-intensive step limits 
the number of variants that can be analyzed and also potentially introduces er-
rors, as extended periods of colony picking represent a challenge to body and 
mind.  
While systems for automated colony picking are available for industrial appli-
cations, the selection criterion is the color of a colony (e.g. blue/white screen-
ing). These systems are not suited for fluorescence applications and would have 
to be retrofitted for this purpose. Adding to that, as these appliances are scaled 
for industrial purposes, they are relatively expensive. Therefore, the aim was to 
eliminate the bottleneck in the screening procedure, by building a low cost, in-
tegrated automated screening system, which provides online imaging, analysis 
and colony picking. This would increase throughput for directed evolution ap-
plications, while reducing human error. Furthermore, a focus was put on improv-
ing data quality, by enhancing wide field fluorescence imaging capability of this 
set-up.  
This project was undertaken in a collaborative effort with David NG, who wrote 
the software controlling the imaging set-up.  
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3.2.1 Mechanical components 
3.2.1.1 3D Manipulator 
The colony picking unit of the integrated screening system had to fulfill the 
following criteria: (1) it had to be fast, to allow high throughput applications, (2) 
it had to be very precise and accurate in order to be able to successfully pick 
individual colonies, and (3) it had to be flexible to allow for different configura-
tions (e.g. inoculating liquid media or re-plating on solid media). With these cri-
teria in mind, the choice for the 3D manipulator fell on a delta robot design. The 
delta robot is a type of parallel robot and was first envisioned by Clavel (1988) 
for pick and place applications. It has three degrees of freedom in translation 
and allows for fast movement (Merlet 2006). Recently, delta robot designs have 
become very popular in the 3D printing community for the use in fused deposi-
tion modeling printers (FDM). Because FDM printers have similar requirements 
as the envisioned picking system (3D manipulator with high resolution, precision 
and speed), its design was adapted from an existing open source 3D printer de-
sign. Specifically, a 3D printer developed by Johann Rocholl in 2012, the “Ros-
tock”, was used as the base for a colony picking system. 
The colony picking system consisted of a triangular platform, harboring the 
pick head, which was held in place by three pairs of parallel arms made of car-
bon fiber tubes. The parallel arms in turn were mounted to three carriages, 
which were seated on vertical linear motion systems. The arms were connected 
with the platform and the carriages via custom build, magnetic, universal ball-
joints, to ensure smooth motion in all directions with minimum tolerances. The 
linear motion systems, consisted of three pairs of 600 mm hardened steel rods 
fitted with linear bearings. They were positioned at 120° intervals on the edge 
of a circle with a radius of 210 mm, encompassing a cylindrical volume. The car-
riages seated with linear bearings on these rails were driven vertically by geared 
belts through the action of three NEMA 17 stepper motors mounted at the base 
of each individual column. Because of the fixed length of the arms and their 
parallel configuration, vertical movement of the three carriages could be con-
verted into 3 degrees of translation movement of the platform harboring the 
pick head. This manipulator set-up allowed three-dimensional movement of the 
pick head within a cylindrical volume with a radius of 210 mm and a height of 
200 mm, with a resolution of 0.05 mm in X/Y/Z.  
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Figure 3.6 Automated screening set-up 
1) camera, 2) zoom lens 3) filter wheel 4) illumination LED in tube 5) bottom illumination LED 
array 6) carriage 7) NEMA 17 stepper motor 8) gear belt 9) linear rail system 10) magnetic ball 
joints 11) parallel arms from carbon fiber rods 12) pick head 13) electro magnet 14) steel rod 15) 
sphere testing electrode 16) deep multi-well plate for inoculation 17) 96 well plate harboring 
steel spheres 18) agar plate 19) controller board 20) housing of MDF 
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3.2.1.2 Pick Head 
For the pick head several important aspects had to be addressed. In order to 
avoid cross-contamination, tips had to be sterilized in between colonies in a 
fast manner. Colonies had to be picked from agar plates with varying heights 
and from blotting paper, rendering hard coding of height coordinates useless. 
Furthermore, it was desirable to be able to inoculate small liquid cultures in 
deep multi-well plates and to re-streak clones onto selective agar plates. 
In order to address these issues, we designed a special pick head. Usually 
picking tips are sterilized either by heat or by dipping them into sterilization 
solutions. This procedure is speed limiting and would cause build-up of residues 
over time. Therefore, we opted for a replaceable tip, which is brought into con-
tact with the bacterial colony, used for inoculation and then discarded. As a re-
placeable tips 2 mm steel spheres were used, which were placed individually in 
96 well plates with V-bottom. The pick head itself consisted of a steel rod resting 
inside a copper coil. When put under load the coil induced a magnetic field in-
side the steel rod, lifting it vertically by around 5 mm (see Figure 3.7). The mag-
netized rod then was used to lift the steel spheres and transport them inside 
the volume of the 3D manipulator. When the electro magnet was turned off, the 
rod would drop into its initial position, ejecting the steel sphere downward in 
the process. This simple system allowed to quickly picking-up sterilized steel 
spheres from a 96 well plate, dipping them into a colony and then transferring 
the sphere into a deep well plate, inoculating liquid medium. For each colony, a 
fresh sterilized steel sphere was used, avoiding cross contamination.  
Because of the varying heights of surfaces which were picked from, a  
responsive system was built to detect when the steel sphere touched the sur-
face harboring colonies. For detection, an electrode was connected to either the 
agar plate or to a movable steel stage on which the blotting paper was placed. 
The other side of the detection circuit was connected to the steel rod. For pick-
ing, a steel sphere was picked up and then continuously lowered  
towards the agar plate. As soon as the sphere touched the agar plate, the circuit 
was closed, triggering the halt of the pick head. This system was also used to 
detect, if a steel sphere had been successfully picked up. This was achieved by 
first picking up a steel sphere and then lowering it over a test-electrode with a 
fixed height. The detection circuit could only be triggered if a sphere was pre-
sent, if no sphere was detected, the pick head would return and try to pick up 
another sphere. To prevent the steel rod from triggering the detection circuit, 
its end was isolated using a silicone sleeve. 
The standard picking routine was as follows: A fresh sphere was picked up by 
the pick head and then transferred to the testing electrode, to test whether a 
sphere was present. If no sphere was detected the head was sent to pick up 
another sphere Successful sphere detection would cause the pick head to move 
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above the selected colony. Then the head was lowered until the detection circuit 
was triggered, bringing the sphere in contact with bacterial material. The head 
was then lifted, and moved above well of a 24-deep well plate filled with selec-
tive liquid medium. For inoculation, the electromagnet was turned off, deposit-
ing the sphere into the well. If colonies were re-plated, the head was moved 
above a selective agar plate and lowered until the detection circuit was trig-
gered. Then the head moved in a square pattern to streak out the bacteria. These 
squares were placed into a two-dimensional grid, to allow easy identification. 
After plating, the steel sphere was moved over a beaker glass filled with sterili-
zation solution and discarded.  
 
 
Figure 3.7 Pick head function 
A) pick head with disengaged electromagnet; 1) steel sphere 2) steel rod 3) isolation 4) electro-
magnet B) pick head with engaged electromagnet  
  
Results – Automated Set-up for Biosensor Screening 
100 
3.2.2 Imaging Set-up 
3.2.2.1 Illumination 
An important factor for biosensor assessment was the frequency of pictures 
that could be taken within a given time span. To reduce exposure time very 
bright single-color LEDs (Luxeon® Rebel, Phillips) were used as a light source. 
Another advantage of using LEDs was that they could be switched rapidly, fur-
ther reducing time between pictures. LEDs were fitted with culminating lens as-
semblies and placed at the end of a 100 mm steel tubes. To reduce the emission 
bandwidth, 25 mm bandpass filters were fitted into the other end of the steel 
tubes and held in place by set-screws. The tubes were then fixed to the roof of 
the screening set-up and pointed towards the plate area. This assembly focused 
a homogenous light beam towards the plate area, while reducing scattering into 
other directions. In total, six light sources using different LEDS  
(royal blue, blue, cyan, green, amber and red) were installed in this manner, 
spanning the visible spectrum. Their emission spectrum could be adjusted by 
using different bandpass filters.  
To increase the flexibility of the automated screening set-up it would be of 
use to be able to detect non-fluorescent colonies on agar plates. To achieve 
that, the plate area was fitted with a translucent, opaque bottom with a white 
LED array underneath. With this bottom illumination, colonies could be identi-
fied as dark silhouettes against a white background. 
The complete screening set-up was housed in a 50 cm x 50 cm x 60 cm box 
made from medium density fiber plates, to exclude ambient light.  
 
 
Figure 3.8 LED illumination system 
1) bandpass filter 2) LED with culminating lens assembly 3) steel tube 4) holder 
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3.2.2.2 Filter and Camera  
For imaging a CoolSNAP–HQ (Visitron Systems) CCD camera was used. In order 
to capture as much light as possible and to maximize the plate area on the cam-
era sensor, the camera was fitted with a 50 mm manual zoom lens. This non-
standard arrangement required a custom built filter wheel, which was placed in 
front of the zoom lens. The filter wheel contained seven 50 mm bandpass filters 
and was housed in a hexagonal box made from black acrylic. The wheel was 
turned by a NEMA 17 stepper motor and fitted with a 5 mm cube neodymium 
magnet. This magnet could be detected by a Hall-effect sensor in the housing 
and served as fixed homing point for the filter wheel.  
3.2.3 Controls and Software 
All mechanical components of the screening set-up (3D manipulator, pick 
head, filter wheel) and the LEDS were controlled by a Sanguinololu 1.3b micro-
controller board. This controller board is Arduino based and was the developed 
by 3D printing community for the use in 3D printers and CNC machines. The firm-
ware used, was Marlin 1.0.0.0. The board was connected via USB to the screening 
computer and operated through G-Code, a low-level programming language for 
machine tools. The Sanguinololu was fitted with 4 Polulu stepper driver boards, 
to control the four NEMA 17 stepper motors (three for the 3D manipulator, one 
for the filter wheel). The LEDs and the plate detection circuit were controlled 
using digital pins, provided by the board. The board was powered using a 15 V 
power supply. 
On the software side, the screening set-up was controlled by a python pro-
gram. This program provided high level functions (e.g. pick next colony, take 
picture etc.) and translated these functions into G-Code to communicate with 
the microcontroller board. The camera was controlled through the python API 
of µManager and also integrated into high level functions.  
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3.3 Novel genetically encoded Sensors for cGMP 
From the existing genetically encoded biosensors for cGMP (see 1.3.3.1), cGi500 
(Russwurm et al. 2007) was chosen as a starting point for the development of 
improved cGMP sensors. cGi500 was seen as the most promising candidate for 
several reasons: (1) it displayed a comparatively high dynamic range, (2) the sys-
tematic approach the authors took in establishing the sensor  
presented a solid knowledge foundation, (3) recently detailed structural  
insights into the function of the cGKI based binding domains became available 
(Kim et al. 2011, Huang et al. 2014, Huang et al. 2014) thanks to the continued 
efforts of the group of Choel Kim, and (4) the mechanism of decreasing FRET 
with cGMP binding was seen as favorable for the development of FRET based 
single emission sensors. 
CGi500 was assembled de novo, based on the detailed description provided 
by Russwurm et al. (2007) and used as a reference construct. To that end CFP 
W1B and YFP 10C (Tsien 1998) were amplified using primers 17/18 and 19/20, re-
spectively. The cGKI binding domain was de novo synthesized as a linear  
GeneArt™ String (Thermo Scientific) based on the bovine cGKI protein sequence 
(GenBank® accession X16086.1) and optimized for E. coli expression, using the 
algorithm provided by the GenerArt™ web interface. Linear fragments were as-
sembled in pRSET SL II (and later transferred to pRSET SL III) via SLiCE reaction 
and confirmed with Sanger sequencing. 
Contrary to the results published by (Russwurm et al. 2007) the dynamic range 
of this sensor was measured as 29.6 % (77 % in the original publication), when 
expressed and purified from E. coli. This discrepancy could have been caused by 
the N-terminal fusion purification tag in pRSET SL II. However, results obtained 
from transferring cGi500 into the mammalian expression vector pcDNA3 SL II, 
omitting the purification tag, and expressing the sensor in HEK 293 were in good 
agreement with the results from purified proteins from E. coli. Although not ex-
plicitly stated in the original publication, it was assumed that this dynamic range 
was based on measurements corrected for bleed through and cross excitation, 
which increases the nominal values. For the purpose of this work, bleed through 
and cross excitation were not taken into account and only uncorrected values 
are given, as corrected spectra are calculated from several error-prone meas-
urements, introducing additional noise into the system while not adding imme-
diately useful information. Despite this discrepancy, cGi500 in pRSET SL II was 
used as a reference construct, to compare new sensor variants to. 
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3.3.1 Improvement of Brightness of cGKI based FRET Sensors 
The brightness of a fluorescent protein, as given by the product of quantum 
yield and extinction coefficient (𝛷 ∗ 𝜀), is an important intrinsic property. As de-
scribed in 1.1.2 both the quantum yield of the donor fluorophore and extinction 
coefficient of the acceptor fluorophore impact the Förster radius R0 and there-
fore directly influence the performance of a FRET sensor. Furthermore, in imag-
ing applications brighter fluorophores are preferred, as they increase the signal 
to noise ratio in biological samples with background fluorescence and allow re-
duced exposure times, thus increasing temporal resolution and decreasing 
photo toxic effects.  
While ECFP and EYFP were very popular in early FRET sensors, these fluores-
cent proteins have considerable downsides (Kremers et al. 2006). Especially 
ECFP is very critical, as it is very dim (𝛷 ∗ 𝜀 = 13), with low quantum yield (0.4) 
and low extinction coefficient (32.5 mM–1cm–1) (Tsien 1998). While EYFP is much 
brighter than ECFP (𝛷 ∗ 𝜀 = 50.9) it is very environmentally sensitive (Griesbeck 
et al. 2001). Over the last decade many variants of these fluorescent proteins 
became available, which improved upon these downsides.  
The first objective of this project was to find suitable cyan and yellow fluores-
cent proteins to replace ECFP and EYFP in cGi500. As potential donors, the bright 
cyan fluorescent protein variants mCerulean3 (Markwardt et al. 2011) and mTur-
qouise2 (Goedhart et al. 2012) were chosen, because of their very high quantum 
yields (0.8 and 0.93, respectively). As acceptors, the EYFP variants mVenus 
(Kremers et al. 2006), mCitrine (Griesbeck et al. 2001) and Ypet (Nguyen and 
Daugherty 2005) were picked, because of their reduced environmental sensitiv-
ity and increased extinction coefficients.  
Furthermore, as the FRET efficiency is highly dependent on the orientation 
and distance between the fluorophores, this step was also used to methodically 
explore possible configurations of these fluorescent proteins, to harness poten-
tial improvements based on variations in these variables.  
Nagai et al. (2004) demonstrated the improvement of the dynamic range of 
FRET sensors through the usage of circular permutated proteins, as their  
spatial orientations are shifted due to the relocation of the termini into loops 
connecting β-sheets. To explore this strategy, the circular permutated fluores-
cent proteins cpVenusCD174 and cpCitineCD174 (Thestrup et al. 2014) were also 
considered as potential acceptors.  
Shimozono et al. (2006) showed that C-terminal truncation of N-terminally 
positioned fluorescent proteins can increase FRET efficiency by reducing the 
distance between the FRET partners. Therefore, N-terminally positioned fluo-
rescent proteins were used both in an 11 amino acid truncated (CΔ11) and a non-
truncated version.   
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Surprisingly, many unimolecular FRET sensors are constructed with an  
N-terminal donor fluorescent protein and a C-terminal acceptor fluorescent 
protein. Although this arrangement seems intuitive, it should not be a require-
ment for FRET. All combinations of fluorescent proteins were therefore assem-
bled both in an N-terminal donor and a C-terminal donor configuration, to thor-
oughly assess which of these would work the best.  
Sensors were constructed in a permutated modular manner, amplifying all 
variants for each individual component, and then assembling all possible com-
binations in pRSET SL II using SLiCE. This was achieved by keeping homologous 
regions for all sensors the same: N-terminal fluorescent proteins (FP I) were am-
plified with 21 bp homologous overhangs to the vector on the 5’-end and 21 bp 
homologous overhangs to the sensor domain on the 3’-end (with or without 
truncation). The sensor (SD) domain itself was amplified without overhangs, as 
a universal connector between varying fluorescent proteins. C-terminal fluores-
cent proteins (FP II) finally, were amplified with 21 bp homologous overhangs to 
the sensor domains on the 5’-end and 21 bp homologous overhangs to the 
downstream homology region in the vector. After cloning, correct assembly was 
confirmed via colony PCR. Sensor prototypes were expressed in E. coli, purified 
and their dynamic range was assessed via fluorescence spectroscopy.  
Table 3-1 depicts the results of this initial screen of improved cyan/yellow 
FRET pairs. The wide variety of observed dynamic ranges suggested that this 
approach was very successful. Some configurations did not result in functional 
sensors at all, while others outperformed cGi500. Notably, sensors with circular 
permutated fluorescent proteins performed on average worse than their non-
permutated counterparts, with no variant displaying a dynamic range above 
21 %. Most of the sensors, which showed no measurable ratio change, had mTur-
quoise2 as a donor fluorescent protein. The four best performing sensors all 
used Ypet as acceptor, clearly demonstrating its superiority. Interestingly, sen-
sors with C-terminal donors demonstrated better performance than sensors 
with N-terminal donors. The four best performing sensor prototypes, named A1–
A4, were further characterized (see Table 3-2) and used as base constructs for 
further improvement efforts.  
All four sensors displayed increased dynamic range compared to cGi500 and 
higher affinity towards cGMP, but also relatively high affinity to cAMP. Besides 
that, the intrinsic brightness of the sensors was improved significantly in all 
constructs, with the donor brightness being more than doubled (ECFP 13, mCeru-
lean3 32, mTurquoise2 27.9) and the acceptor brightness increased 1.6 fold (EYFP 
50.9, Ypet 80.1). 
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Table 3-1 Sensor variants with improved fluorescent proteins 
FP I P1,P2 SD P1,P2 FP II P1,P2 ΔR/R 
mCerulean3 17,21 CNB-A CNB-B 40,41 mVenus 23,24 12.0 % 
mCerulean3 CΔ11 17,22 CNB-A CNB-B 40,41 mVenus 23,24 18.7 % 
mTurquoise2 17,21 CNB-A CNB-B 40,41 mVenus 23,24 18.6 % 
mTurquoise2 CΔ11 17,22 CNB-A CNB-B 40,41 mVenus 23,24 18.5 % 
mCerulean3 17,21 CNB-A CNB-B 40,41 mCitrine SF 23,25 15.9 % 
mCerulean3 CΔ11 17,22 CNB-A CNB-B 40,41 mCitrine SF 23,25 20.1 % 
mTurquoise2 17,21 CNB-A CNB-B 40,41 mCitrine SF 23,25 24.6 % 
mTurquoise2 CΔ11 17,22 CNB-A CNB-B 40,41 mCitrine SF 23,25 0.5 % 
mCerulean3 17,21 CNB-A CNB-B 40,41 Ypet 26,27 24.0 % 
mCerulean3 CΔ11 17,22 CNB-A CNB-B 40,41 Ypet 26,27 38.7 % 
mTurquoise2 17,21 CNB-A CNB-B 40,41 Ypet 26,27 0 % 
mTurquoise2 CΔ11 17,22 CNB-A CNB-B 40,41 Ypet 26,27 23.7 % 
mCerulean3 17,21 CNB-A CNB-B 40,41 cpVenusCD174 28,29 11.8 % 
mCerulean3 CΔ11 17,22 CNB-A CNB-B 40,41 cpVenusCD174 28,29 17.6 % 
mTurquoise2 17,21 CNB-A CNB-B 40,41 cpVenusCD174 28,29 16.2 % 
mTurquoise2 CΔ11 17,22 CNB-A CNB-B 40,41 cpVenusCD174 28,29 18.4 % 
mCerulean3 17,21 CNB-A CNB-B 40,41 cpCitineCD174 30,31 15.4 % 
mCerulean3 CΔ11 17,22 CNB-A CNB-B 40,41 cpCitineCD174 30,31 16.5 % 
mTurquoise2 17,21 CNB-A CNB-B 40,41 cpCitineCD174 30,31 17.3 % 
mTurquoise2 CΔ11 17,22 CNB-A CNB-B 40,41 cpCitineCD174 30,31 20.5 % 
mVenus 17,21 CNB-A CNB-B 40,41 mCerulean3 23,20 21.3 % 
mVenus CΔ11 17,22 CNB-A CNB-B 40,41 mCerulean3 23,20 6.4 % 
mVenus 17,21 CNB-A CNB-B 40,41 mTurquoise2 23,20 0 % 
mVenus CΔ11 17,22 CNB-A CNB-B 40,41 mTurquoise2 23,20 0.6 % 
mCitrine SF 17,32 CNB-A CNB-B 40,41 mCerulean3 23,20 23.3 % 
mCitrine SF CΔ11 17,22 CNB-A CNB-B 40,41 mCerulean3 23,20 25.3 % 
mCitrine SF 17,32 CNB-A CNB-B 40,41 mTurquoise2 23,20 31.6 % 
mCitrine SF CΔ11 17,22 CNB-A CNB-B 40,41 mTurquoise2 23,20 36.7 % 
Ypet 33,34 CNB-A CNB-B 40,41 mCerulean3 23,20 1.9 % 
Ypet CΔ11 33,35 CNB-A CNB-B 40,41 mCerulean3 23,20 40.5 % 
Ypet 33,34 CNB-A CNB-B 40,41 mTurquoise2 23,20 41.3 % 
Ypet CΔ11 33,35 CNB-A CNB-B 40,41 mTurquoise2 23,20 49.7 % 
cpVenusCD174 38,39 CNB-A CNB-B 40,41 mCerulean3 23,20 18.5 % 
cpVenusCD174 38,39 CNB-A CNB-B 40,41 mTurquoise2 23,20 0.4 % 
cpCitineCD174 36,37 CNB-A CNB-B 40,41 mCerulean3 23,20 18.7 % 
cpCitineCD174 36,37 CNB-A CNB-B 40,41 mTurquoise2 23,20 0.2 % 
P1,P2 Primer pair used to amplify the domain  
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Table 3-2 Characteristics of cGi500 based sensors with improved fluorophores 
Name FP I SD FP II ΔR/R Kd[cGMP] Kd[cAMP] 
cGi500 ECFP (W1B) CNB-A CNB-B EYFP (10C) 29.6 % 470 nM1 >100 µM1 
A1 mCerulean3 CΔ11 CNB-A CNB-B Ypet 38.7 % 377.0 nM 71.4 µM 
A2 Ypet CΔ11 CNB-A CNB-B mCerulean3 40.5 % 364.5 nM 127.8 µM 
A3 Ypet CNB-A CNB-B mTurquoise2 41.3 % 300.2 nM 29.7 µM 
A4 Ypet CΔ11 CNB-A CNB-B mTurquoise2 49.7 % 377.5 nM 57.5 µM 
1as reported by Russwurm et al. (2007) 
3.3.2 Improvement of Binding Sites 
An important aspect for the function or a biosensor for cGMP is its selectivity 
towards cGMP over the structurally similar cAMP, which is typically more abun-
dant in cells (Nikolaev and Lohse 2009). The cGMP sensor cGi500 is based on a 
conformational change in the cyclic nucleotide binding domain of the  
bovine cGKI, when binding to cGMP (Russwurm et al. 2007) (see Figure 3.9). The 
cyclic nucleotide binding domain of cGKI consists of two binding sites: a high 
affinity binding site (CNB-A) and a low affinity binding site (CNB-B) (Kim et al. 
2011). Recent studies showed, that CNB-A, while having a very high affinity, only 
displays poor selectivity (~2 fold) between cGMP and cAMP (Kim et al. 2011). In 
fact Huang et al. (2014) could demonstrate that the selectivity of cGKI for cGMP 
is mediated by the second, low affinity binding site (CNB-B). Taken together, the 
assumption was made, that in a cellular environment the combination of poor 
selectivity and high affinity of CNB-A and the relatively high concentration of 
cAMP would lead to a saturation of this binding site, reducing its contribution to 
the biosensor functionality. 
 
Figure 3.9 Structure scheme of cGi500-like fluorescent biosensors 
Sensor domain (SD) is sandwiched between two fluorescent proteins (FPI, FPII) and consists of 
two binding sites (CNB-A, CNB-B). CNB-A: high affinity binding site with low selectivity (~2 fold) 
CNB-B: low affinity binding site with higher selectivity (~240 fold)(Huang et al. 2014)  
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3.3.2.1 Sensors with duplicated CNB-B Binding Site 
To increase both the selectivity and the dynamic range of the initial prototype 
sensors, the sensor domain was modified to incorporate the knowledge gained 
from the structure of cGKI. While sharing only 37 % sequence homology CNB-A 
and CNB-B are structurally very similar, displaying two N-terminal α-helices, an 
8 stranded anti-parallel β-barrel, which comprises the cyclic nucleotide binding 
pocket, and an α-Helix at the C-terminus, which is the effector of the conforma-
tional change upon ligand binding (Kim et al. 2011, Huang et al. 2014). It was 
reasoned, that exchanging the CNB-A binding site with a copy of CNB-B while 
keeping the overall sensor structure constant, would improve the functionality 
of the sensor, because: (1) both binding sites would be selective for cGMP and 
(2) both binding sites would contribute in the conformational change of the mol-
ecule.  
In order to duplicate CNB-B, this binding site was amplified using primers 
44/45. Then, the base constructs A1–A4 were all linearized with primers 42/43, 
omitting CNB-A. The linearized backbones were then assembled with the second 
binding site in a SLiCE reaction, yielding the constructs depicted in Table 3-3. 
This replaced CNB-A after its first α-helix with the homologous sequence of CNB-
B, retaining a 29 amino acid chain from the N-terminus of the original cGi500 
binding domain (see Figure 3.10).  
 
 
Figure 3.10 Structure scheme of biosensors with duplicated CNB-B binding site 
CNB-A in cGi500 like sensors is replaced with a copy of the structurally homologous CNB-B 
binding site 
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The resulting prototype sensors were expressed in E. coli, purified and then 
characterized regarding their dynamic range and binding constants towards 
cGMP and cAMP (see Table 3-3). The results of this binding site graft supported 
the assumptions made, going into this project. All sensors with duplicated CNB-
B binding site displayed improved selectivity for cGMP over cAMP. As expected 
the affinity for cGMP decreased slightly, because of CNB-Bs lower affinity to-
wards cGMP. 
Interestingly, the dynamic range of sensors incorporating mTurquoise2 as a 
donor increased only negligible, while sensors with mCerulean3 almost doubled 
in dynamic range. This underlined the observations from earlier experiments 
that the use of mCerulean3, although very similar to mTurquoise2, had an ad-
vantage in the context of the cGMP sensor. Furthermore, it was noted that the 
sensors B2 (see 6.2.1) and B3 (6.2.2) performed comparably, incorporating the 
same fluorophores but in opposite configuration with the N-terminal fluoro-
phore being truncated. In this particular arrangement, the donor and acceptor 
positions were apparently interchangeable. Because of their improved dynamic 
range sensors B2 and B3 were transferred into pSinRep5 SL and further charac-
terized in brain slices (see 3.3.5), to assess the comparability of in vitro data with 
in vivo conditions.  
 
Table 3-3 Characteristics of cGMP sensors with duplicated CNB-B binding site  
Name FP I SD FP II ΔR/R Kd[cGMP] Kd[cAMP] 
cGi500 ECFP (W1B) CNB-A CNB-B EYFP (10C) 29.6 % 470 nM1 >100 µM1 
B3 mCerulean3 CΔ11 2 x CNB-B Ypet 72.6% 614.6 nM 148.7 µM 
B2 Ypet CΔ11 2 x CNB-B mCerulean3 71.8% 474.5 nM 203.6 µM 
- Ypet 2 x CNB-B mTurquoise2 47.5% n.d. n.d. 
B1 Ypet CΔ11 2 x CNB-B mTurquoise2 53.5% 570.1 nM 251.4 µM 
1as reported by Russwurm et al. (2007) 
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3.3.2.2 Sensors with single CNB-B Binding Site 
The second option which was explored to improve on the cGi500 binding do-
main, was to delete the CNB-A binding site altogether. Besides potentially in-
creasing specificity for cGMP, this approach had the additional advantage of 
simplifying the binding kinetics of resulting sensors. Biosensors with multiple 
binding sites often display cooperative binding, which poses considerable chal-
lenges, when cells with different base levels of analyte are compared (Rose et 
al. 2014). Furthermore, the biological impact of recombinantly  
expressed sensor can be reduced, by reducing the number of binding sites. Pro-
teins which have affinity to an analyte will inadvertently buffer the intracellular 
concentration of this analyte, thus reducing its “free” concentration and there-
fore influencing the biological system (Rose et al. 2014). 
In order to delete the CNB-A binding site, the base sensors A1–A4 were  
linearized by amplification with primers 43/44, omitting CNB-A. The linear PCR 
products were then circularized in a SLiCE reaction, yielding the constructs de-
picted in Table 3-4. Similarly to biosensors with duplicated CNB-B binding sites, 
the 29 amino acid N-terminal peptide of the original cGi500 binding  
domain was retained.  
 
Figure 3.11 Structure scheme of biosensors with single CNB-B binding site 
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In contrast to the results obtained with duplicated CNB-B binding sites, single 
binding site sensors with C-terminal donors displayed clearly reduced dynamic 
ranges compared to the original prototypes. The construct C1 (see 6.2.3) with an 
N-terminal donor, on the other hand, showed a dramatically increased dynamic 
range. Donor and acceptor position apparently played an important role in the 
context of this sensor construct, as opposed to the sensors with duplicated CNB-
B binding site. This underlined the necessity for in-depth exploration of possible 
sensor configurations during the biosensor development process, as results 
from different systems cannot necessarily be transferred. 
Besides its superior dynamic range, the sensor variant C1 was also highly se-
lective with a 1,900 fold discrimination between cGMP and cAMP (compared to 
430 fold and 230 fold in B2 and B3 respectively). The loss in affinity was more 
pronounced than observed with duplicated CNB-B binding sites, indicating that 
the configuration of a cGMP biosensor can have considerable influence on its 
affinity, despite the usage of the same binding domain.  
C1 was considered a very promising prototype, because of its large dynamic 
range and high selectivity and was therefore sub-cloned into pSinRep5 SL and 
further characterized in brain slices (see 3.3.5) 
 
Table 3-4 Characteristics of cGMP sensors with single CNB-B binding site 
Name FP I SD FP II ΔR/R Kd[cGMP] Kd[cAMP] 
cGi500 ECFP (W1B) CNB-A CNB-B EYFP (10C) 29.6 % 470 nM1 >100 µM1 
C1 mCerulean3 CΔ11 CNB-B Ypet 81.4 % 1.7 µM 3.3. mM 
- Ypet CNB-B mTurquoise2 20.8 % n.d. n.d. 
- Ypet CΔ11 CNB-B mTurquoise2 15.2 % n.d. n.d. 
- Ypet CΔ11 CNB-B mCerulean3 25.4 % n.d. n.d. 
1as reported by Russwurm et al. (2007) 
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3.3.2.3 cGKII based Sensors 
Very recently Campbell et al. (2016) solved the crystal structure for the cyclic 
nucleotide binding domains of the human cGKII, determined the binding con-
stants for its cyclic nucleotide binding sites and elucidated the mechanisms of 
cGMP binding. This study revealed, that similar to cGKI, the second cyclic  
nucleotide binding domain (CNB-BII) is responsible for the cGMP selectivity of 
this protein kinase. Strikingly, the selectivity for cGMP of CNB-BII is even higher 
(500 fold) than in CNB-B of cGKI (240 fold). The authors linked this selectivity to 
a different nucleotide binding mechanism, in which cGMP is completely encap-
sulated by the binding pocket. Adding to that, CNB-BII has a seven fold higher 
affinity towards cGMP than CNB-B (31.2 nM and 215 nM, respectively)(Campbell 
et al. 2016).  
In order to marry high selectivity with high affinity, a sensor was constructed 
based on the prototype sensor C1, using the CNB-BII binding site of cGKII. To that 
end, the vector encoding C1 was linearized by amplification with primers 43/46. 
A linear DNA fragment encoding residues 291–419 of the human cGKII with 21 bp 
homologues regions towards the linearized vector on either end was de novo 
synthesized as a GeneArt™ String (Thermo Scientific). Linearized backbone and 
the fragment encoding CNB-BII were then assembled in a SLiCE reaction, yield-
ing the sensor prototype D1 (see 6.2.4). The sensor was expressed in E. coli, pu-
rified and characterized in vitro (see Table 3-5).  
The observed characteristics of this sensor were very promising. D1 exhibited 
outstanding selectivity for cGMP over cAMP. It was so high in fact, that the affin-
ity for cAMP could only be estimated, because part of the binding curve lay out-
side of the solubility range for cAMP. Furthermore, D1 had a higher  
affinity for cGMP than C1. Although this improvement was not as striking as it 
would have been predicted from the affinity of CNB-BII, it was an improvement 
none the less. This furthermore underlined the susceptibility of the affinity of 
nucleotide binding domains to changes in their local environment that was ob-
served before. The dynamic range of D1 was only 42.8 %, which is relatively low 
in comparison with the sensors B2, B3 and C1, but because of its other promising 
characteristics it was considered as a base construct for further improvement. 
D1 was transferred to pSinRep5 SL and evaluated in brain slices (see 3.3.5). 
 
Table 3-5 Characteristics of cGMP sensors with single CNB-BII binding site 
Name FP I SD FP II ΔR/R Kd[cGMP] Kd[cAMP] 
cGi500 ECFP (W1B) CNB-A CNB-B EYFP (10C) 29.6 % 470 nM1 >100 µM1 
C1 mCerulean3 CΔ11 CNB-B Ypet 81.4 % 1.7 µM 3.3. mM 
D1 mCerulean3 CΔ11 CNB-BII Ypet 42.8 % 955 nM ~24 mM 
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3.3.3 Color Variants 
FRET sensors based on the CFP/YFP pair have been very popular in the past 
and are still commonly used (compare FRET sensor list compiled by Miyawaki 
and Niino (2015)). However, this pair has a number of downsides, which make it 
desirable to establish FRET sensors with different fluorescent proteins. For  
example, compared to other fluorescent proteins, CFP variants are very dim, 
even the brightest are less than half as bright as other engineered modern flu-
orescent proteins (see Table 1-1 under 1.1.4). Furthermore, the 440 nm laser line, 
which is required to excite CFP/YFP pairs is not as commonly available as the 
488 nm laser line, which is used for GFP excitation (Miyawaki and Niino 2015). 
For cGMP based FRET sensors specifically, a combination with optogenetic actu-
ators like the light activated guanylate cyclase BlgC (Ryu et al. 2010), would be 
interesting. However, this cyclase is activated by blue light, which would selec-
tively bleach CFP.  
In order to provide potential alternatives for various applications, other po-
tential FRET pairs for a cGMP sensor were investigated. The choice fell on 
green/orange pairs, because they are easily excitable with the 488 nm line, have 
less spectral overlap with BLUF domain based tools such as BlgC and recently, 
with Clover and mNeongreen, very bright green fluorescent proteins became 
available (Lam et al. 2012, Shaner et al. 2013).  
Both Clover and mNeongreen were combined with mKO3 and its circular per-
mutated variant mKO3 cp53. mKO3 is a bright orange fluorescent protein without 
dead-end green intermediates common in orange FPs (Litzlbauer 2015). Proto-
type sensors were constructed in a modular fashion, amplifying individual com-
ponents with homologous overhangs and subsequently assembling them in 
SLiCE reactions, as described before (see 3.3.1). Sensors were expressed in 
E. coli, purified and characterized in vitro.  
The results of these experiments are listed in Table 3-6. Both of the earlier 
developed sensor domains (2 x CNB-B and CNB-B) were tested. The overall per-
formance of all green/orange sensors was rather poor in comparison with 
CFP/YFP based sensors. This result was somewhat surprising, as the spectral 
compatibility between these pairs was comparable to CFP/YFP pairs used in ear-
lier sensors (mCerulean3-Ypet R0=10.1 nm, Clover-mKO3 R0=10.2 nm, mNeon-
green-mKO3 R0=10.3 nm, with 𝜅2 = 2 3⁄ , calculated using a|e UV-Vis-IR Spectral 
Software 2.2, FloorTools). On the other hand, so far the sensor domains had been 
optimized using CFP/YFP FRET as a read-out. Since FRET efficiency is very sus-
ceptible to chances in orientation (see 1.1.2), it is plausible to assume that new 
fluorophores with different dipole transition moments are less effective for a 
given sensor configuration. To optimize the dynamic range of sensors  
using green/orange pairs, linker regions between sensor domains and fluores-
cent proteins would have to be investigated, to adjust the angles between func-
tional elements to be more suitable.  
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Table 3-6 Green-orange cGMP sensor variants 
FP I P1,P2 SD P1,P2 FP II P1,P2 ΔR/R 
Clover 17,21 CNB-B 40,41 mKO3 51,52 25.1 % 
Clover 17,21 CNB-B 40,41 mKO3 cp53 53,54 12.6 % 
mNeongreen 17,21 CNB-B 40,41 mKO3 51,52 17.0 % 
mNeongreen 17,21 CNB-B 40,41 mKO3 cp53 53,54 – 
mKO3 47,48 CNB-B 40,41 Clover 23,20 10.0 % 
mKO3 47,48 CNB-B 40,41 mNeongreen 23,20 10.7 % 
mKO3 cp53 49,50 CNB-B 40,41 Clover 23,20 – 
mKO3 cp53 49,50 CNB-B 40,41 mNeongreen 23,20 12.1 % 
Clover 17,21 2 x CNB-B 40,41 mKO3 51,52 22.9 % 
Clover 17,21 2 x CNB-B 40,41 mKO3 cp53 53,54 13.3 % 
mNeongreen 17,21 2 x CNB-B 40,41 mKO3 51,52 21.0 % 
mNeongreen 17,21 2 x CNB-B 40,41 mKO3 cp53 53,54 11.6 % 
mKO3 47,48 2 x CNB-B 40,41 Clover 23,20 9.0 % 
mKO3 47,48 2 x CNB-B 40,41 mNeongreen 23,20 11.9 % 
mKO3 cp53 49,50 2 x CNB-B 40,41 Clover 23,20 6.8 % 
mKO3 cp53 49,50 2 x CNB-B 40,41 mNeongreen 23,20 14.8 % 
P1,P2 Primer pair used to amplify the domain  
 
3.3.4 Single Emission, red cGMP Sensors 
Depending on the application, single emission biosensors are sometimes of 
advantage: (1) imaging is less complex than with dual emission sensors, as only 
a single fluorescent protein has to be monitored (Miyawaki and Niino 2015),  
(2) the use of a single fluorescent protein allows to image with very wide filters, 
thus gathering more light, enabling shorter exposure times (3) because of their 
smaller “spectral footprint” they can be combined with other ontogenetic tools. 
Furthermore, it would be of advantage to use red-shifted biosensors, as tissue 
penetration increases with longer wavelength due to reduced scattering 
(Helmchen and Denk 2005). This motivated the development of a red-shifted 
single emission biosensor for cGMP, as such a sensor could be combined with 
activity sensors, like Twich2B (Thestrup et al. 2014) or GCamP6s (Chen et al. 2013) 
or with cAMP sensors like Epac-SH134 (Polito et al. 2013). 
Pettikiriarachchi et al. (2012) described the use of the monomeric chromopro-
tein Ultramarine as a dark acceptor in a FRET based biosensor. In such a sensor, 
a fluorescent protein (FP) is coupled to a chromoprotein (CP) via a sensor do-
main (SD) (see Figure 3.12). In the ligand-free state the fluorescence emission of 
the FP is quenched by the chromoprotein through FRET. Upon ligand binding, a 
conformational change in the sensor domain reduces the FRET efficiency 
through changes in orientation and distance, increasing the fluorescence emis-
sion in the process. Since all FRET sensors based on the cGK cGMP binding do-
mains displayed a decrease in their FRET ratio after cGMP, it was seen as very 
suitable for this type of sensor. 
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Figure 3.12 Model for FRET based single emission cGMP sensors 
A sensor domain (SD) is sandwiched between a single donor fluorescent protein (FP) and an 
acceptor chromoprotein (CP). The brightness of the FP is modulated by ligand binding to the 
SD, reducing FRET efficiency through conformational change.  
The DNA encoding Ultramarine was de novo synthesized as a linear GeneArt™ 
String (Thermo Scientific) based on the protein sequence in the crystal structure 
of Rtms5 (Beddoe et al. 2003) and the mutations reported by Pettikiriarachchi et 
al. (2012), which were introduced into Rtms5 to produce Ultramarine. The 
sequence was optimized for E. coli expression using the algorithm provided by 
the GeneArt™ web interface. The linear DNA fragment was cloned into pRSETSL II 
via SLiCE reaction and sequence identity was confirmed with Sanger sequencing.  
Red single emission cGMP sensors were assembled in similar fashion as 
described before. Several donor fluorescent proteins were combined with 
ultramarine as dark acceptor, in N-terminal and C-terminal configuration using 
the sensor domains CNB-B and 2 x CNB-B. The following fluorescent proteins 
were used as donors: the red fluorescent protein mRuby2 (Lam et al. 2012), the 
afford mentioned orange fluorescent proteins mKO3 and mKO3 cp53 and one 
fragment of the tandem dimer tdTomato (Shaner et al. 2004) encoding a single 
fluorescent protein. Prototype sensors were assembled in SLiCE reactions, 
expressed in E. coli and characterized in vitro. 
Table 3-7 depicts results obtained from the characterization of these 
biosensors. Overall sensor performance with respect to the change in 
fluorescence intensity was very promising. As a site note it should be pointed 
out, that ΔF/F, which is used as a measure for dynamic range in single emission 
sensors, is not directly comparable with ΔR/R, which is used to characterize FRET 
sensors. As a point of reference, the average change in fluorescence intensity 
per channel in the FRET sensor C1 was ~35 %. Interestingly, mRuby2 worked well 
in sensors with 2 x CNB-B in both N- and C-terminal configuration, similar to the 
sensors B2 and B3, but with reduced performance in sensors with single binding 
site.  
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Table 3-7 Red single emission cGMP sensors 
FP I P1,P2 SD P1,P2 FP II P1,P2 ΔF/F 
mRuby2 55,21 CNB-B 40,41 Ultramarine 59,60 13.0 % 
Tomato 17,21 CNB-B 40,41 Ultramarine 59,60 31.2 % 
mKO3 47,48 CNB-B 40,41 Ultramarine 59,60 21.6 % 
mKO3 cp53 49,50 CNB-B 40,41 Ultramarine 59,60 19.0 % 
Ultramarine 57,58 CNB-B 40,41 mRuby2 56,20 15.8 % 
Ultramarine 57,58 CNB-B 40,41 Tomato 23,20 12.9 % 
Ultramarine 57,58 CNB-B 40,41 mKO3 51,52 17.4 % 
Ultramarine 57,58 CNB-B 40,41 mKO3 cp53 53,54 6.7 % 
mRuby2 55,21 2 x CNB-B 40,41 Ultramarine 59,60 20.7 % 
Tomato 17,21 2 x CNB-B 40,41 Ultramarine 59,60 – 
mKO3 47,48 2 x CNB-B 40,41 Ultramarine 59,60 16.8 % 
mKO3 cp53 49,50 2 x CNB-B 40,41 Ultramarine 59,60 11.7 % 
Ultramarine 57,58 2 x CNB-B 40,41 mRuby2 56,20 21.9 % 
Ultramarine 57,58 2 x CNB-B 40,41 Tomato 23,20 17.4 % 
Ultramarine 57,58 2 x CNB-B 40,41 mKO3 51,52 14.2 % 
Ultramarine 57,58 2 x CNB-B 40,41 mKO3 cp53 53,54 11.6 % 
P1,P2 Primer pair used to amplify the domain  
It was furthermore noted, that mKO3 and its circular permutated version mKO3 
cp53, performed similarly, in contrast to the results observed with circular per-
mutated versions of YFP (see 3.3.1).  
The best performing sensor, with respect to dynamic range, incorporated To-
mato in N-terminal position with a single cGMP binding site (see 6.2.5). With a 
ΔF/F of 31.2 % it is comparable in performance to the sensors B2 and B3, which 
displayed an average intensity change of ~30 % per channel. The potential dis-
advantaged of this sensor could be aggregation, since Tomato is not a monomer.  
Overall the results were very encouraging, demonstrating that the concept of 
such a sensor is applicable for cGMP sensors and yielding several prototype 
sensors as the base for further improvement.  
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3.3.5 Characterization of Sensor Variants in murine Brain Slices 
To evaluate the performance of optimized sensors and the validity of in vitro 
data, prototype sensors were recombinantly expressed in brain slices and fur-
ther characterized. Four promising sensor constructs and cGi500 were selected 
and transferred into the viral vector pSinRep5 SL: the single binding site sensors 
C1 (see 3.3.2.2) and D1 (see 3.3.2.3) and the 2 x CNB-B based sensors B2 and B3 
(see 3.3.2.1).  
The following experiments were performed by Dahdjim-Benoît Beltolngar and 
Pierre Vincent of the Université Pierre et Marie Curie. For in depth information 
on experimental procedures the reader is referred to Polito et al. (2013) and 
Polito et al. (2015) In brief, cranial murine brain slices were transduced using 
Sindbis virus particles to recombinantly express cGMP sensors in striatal neu-
rons. CGMP oscillations were induced pharmacologically, applying the NO donor 
DEA/NO, to stimulate soluble guanylate cyclases (cGC), and the PDE inhibitor 
IBMX, to inhibit cGMP degradation.  
Figure 3.13 depicts results of a typical cGMP imaging experiment in the murine 
striatum. The maximum dynamic range of cGMP sensors was estimated by first 
stimulating cGMP production through an NO donor and then inhibiting  
 
Figure 3.13 cGMP imaging with sensor B2 in the striatum of murine brain slices 
sGC is stimulated with the NO donor DEA/NO, producing cGMP. PDEs are inhibited with IBMX, 
reducing cGMP degradation. Color of traces represents ROIs indicated in the left panel. a-e: 
images at time points indicated in the traces.   
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cGMP degradation through the application of an PDE inhibitor. The results of the 
sensor characterization are depicted in Figure 3.14. Overall, the performance ob-
served in striatal neurons reflected data acquired in vitro very well, even if the 
exact values for dynamic range were not reached. This was attributed to the 
artificially optimal conditions in in vitro experiments and the unknown quanti-
ties regarding cGMP levels in the neuronal environment. Both C1 and B2 sensors 
displayed an around two fold larger dynamic range than cGi500, exemplifying 
the improvements made during sensor development. As predicted by the in vitro 
characterization the dynamic range of the cGKII based sensor was on par with 
cGi500. Surprisingly, the sensor B3 exhibited a lower dynamic range than B2, 
even though they performed equally well under in vitro conditions. This could 
be potentially attributed to the fact, that B3 displayed the highest affinity for 
cAMP of all depicted sensors and thus was partially saturated by basal cAMP 
levels. Nevertheless, this highlighted the importance of evaluations under typi-
cal experimental conditions and limitations of the in vitro model system. 
Besides the dynamic range, the selectivity for cGMP over cAMP of individual 
sensors was evaluated. This was achieved, by first stimulating cAMP production 
through the application of forskolin, an adenylate cyclase agonist, recording the 
FRET ratio and then saturating the sensors through NO stimulation and PDE in-
hibition (see Figure 3.15 A). The selectivity for cGMP was estimated by the signal, 
which could be triggered by elevated cAMP levels, as a percentage of the maxi-
mum dynamic range.  
 
 
Figure 3.14 Maximum dynamic range of cGMP sensors in striatal neurons 
Maximum dynamic range of engineered sensors B2, B3, C1 and D1 compared to cGi500. Murine 
striatal neurons were virally transfected with sensor constructs, imaged and stimulated by ap-
plying 100 µM DEA/No and 200 µM IBMX, to estimate maximum dynamic range of each sensor  
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Figure 3.15 Evaluation of Biosensor Selectivity 
A) Traces of a typical selectivity experiment using sensor C1 in striatal neurons. cAMP produc-
tion was stimulated by addition of forskolin. Sensors were then saturated by NO donor stimu-
lation and PDE inhibition to acquire the maximum FRET ratio. B) Maximum signal achieved by 
cAMP stimulation as a fraction of the maximum dynamic range.  
The results obtained from these experiments (see Figure 3.15 B), were in good 
agreement with the in vitro characterization. Both B2 and B3 with relatively low 
in vitro discrimination factors (430 and 240, respectively), exhibited around 20 % 
sensor saturation by cAMP. C1 and D1 on the other hand showed only modest 
signals with cAMP, with D1 performing the best out of all of these sensors. This 
demonstrated that, while having a lower dynamic range than the other improved 
sensors, D1 and its CNB-BII sensor domain could be a valuable assets in future 
biosensors for cGMP.  
Concluding from in vitro data and the results from brain slices, C1 was seen as 
the sensor with the best overall characteristics. It displayed a large dynamic 
range, two fold larger than cGi500, the best FRET sensor to date. Furthermore, it 
incorporated the brightest available versions of both CFP and YFP, improving 
imaging conditions. It displayed simple binding kinetics (Hill coefficient 1) and 
because of its single cGMP binding site only poses minimal buffering potential. 
Adding to that, it was one of the most selective cGMP sensors tested. Despite 
having a relatively low affinity for cGMP, it could still harness its full potential in 
a neuronal environment, demonstrating that cGMP levels in striatal neurons are 
within its operating range.  
In broader consideration, these results established the validity of the  
abstraction of cGMP sensor development in a bacterial environment. In vitro 
data were good predictors of performance in neurons and could therefore be 
successfully used to improve sensor characteristics in a much simpler system. 
This is the basis for high throughput methods like bacterial plate screening 
(Litzlbauer et al. 2015), for further improvement of sensor performance through 
directed evolution.  
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4 Discussion and Outlook 
 
In this work I developed a novel genetically encoded biosensor for cGMP, fea-
turing exceptional brightness, large dynamic range, simple binding kinetics and 
high selectivity. In collaboration we functionally characterized this sensor in ro-
dent brain slices. To date this probe is the best performing FRET based cGMP 
sensor. Furthermore, I provide the first proof of concept of a bright, red single 
emission probe for cGMP, based on the concept of a dark FRET acceptor. 
In order to achieve these results I implemented several improvements in the 
biosensor development pipeline. These improvements include a harmonized 
vector system, which enables background free, multiple fragment cloning and 
rapid sequence independent transfer into mammalian expression systems and 
large viral vectors. Additionally, I established a streamlined, one-step protein 
purification protocol for in vitro biosensor characterization, which reaches  
purity of more than 99 % for the protein of interest. This enabled high parallel-
ization and accurate measurements at the same time.  
Furthermore, we designed and build a cost effective robotic screening system, 
which automates the labor intensive process of directed evolution through bac-
terial plate screening, increasing throughput and simplifying biosensor devel-
opment.  
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4.1 Cyan/yellow cGMP FRET Sensor 
 
One of the most intriguing questions in neurobiology is how the brain is able 
to learn, how information is stored in the brain, and how this information can 
be retrieved even after decades. This astounding phenomenon, which is so cen-
tral to our self-conception, is still poorly understood.  
The current model for learning and memory formation is based on activity 
dependent plasticity of synaptic transmission. Two forms of synaptic plasticity, 
long term potentiation (LTP) and long term depression (LTD) have been linked 
to learning processes. Nitric oxide(NO)/cGMP signaling has been demonstrated 
to be involved in LTP in the hippocampus and the amygdala, two very prominent 
brain regions for the formation and recall of memories.  
The cGMP biosensors I developed in this work will help to address these fun-
damental questions. For instance, genetic targeting of these sensors to specific 
cell-types and brain regions is a powerful tool for deciphering intricate neuronal 
circuits. The ability to repeatedly revisit and interrogate the same neuron pop-
ulation is an important aspect for studying neuronal processes that last a long 
time. Unlike single emission biosensors, FRET sensors provide this ability, as 
cells are permanently labeled in at least one channel, revealing their morphol-
ogy and identity to the observer. This aspect has been demonstrated for FRET 
based calcium sensors in the past (Aramuni and Griesbeck 2013) and will play an 
important role for investigating long term potentiation and depression using 
cGMP sensors.  
In recent years, devices have been developed by several groups, which can be 
implanted into the central nervous system and allow the wireless stimulation 
and interrogation of optogenetic tools in freely behaving animals (Park et al. 
2015, Wu et al. 2015). Once these technologies mature and are combined with 
optogenetic actuators and reporters for cGMP, we will be able to study memory 
formation in a natural environment, unobstructed by experimental set-ups and 
imaging equipment.  
A more immediate application for genetically encoded cGMP sensors is their 
use in drug discovery. Cardio-vascular diseases (CVD), such as hypertension and 
coronary heart disease, are the leading cause of death worldwide (Mendis et al. 
2011). cGMP is the central molecule in the regulation of cardio-vascular homeo-
stasis. Therefore, proteins involved in cGMP signaling are potential drug targets. 
Genetically encoded cGMP sensors could be used as read-outs in cell-based 
high throughput assays for the screening of large candidate compound libraries. 
Further down the line these sensors can also be used to verify the effects of 
candidate drugs in in vivo models.  
In order to achieve these long term goals many challenges have to be met. 
Compared to the performance of current genetically encoded calcium sensors, 
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the imaging of cGMP oscillations in vivo is still in its infancy. The engineering 
effort that went into the development of calcium sensors exemplifies the high 
bars for broad range in vivo applicability (Mank and Griesbeck 2008, Rose et al. 
2014). The central challenge is the increase of the signal/noise ratio. Thus the 
dynamic range of cGMP sensors has to be improved significantly, to be able to 
resolve subtle cGMP transients. Furthermore, sensors have to be bright enough 
to elevate their signal above the level of background fluorescence. A biological 
source of noise is the interaction with the cAMP signaling cascade. Biosensors 
have to be highly specific for cGMP in order to avoid cross talk form cAMP, which 
is much higher concentrated in a cellular environment. In addition, the sensor 
affinity has to be fine-tuned for the cGMP concentration range found in specific 
cell types. Surprisingly little is known about this free cellular cGMP concentra-
tion, besides that it varies greatly between cell types.  
In this work, I developed a cGMP biosensor which offers improvements on all 
of these fronts, overcoming previous limitations. Specifically, the construct C1 
incorporates the brightest cyan and yellow fluorescent proteins available. Its 
dynamic range doubled in comparison to the established sensor cGi500 and it 
displayed a 1,900 fold selectivity for cGMP. Furthermore, results we obtained 
from experiments with the sensor construct D1, incorporating the cyclic nucleo-
tide binding site of cGKII, showed that even higher specificities can be achieved. 
Noteworthy is also, that prototype sensors constructed during my optimization 
efforts, displayed a relatively large spectrum of affinities, even though the same 
binding sites were used. Taken together, this shows that it is possible to tailor 
these variables to specific applications and cell types. 
The improvements of the biosensors presented here are the first step on the 
road towards the ideal biosensor for cGMP. Next, lessons learned from the de-
velopment of genetically encoded calcium sensors will have to be applied to 
cGMP sensors, in order to meet the high standards required for in vivo imaging. 
The next logical step would be, to employ directed evolution and large scale 
screening to improve the performance of these sensors, as it has been done in 
the past for calcium sensors (Litzlbauer et al. 2015).  
I demonstrated that characteristics of cGMP sensors engineered in a bacterial 
background can be directly correlated to their in vivo performance. This is a 
prerequisite for employing high throughput methods, like bacterial plate 
screening in the future. To this end we developed an automated screening sys-
tem, allowing the quantitative evaluation of thousands of sensor variants per 
day.  
The remaining challenge for implementing bacterial plate screening for cGMP 
sensors is the development of a screening protocol. Such a protocol would allow 
the controlled introduction of cGMP into E. coli in the context of bacterial colo-
nies, in order to monitor the performance of individual sensor variants of large 
libraries.  
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Preliminary experiments not included in this work, showed that this is chal-
lenging, as cGMP does not readily permeate through membranes. One solution 
is the use of cGMP analogues, which are modified to increase penetration, such 
as 8-pCPT-cGMP. However, these compounds are prohibitively expensive when 
used in quantities necessary for bacterial plate screening. Adding to that, the 
use of analogues in a directed evolution approach could impose unwanted se-
lection pressure, as sensors are adapted to a different molecule. Probably the 
best approach will be to employ small organic permeation agents such as iso-
propanol or toluene, which have been used for similar purposes before (Paoni 
and Koshland 1979, Litzlbauer et al. 2015). Here conditions have to be fine-tuned 
in order to guarantee, that cGMP can penetrate E. coli cells in  
colonies in an efficient manner without disturbing biosensor functionality or ex-
erting toxicity in bacteria. These conditions can be rapidly optimized using the 
screening set-up developed in this work.  
A more subtle challenge is that cAMP is a central signaling molecule within 
E. coli and regulates the response to diverse stimuli such as availability of spe-
cific carbon sources and osmotic conditions and might interact negatively with 
cGMP sensors, as it is present in high concentration of 20 µM -120 µM (Notley-
McRobb et al. 1997, Balsalobre et al. 2006). It is important to evaluate cAMP sig-
nal contribution to avoid distorted results. This can be achieved by growing 
E. coli expressing candidate sensors on minimal media and then applying glu-
cose while monitoring the FRET ratio. 
The base construct for future directed evolution efforts should be the con-
struct C1, developed in this work. Its major components, fluorescent proteins 
and sensor domain, have been optimized and proven functional in brain slices. 
Next, the sensor performance has to be carefully fine-tuned, with a focus on the 
dynamic range, as this is the key factor for resolving natural cGMP oscillations. 
This can be achieved by introducing randomized linkers in between functional 
domains, to adjust the angles and distance between fluorescent proteins and 
then screening for improved variants, as it has been done successfully in the 
past (Thestrup et al. 2014). 
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4.2 Red single Emission cGMP Sensor 
In this work I furthermore developed single emission cGMP sensors, based on 
FRET from a red fluorescent protein to a chromoprotein. Even though, only a 
handful proof of concept sensors using this principle have been published so 
far, this approach has some advantages.  
Most single emission biosensors are based on the modulation of the chromo-
phore solvent accessibility. This strategy was successfully employed in the past 
to gain relatively large dynamic ranges. However, since this actively disturbs the 
chromophore environment, these achievements come at the cost of overall 
brightness and photo stability of the resulting sensor. These shortcomings then 
have to be addressed by additional mutation and screening steps on top of 
screening efforts for dynamic range and other variables. In contrast, FRET based 
single emission sensors have the advantage that the fluorophore stays intact. 
This allows the use of very bright, optimized fluorescent proteins, transferring 
superior photo characteristic onto resulting sensor constructs. 
Adding to that, FRET based single emission biosensors cannot only be moni-
tored through intensity based measurements, but also by fluorescence lifetime 
imaging (FLIM). Employing FLIM mitigates one of the major downsides of single 
fluorophore biosensors, namely the concentration dependency of the signal in-
tensity. In contrast, the fluorescence life time solely depends on the local envi-
ronment of the chromophore. 
The main impendence for this approach is the availability of suitable dark 
acceptors. The first sensors using this concept were based on variants of YFP 
with low quantum yields (Ganesan et al. 2006, Murakoshi et al. 2008). However, 
these dark YFP variants still retained some fluorescence, thus diminishing the 
advantages of a single emission sensor. Only recently, the engineered chromo-
protein Ultramarine has become available (Pettikiriarachchi et al. 2012), which 
behaved as a true dark acceptor in my experiments. To date, this chromoprotein 
remains the only viable dark acceptor, limiting this approach to orange and red 
fluorescent proteins.  
A host of chromoproteins with different spectral characteristics from various 
coral species are known (Alieva et al. 2008). However, these chromoproteins are 
all either tetramers or higher order oligomers and thus not suitable for  
biosensor development. In order to expand this approach to the full spectral 
pallet of fluorescent proteins, wild type chromoproteins with suitable absorp-
tion spectra would first have to be converted into monomers. While this has 
been done before, the requirement for this additional engineering step proba-
bly deterred the wide spread implementation of this type of sensor. 
Furthermore, red single emission cGMP sensors have a number of advantages 
for certain applications. Firstly, shifting into the red part of the visual spectrum 
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is beneficial for imagining in general. There is less auto-fluorescence in the red 
part of the spectrum. Besides that, one of the limitations of biosensors emitting 
in the blue-yellow part of the spectrum is the imaging depth, which only allows 
the investigation of surface features of the brain. This can be partially mitigated 
by using more red-shifted fluorescent proteins, as longer wavelengths experi-
ence reduced scattering, which increases penetration.  
To harness these benefits completely it would be ideal to shift into the near 
infrared part of the electromagnetic spectrum, in which tissue is almost trans-
parent. However, photo-physical characteristics of far-red fluorescent proteins 
decline drastically the longer their emission wavelengths is. Specifically quan-
tum yields are extremely reduced, e.g. fluorescent proteins with emission max-
ima around 650 nm only display a quantum yield of 0.2, while all fluorescent 
proteins with emissions greater than 670 nm have quantum yields below 0.11. 
This anti-correlation between emission wavelengths and quantum yield is 
probably caused by the fact that, as the wavelength increases, conjugated  
π-systems within the chromophore have to get extended in order absorb pho-
tons. This in turn has a negative impact on the quantum yield, as it becomes 
increasingly difficult to stabilize larger and larger chromophores within the con-
fines of a protein structure.  
Because of their low quantum yields, far-red and infrared fluorescent pro-
teins are extremely dim and therefore not very suited for demanding imaging 
applications. FRET based biosensors in particular are negatively impacted by 
low quantum yields, as the Förster radius decreases significantly. Therefore, the 
use of orange and red fluorescent proteins, as demonstrated in this work, is a 
good compromise between tissue penetration on one side and sensor function-
ality on the other side.  
Another aspect is related to possible application scenarios for cGMP sensors. 
When addressing questions related to long term potentiation of synaptic trans-
mission, the need for combination of cGMP sensors with other optogenetic tools 
is conceivable. Specifically it would be interesting to combine cGMP imaging 
with calcium imaging, in order to correlate activity with cGMP oscillations, to 
elucidate LTP processes. Furthermore, the combination with optogenetic actua-
tors could provide the ability to test hypothesis conceived during activity/cGMP 
imaging. However, the most optimized activity sensors (GCamP6s, Twitch2B) and 
actuators (ChR2) all operate in the blue-yellow part of the spectrum, potentially 
overlapping and interfering with cGMP sensors based on cyan/yellow fluores-
cent proteins. Therefore, the sensors based on single red fluorescent proteins, 
I developed in this work, presents an excellent alternative for these applica-
tions.  
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4.3 Improvements of Biosensor Development Pipeline 
The engineering of biosensors for in vivo applications is a long and labor-
intensive process. This is best exemplified by genetically encoded calcium sen-
sors, which took the concerted efforts of several groups for more than 15 years 
from the first concepts to the refined tools we have today. Even after such a long 
development time, there is still room for improvement in current calcium sen-
sors (Rose et al. 2014). Therefore, streamlining this development process is cru-
cial, as there are many other potential targets for biosensors. The methods I 
developed and described in this work represent a generic pipeline for the engi-
neering of genetically encoded biosensors. They focus on fast turnaround times, 
parallelization and elimination of bottlenecks.  
The first stage of this development process is the prototyping phase, in which 
the major functional elements of a biosensor, such as fluorescent proteins and 
sensor domains, are selected and optimized. These prototypes are later refined 
through directed evolution and screening. As experience has shown it is crucial 
to optimize and fix the main functional domains first, as later changes of these 
components often render improvements made during screening obsolete. This 
is best exemplified by results presented in this work. Even exchanging a fluo-
rescent protein for a slightly different variant of the same fluorescent protein 
had dramatic effects on sensor performance. The reason for this is that while 
biosensor engineering superficially looks like a modular building block system, 
it is still inherently unpredictable, because individual domains are not folding 
in isolation of each other. 
One of the main bottlenecks in the prototyping phase is the cloning of  
individual components. Traditional cloning methods based on restriction en-
zymes usually require several steps for the assembly of a typical FRET sensor 
and are limited by the availability of restriction sites. The introduction of mod-
ern assembly cloning methods based on in vitro homologous recombination 
(e.g. SLiCE, Gibbson assembly), I present in this work, streamlined this process 
considerably. In addition, I established an effective counter-selection strategy 
in a harmonized vector system for biosensor development. In combination these 
two methods enable background free biosensor assembly from multiple frag-
ments in one-step. This allows the parallel assembly of several dozen complex 
prototype sensors, greatly increasing throughput in this crucial phase. Further 
down the line, the harmonized vector system I established allows for rapid, ef-
ficient transfer of biosensor prototypes into large viral vectors, in order to  
obtain fast feedback from expression in mammalian systems.  
These new DNA assembly methods are very powerful and could spawn inno-
vations in the biosensor development pipeline. Specifically, they enable the in-
troduction of recombination steps during directed evolution of randomized 
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linker libraries. Typically during the refinement of a FRET sensor the two linker 
regions between sensor domain and fluorescent proteins are randomized and 
then screened. The candidate with the best performance then becomes the new 
base construct and is further randomized. Usually, sensors which performed 
well but not as good as the best will be discarded. This is very unfortunate be-
cause these variants harbor valuable information. It is conceivable that they 
contain a good linker region which is paired with a suboptimal region.  
To harness this information, well performing constructs would be first pooled 
and then their linker regions could be isolated via PCR, splitting paired linker 
regions. These two libraries of isolated linkers can then be reassembled using 
SLiCE, randomly recombining linker variants. This reassembly step is  
crucial and can only be performed with the needed efficiency employing these 
new cloning techniques. The resulting library of reassembled sensor variants 
has potentially a much higher chance of yielding variants that outperform the 
initially best sensor. This is because the fitness of the linker population is much 
higher than in random libraries, as they already underwent a selection proce-
dure. In addition to that, these libraries are much less complex and could there-
fore conceivably be screened to completion. This introduces a recombination 
event into directed evolution which is analogue to sexual reproduction.  
Another important bottleneck in the biosensor development pipeline is the 
screening of the sensor libraries. We previously described a method for the 
screening of large biosensor libraries in bacterial colonies (Litzlbauer et al. 
2015). In brief, biosensor libraries are expressed in bacterial colonies. These col-
onies are then imaged in a wide field fluorescence imaging set-up and then ex-
posed to the target molecule. Through this process up to 1,000 different variants 
can be assessed in parallel on one plate. Through software analysis the best 
performing variants are identified and later picked by hand. The requirement 
for manual colony picking represents a major bottleneck for this method and 
can potentially lead to errors, as colonies have to be visually identified. 
Building on this approach we designed and build a low cost robotic screening 
system with enhanced imaging capabilities and automated colony picking. It is 
based on recent developments in the DIY 3D printing community and  
features an innovative picking mechanism, which allows fast colony picking 
without cross contamination. Imaging data is acquired and analyzed on the fly 
and promising variants can be picked in a continuous process.  
Besides biosensor screening this robotic system can be used for other appli-
cations. Examples are the improvement of fluorescent protein characteristics, 
such as brightness, photo stability and pH stability or blue/white selection in 
high throughput cloning. Because of the low cost nature of this robotic system 
(all individual parts can be acquired for less than 1,000 €, excluding the camera), 
it can provide easy access to high throughput screening technology for less af-
fluent laboratories, thus reducing entry hurdles into fields which require such 
instruments. 
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6 Appendix 
6.1 Plasmid Sequences 
6.1.1 pRSET SL 
GenBank Header 
LOCUS       pRSET_SL2887 bp DNA SYN 06-APR-2016 
DEFINITION  pRSET_SL 
ACCESSION     
KEYWORDS     
SOURCE     
  ORGANISM  other sequences; artificial sequences; vectors. 
FEATURES             Location/Qualifiers 
     promoter        20..38 
                     /label=T7_promoter 
     misc_feature    75..91 
                     /label=T7_transl_en_RBS 
     misc_feature    112..129 
                     /label=6xHis 
     misc_feature    133..165 
                     /label=T7_gene10_leader 
     terminator      254..382 
                     /label=T7_terminator 
     rep_origin      471..777 
                     /label=f1_origin 
     promoter        970..998 
                     /label=AmpR_promoter 
     gene            1040..1900 
                     /gene="beta lactamase" 
     rep_origin      2055..2674 
                     /label=pBR322_origin 
     misc_feature    214..222 
                     /note="3xSTOP" 
      misc_feature    169..207 
                     /note="upstream homologous region" 
     misc_feature    214..246 
                     /note="downstream homologous region" 
     misc_feature    199..207 
                     /note="Kozak_Start" 
     source          1..2895 
                     /dnas_title="pRSET_SL" 
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DNA  
ORIGIN       
        1 GATCTCGATC CCGCGAAATT AATACGACTC ACTATAGGGA GACCACAACG GTTTCCCTCT 
       61 AGAAATAATT TTGTTTAACT TTAAGAAGGA GATATACATA TGCGGGGTTC TCATCATCAT 
      121 CATCATCATG GTATGGCTAG CATGACTGGT GGACAGCAAA TGGGTCGGGA TCTGTACGAC 
      181 GATGACGATA AGGATCCGGC CACCATGGAT ATCTGATAAT AGGAATTCCT ATAGTGTCAC 
      241 CTAAATGATC CGGCTGCTAA CAAAGCCCGA AAGGAAGCTG AGTTGGCTGC TGCCACCGCT 
      301 GAGCAATAAC TAGCATAACC CCTTGGGGCC TCTAAACGGG TCTTGAGGGG TTTTTTGCTG 
      361 AAAGGAGGAA CTATATCCGG ATCTGGCGTA ATAGCGAAGA GGCCCGCACC GATCGCCCTT 
      421 CCCAACAGTT GCGCAGCCTG AATGGCGAAT GGGACGCGCC CTGTAGCGGC GCATTAAGCG 
      481 CGGCGGGTGT GGTGGTTACG CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG 
      541 CTCCTTTCGC TTTCTTCCCT TCCTTTCTCG CCACGTTCGC CGGCTTTCCC CGTCAAGCTC 
      601 TAAATCGGGG GCTCCCTTTA GGGTTCCGAT TTAGTGCTTT ACGGCACCTC GACCCCAAAA 
      661 AACTTGATTA GGGTGATGGT TCACGTAGTG GGCCATCGCC CTGATAGACG GTTTTTCGCC 
      721 CTTTGACGTT GGAGTCCACG TTCTTTAATA GTGGACTCTT GTTCCAAACT GGAACAACAC 
      781 TCAACCCTAT CTCGGTCTAT TCTTTTGATT TATAAGGGAT TTTGCCGATT TCGGCCTATT 
      841 GGTTAAAAAA TGAGCTGATT TAACAAAAAT TTAACGCGAA TTTTAACAAA ATATTAACGC 
      901 TTACAATTTA GGTGGCACTT TTCGGGGAAA TGTGCGCGGA ACCCCTATTT GTTTATTTTT 
      961 CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA CCCTGATAAA TGCTTCAATA 
     1021 ATATTGAAAA AGGAAGAGTA TGAGTATTCA ACATTTCCGT GTCGCCCTTA TTCCCTTTTT 
     1081 TGCGGCATTT TGCCTTCCTG TTTTTGCTCA CCCAGAAACG CTGGTGAAAG TAAAAGATGC 
     1141 TGAAGATCAG TTGGGTGCAC GAGTGGGTTA CATCGAACTG GATCTCAACA GCGGTAAGAT 
     1201 CCTTGAGAGT TTTCGCCCCG AAGAACGTTT TCCAATGATG AGCACTTTTA AAGTTCTGCT 
     1261 ATGTGGCGCG GTATTATCCC GTATTGACGC CGGGCAAGAG CAACTCGGTC GCCGCATACA 
     1321 CTATTCTCAG AATGACTTGG TTGAGTACTC ACCAGTCACA GAAAAGCATC TTACGGATGG 
     1381 CATGACAGTA AGAGAATTAT GCAGTGCTGC CATAACCATG AGTGATAACA CTGCGGCCAA 
     1441 CTTACTTCTG ACAACGATCG GAGGACCGAA GGAGCTAACC GCTTTTTTGC ACAACATGGG 
     1501 GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG AATGAAGCCA TACCAAACGA 
     1561 CGAGCGTGAC ACCACGATGC CTGTAGCAAT GGCAACAACG TTGCGCAAAC TATTAACTGG 
     1621 CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC TGGATGGAGG CGGATAAAGT 
     1681 TGCAGGACCA CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG 
     1741 AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC 
     1801 CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA 
     1861 GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA CTGTCAGACC AAGTTTACTC 
     1921 ATATATACTT TAGATTGATT TAAAACTTCA TTTTTAATTT AAAAGGATCT AGGTGAAGAT 
     1981 CCTTTTTGAT AATCTCATGA CCAAAATCCC TTAACGTGAG TTTTCGTTCC ACTGAGCGTC 
     2041 AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT TTTTTTCTGC GCGTAATCTG 
     2101 CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT TGTTTGCCGG ATCAAGAGCT 
     2161 ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG CAGATACCAA ATACTGTTCT 
     2221 TCTAGTGTAG CCGTAGTTAG GCCACCACTT CAAGAACTCT GTAGCACCGC CTACATACCT 
     2281 CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT GTCTTACCGG 
     2341 GTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG TCGGGCTGAA CGGGGGGTTC 
     2401 GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA CTGAGATACC TACAGCGTGA 
     2461 GCTATGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG GACAGGTATC CGGTAAGCGG 
     2521 CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG GGAAACGCCT GGTATCTTTA 
     2581 TAGTCCTGTC GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTTGTGAT GCTCGTCAGG 
     2641 GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT TTACGGTTCC TGGCCTTTTG 
     2701 CTGGCCTTTT GCTCACATGT TCTTTCCTGC GTTATCCCCT GATTCTGTGG ATAACCGTAT 
     2761 TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA ACGACCGAGC GCAGCGAGTC 
     2821 AGTGAGCGAG GAAGCGGAAG AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC 
     2881 GATTCATTAA TGCAG 
// 
  
Appendix - pRSET SL II 
145 
 
6.1.2 pRSET SL II 
GenBank header 
LOCUS       pRSET_SL_II 2887 bp DNA SYN 06-APR-2016 
DEFINITION  pRSET_SL_II 
ACCESSION     
KEYWORDS     
SOURCE     
  ORGANISM  other sequences; artificial sequences; vectors. 
FEATURES             Location/Qualifiers 
     promoter        20..38 
                     /label=T7_promoter 
     misc_feature    75..91 
                     /label=T7_transl_en_RBS 
     misc_feature    112..129 
                     /label=6xHis 
     misc_feature    133..165 
                     /label=T7_gene10_leader 
     terminator      1737..1865 
                     /label=T7_terminator 
     rep_origin      1954..2260 
                     /label=f1_origin 
     promoter        2453..2481 
                     /label=AmpR_promoter 
     gene            2523..3383 
                     /gene="beta lactamse" 
     rep_origin      3538..4157 
                     /label=pBR322_origin 
     misc_feature    1697..1705 
                     /note="3xSTOP" 
     misc_feature    169..207 
                     /note="upstream homologous region" 
     misc_feature    1697..1729 
                     /note="downstream homologous region" 
     misc_feature    199..207 
                     /note="Kozak_Start" 
     Promoter        214..268 
                     /label=LPP5 promoter 
     gene            269..1690 
                     /gene="sacB" 
     source          1..4378 
                     /dnas_title="pRSET_SL_II" 
  
Appendix - pRSET SL II 
146 
DNA 
ORIGIN       
        1 GATCTCGATC CCGCGAAATT AATACGACTC ACTATAGGGA GACCACAACG GTTTCCCTCT 
       61 AGAAATAATT TTGTTTAACT TTAAGAAGGA GATATACATA TGCGGGGTTC TCATCATCAT 
      121 CATCATCATG GTATGGCTAG CATGACTGGT GGACAGCAAA TGGGTCGGGA TCTGTACGAC 
      181 GATGACGATA AGGATCCGGC CACCATGGAT ATCAAACTGC AGTTGACAAC ATAAAAACTT 
      241 TGTGTTATAC TTGTAACGTA AGGAGGTAAT GAACATCAAA AAGTTTGCAA AACAAGCAAC 
      301 AGTATTAACC TTTACTACCG CACTGCTGGC AGGAGGCGCA ACTCAAGCGT TTGCGAAAGA 
      361 AACGAACCAA AAGCCATATA AGGAAACATA CGGCATTTCC CATATTACAC GCCATGATAT 
      421 GCTGCAAATC CCTGAACAGC AAAAAAATGA AAAATATCAA GTTCCTGAAT TCGATTCGTC 
      481 CACAATTAAA AATATCTCTT CTGCAAAAGG CCTGGACGTT TGGGACAGCT GGCCATTACA 
      541 AAACGCTGAC GGCACTGTCG CAAACTATCA CGGCTACCAC ATCGTCTTTG CATTAGCCGG 
      601 AGATCCTAAA AATGCGGATG ACACATCGAT TTACATGTTC TATCAAAAAG TCGGCGAAAC 
      661 TTCTATTGAC AGCTGGAAAA ACGCTGGCCG CGTCTTTAAA GACAGCGACA AATTCGATGC 
      721 AAATGATTCT ATCCTAAAAG ACCAAACACA AGAATGGTCA GGTTCAGCCA CATTTACATC 
      781 TGACGGAAAA ATCCGTTTAT TCTACACTGA TTTCTCCGGT AAACATTACG GCAAACAAAC 
      841 ACTGACAACT GCACAAGTTA ACGTATCAGC ATCAGACAGC TCTTTGAACA TCAACGGTGT 
      901 AGAGGATTAT AAATCAATCT TTGACGGTGA CGGAAAAACG TATCAAAATG TACAGCAGTT 
      961 CATCGATGAA GGCAACTACA GCTCAGGCGA CAACCATACG CTGAGAGATC CTCACTACGT 
     1021 AGAAGATAAA GGCCACAAAT ACTTAGTATT TGAAGCAAAC ACTGGAACTG AAGATGGCTA 
     1081 CCAAGGCGAA GAATCTTTAT TTAACAAAGC ATACTATGGC AAAAGCACAT CATTCTTCCG 
     1141 TCAAGAAAGT CAAAAACTTC TGCAAAGCGA TAAAAAACGC ACGGCTGAGT TAGCAAACGG 
     1201 CGCTCTCGGT ATGATTGAGC TAAACGATGA TTACACACTG AAAAAAGTGA TGAAACCGCT 
     1261 GATTGCATCT AACACAGTAA CAGATGAAAT TGAACGCGCG AACGTCTTTA AAATGAACGG 
     1321 CAAATGGTAC CTGTTCACTG ACTCCCGCGG ATCAAAAATG ACGATTGACG GCATTACGTC 
     1381 TAACGATATT TACATGCTTG GTTATGTTTC TAATTCTTTA ACTGGCCCAT ACAAGCCGCT 
     1441 GAACAAAACT GGCCTTGTGT TAAAAATGGA TCTTGATCCT AACGATGTAA CCTTTACTTA 
     1501 CTCACACTTC GCTGTACCTC AAGCGAAAGG AAACAATGTC GTGATTACAA GCTATATGAC 
     1561 AAACAGAGGA TTCTACGCAG ACAAACAATC AACGTTTGCG CCAAGCTTCC TGCTGAACAT 
     1621 CAAAGGCAAG AAAACATCTG TTGTCAAAGA CAGCATCCTT GAACAAGGAC AATTAACAGT 
     1681 TAACAAATAA GATATCTGAT AATAGGAATT CCTATAGTGT CACCTAAATG ATCCGGCTGC 
     1741 TAACAAAGCC CGAAAGGAAG CTGAGTTGGC TGCTGCCACC GCTGAGCAAT AACTAGCATA 
     1801 ACCCCTTGGG GCCTCTAAAC GGGTCTTGAG GGGTTTTTTG CTGAAAGGAG GAACTATATC 
     1861 CGGATCTGGC GTAATAGCGA AGAGGCCCGC ACCGATCGCC CTTCCCAACA GTTGCGCAGC 
     1921 CTGAATGGCG AATGGGACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT 
     1981 ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC 
     2041 CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT 
     2101 TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT 
     2161 GGTTCACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC 
     2221 ACGTTCTTTA ATAGTGGACT CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGTC 
     2281 TATTCTTTTG ATTTATAAGG GATTTTGCCG ATTTCGGCCT ATTGGTTAAA AAATGAGCTG 
     2341 ATTTAACAAA AATTTAACGC GAATTTTAAC AAAATATTAA CGCTTACAAT TTAGGTGGCA 
     2401 CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA 
     2461 TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA AAAAGGAAGA 
     2521 GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC 
     2581 CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG 
     2641 CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC 
     2701 CCGAAGAACG TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT 
     2761 CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT 
     2821 TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT 
     2881 TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC CAACTTACTT CTGACAACGA 
     2941 TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC 
     3001 TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA 
     3061 TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG 
     3121 CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC 
     3181 GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT 
     3241 CTCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT 
     3301 ACACGACGGG GAGTCAGGCA ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG 
     3361 CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA CTTTAGATTG 
     3421 ATTTAAAACT TCATTTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA 
     3481 TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA 
     3541 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA 
     3601 AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA 
     3661 AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT 
     3721 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT 
     3781 TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT 
     3841 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT 
     3901 TGGAGCGAAC GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA 
     3961 CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG 
     4021 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC 
     4081 GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA 
     4141 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA 
     4201 TGTTCTTTCC TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG 
     4261 CTGATACCGC TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG 
     4321 AAGAGCGCCC AATACGCAAA CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAG//  
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6.1.3 pRSET SL III 
GenBank Header  
LOCUS       pRSET_SL_III 2887 bp DNA SYN 06-APR-2016 
DEFINITION  pRSET_SL_III 
ACCESSION     
KEYWORDS     
SOURCE     
  ORGANISM  other sequences; artificial sequences; vectors. 
FEATURES             Location/Qualifiers 
     promoter        20..38 
                     /label=T7_promoter 
     misc_feature    75..91 
                     /label=T7_transl_en_RBS 
     misc_feature    148..180 
                     /label=T7_gene10_leader 
     terminator      1752..1880 
                     /label=T7_terminator 
     rep_origin      1969..2275 
                     /label=f1_origin 
     promoter        2468..2496 
                     /label=AmpR_promoter 
     gene            2538..3398 
                     /gene="beta lactamase" 
     rep_origin      3553..4172 
                     /label=pBR322_origin 
     misc_feature    1712..1720 
                     /note="3xSTOP" 
     misc_feature    184..222 
                     /note="upstream homologous region" 
     misc_feature    1712..1744 
                     /note="downstream homologous region" 
     misc_feature    214..222 
                     /note="Kozak_Start" 
     Promoter        229..283 
                     /label=LPP5 promoter 
     gene            284..1705 
                     /gene="sacB" 
     misc_feature    112..141 
                     /note="10 x His " 
     source          1..4393 
                     /dnas_title="pRSET_SL_III" 
  
Appendix - pRSET SL III 
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DNA 
ORIGIN       
        1 GATCTCGATC CCGCGAAATT AATACGACTC ACTATAGGGA GACCACAACG GTTTCCCTCT 
       61 AGAAATAATT TTGTTTAACT TTAAGAAGGA GATATACATA TGCGGGGTTC TCATCATCAT 
      121 CATCATCACC ATCACCATCA CCGCGGTATG GCTAGCATGA CTGGTGGACA GCAAATGGGT 
      181 CGGGATCTGT ACGACGATGA CGATAAGGAT CCGGCCACCA TGGATATCAA ACTGCAGTTG 
      241 ACAACATAAA AACTTTGTGT TATACTTGTA ACGTAAGGAG GTAATGAACA TCAAAAAGTT 
      301 TGCAAAACAA GCAACAGTAT TAACCTTTAC TACCGCACTG CTGGCAGGAG GCGCAACTCA 
      361 AGCGTTTGCG AAAGAAACGA ACCAAAAGCC ATATAAGGAA ACATACGGCA TTTCCCATAT 
      421 TACACGCCAT GATATGCTGC AAATCCCTGA ACAGCAAAAA AATGAAAAAT ATCAAGTTCC 
      481 TGAATTCGAT TCGTCCACAA TTAAAAATAT CTCTTCTGCA AAAGGCCTGG ACGTTTGGGA 
      541 CAGCTGGCCA TTACAAAACG CTGACGGCAC TGTCGCAAAC TATCACGGCT ACCACATCGT 
      601 CTTTGCATTA GCCGGAGATC CTAAAAATGC GGATGACACA TCGATTTACA TGTTCTATCA 
      661 AAAAGTCGGC GAAACTTCTA TTGACAGCTG GAAAAACGCT GGCCGCGTCT TTAAAGACAG 
      721 CGACAAATTC GATGCAAATG ATTCTATCCT AAAAGACCAA ACACAAGAAT GGTCAGGTTC 
      781 AGCCACATTT ACATCTGACG GAAAAATCCG TTTATTCTAC ACTGATTTCT CCGGTAAACA 
      841 TTACGGCAAA CAAACACTGA CAACTGCACA AGTTAACGTA TCAGCATCAG ACAGCTCTTT 
      901 GAACATCAAC GGTGTAGAGG ATTATAAATC AATCTTTGAC GGTGACGGAA AAACGTATCA 
      961 AAATGTACAG CAGTTCATCG ATGAAGGCAA CTACAGCTCA GGCGACAACC ATACGCTGAG 
     1021 AGATCCTCAC TACGTAGAAG ATAAAGGCCA CAAATACTTA GTATTTGAAG CAAACACTGG 
     1081 AACTGAAGAT GGCTACCAAG GCGAAGAATC TTTATTTAAC AAAGCATACT ATGGCAAAAG 
     1141 CACATCATTC TTCCGTCAAG AAAGTCAAAA ACTTCTGCAA AGCGATAAAA AACGCACGGC 
     1201 TGAGTTAGCA AACGGCGCTC TCGGTATGAT TGAGCTAAAC GATGATTACA CACTGAAAAA 
     1261 AGTGATGAAA CCGCTGATTG CATCTAACAC AGTAACAGAT GAAATTGAAC GCGCGAACGT 
     1321 CTTTAAAATG AACGGCAAAT GGTACCTGTT CACTGACTCC CGCGGATCAA AAATGACGAT 
     1381 TGACGGCATT ACGTCTAACG ATATTTACAT GCTTGGTTAT GTTTCTAATT CTTTAACTGG 
     1441 CCCATACAAG CCGCTGAACA AAACTGGCCT TGTGTTAAAA ATGGATCTTG ATCCTAACGA 
     1501 TGTAACCTTT ACTTACTCAC ACTTCGCTGT ACCTCAAGCG AAAGGAAACA ATGTCGTGAT 
     1561 TACAAGCTAT ATGACAAACA GAGGATTCTA CGCAGACAAA CAATCAACGT TTGCGCCAAG 
     1621 CTTCCTGCTG AACATCAAAG GCAAGAAAAC ATCTGTTGTC AAAGACAGCA TCCTTGAACA 
     1681 AGGACAATTA ACAGTTAACA AATAAGATAT CTGATAATAG GAATTCCTAT AGTGTCACCT 
     1741 AAATGATCCG GCTGCTAACA AAGCCCGAAA GGAAGCTGAG TTGGCTGCTG CCACCGCTGA 
     1801 GCAATAACTA GCATAACCCC TTGGGGCCTC TAAACGGGTC TTGAGGGGTT TTTTGCTGAA 
     1861 AGGAGGAACT ATATCCGGAT CTGGCGTAAT AGCGAAGAGG CCCGCACCGA TCGCCCTTCC 
     1921 CAACAGTTGC GCAGCCTGAA TGGCGAATGG GACGCGCCCT GTAGCGGCGC ATTAAGCGCG 
     1981 GCGGGTGTGG TGGTTACGCG CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT 
     2041 CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA 
     2101 AATCGGGGGC TCCCTTTAGG GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA 
     2161 CTTGATTAGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT 
     2221 TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC 
     2281 AACCCTATCT CGGTCTATTC TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG 
     2341 TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGCTT 
     2401 ACAATTTAGG TGGCACTTTT CGGGGAAATG TGCGCGGAAC CCCTATTTGT TTATTTTTCT 
     2461 AAATACATTC AAATATGTAT CCGCTCATGA GACAATAACC CTGATAAATG CTTCAATAAT 
     2521 ATTGAAAAAG GAAGAGTATG AGTATTCAAC ATTTCCGTGT CGCCCTTATT CCCTTTTTTG 
     2581 CGGCATTTTG CCTTCCTGTT TTTGCTCACC CAGAAACGCT GGTGAAAGTA AAAGATGCTG 
     2641 AAGATCAGTT GGGTGCACGA GTGGGTTACA TCGAACTGGA TCTCAACAGC GGTAAGATCC 
     2701 TTGAGAGTTT TCGCCCCGAA GAACGTTTTC CAATGATGAG CACTTTTAAA GTTCTGCTAT 
     2761 GTGGCGCGGT ATTATCCCGT ATTGACGCCG GGCAAGAGCA ACTCGGTCGC CGCATACACT 
     2821 ATTCTCAGAA TGACTTGGTT GAGTACTCAC CAGTCACAGA AAAGCATCTT ACGGATGGCA 
     2881 TGACAGTAAG AGAATTATGC AGTGCTGCCA TAACCATGAG TGATAACACT GCGGCCAACT 
     2941 TACTTCTGAC AACGATCGGA GGACCGAAGG AGCTAACCGC TTTTTTGCAC AACATGGGGG 
     3001 ATCATGTAAC TCGCCTTGAT CGTTGGGAAC CGGAGCTGAA TGAAGCCATA CCAAACGACG 
     3061 AGCGTGACAC CACGATGCCT GTAGCAATGG CAACAACGTT GCGCAAACTA TTAACTGGCG 
     3121 AACTACTTAC TCTAGCTTCC CGGCAACAAT TAATAGACTG GATGGAGGCG GATAAAGTTG 
     3181 CAGGACCACT TCTGCGCTCG GCCCTTCCGG CTGGCTGGTT TATTGCTGAT AAATCTGGAG 
     3241 CCGGTGAGCG TGGGTCTCGC GGTATCATTG CAGCACTGGG GCCAGATGGT AAGCCCTCCC 
     3301 GTATCGTAGT TATCTACACG ACGGGGAGTC AGGCAACTAT GGATGAACGA AATAGACAGA 
     3361 TCGCTGAGAT AGGTGCCTCA CTGATTAAGC ATTGGTAACT GTCAGACCAA GTTTACTCAT 
     3421 ATATACTTTA GATTGATTTA AAACTTCATT TTTAATTTAA AAGGATCTAG GTGAAGATCC 
     3481 TTTTTGATAA TCTCATGACC AAAATCCCTT AACGTGAGTT TTCGTTCCAC TGAGCGTCAG 
     3541 ACCCCGTAGA AAAGATCAAA GGATCTTCTT GAGATCCTTT TTTTCTGCGC GTAATCTGCT 
     3601 GCTTGCAAAC AAAAAAACCA CCGCTACCAG CGGTGGTTTG TTTGCCGGAT CAAGAGCTAC 
     3661 CAACTCTTTT TCCGAAGGTA ACTGGCTTCA GCAGAGCGCA GATACCAAAT ACTGTTCTTC 
     3721 TAGTGTAGCC GTAGTTAGGC CACCACTTCA AGAACTCTGT AGCACCGCCT ACATACCTCG 
     3781 CTCTGCTAAT CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT CTTACCGGGT 
     3841 TGGACTCAAG ACGATAGTTA CCGGATAAGG CGCAGCGGTC GGGCTGAACG GGGGGTTCGT 
     3901 GCACACAGCC CAGCTTGGAG CGAACGACCT ACACCGAACT GAGATACCTA CAGCGTGAGC 
     3961 TATGAGAAAG CGCCACGCTT CCCGAAGGGA GAAAGGCGGA CAGGTATCCG GTAAGCGGCA 
     4021 GGGTCGGAAC AGGAGAGCGC ACGAGGGAGC TTCCAGGGGG AAACGCCTGG TATCTTTATA 
     4081 GTCCTGTCGG GTTTCGCCAC CTCTGACTTG AGCGTCGATT TTTGTGATGC TCGTCAGGGG 
     4141 GGCGGAGCCT ATGGAAAAAC GCCAGCAACG CGGCCTTTTT ACGGTTCCTG GCCTTTTGCT 
     4201 GGCCTTTTGC TCACATGTTC TTTCCTGCGT TATCCCCTGA TTCTGTGGAT AACCGTATTA 
     4261 CCGCCTTTGA GTGAGCTGAT ACCGCTCGCC GCAGCCGAAC GACCGAGCGC AGCGAGTCAG 
     4321 TGAGCGAGGA AGCGGAAGAG CGCCCAATAC GCAAACCGCC TCTCCCCGCG CGTTGGCCGA 
     4381 TTCATTAATG CAG //  
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6.1.4 pcDNA3 SL 
GenBank Header 
LOCUS       pcDNA3_SL               5390 bp    DNA            06-APR-2016 
FEATURES             Location/Qualifiers 
     misc_feature    0..0 
                     /note="1. pcDNAII 3013bp, M13 ori/amp gene -> pcDNA3 
                     5446bp" 
     gene            2095..2889 
                     /gene="Neomycin resistance gene" 
     promoter        864..882 
                     /note="T7_promoter" 
     promoter        complement(943..960) 
                     /note="PRO bacteriophage Sp6" 
     rep_origin      3576..4249 
                     /note="ORI E. coli pMB1 (ColE1 and pBR322)" 
     gene            complement(4494..5254) 
                     /gene="beta lactamase" 
     rep_origin      1734..2059 
                     /note="f1 origin" 
     polyA_signal    962..1193 
                     /note="BGA polyA" 
     promoter        209..863 
                     /note="CMV promoter" 
     polyA_signal    2944..3316 
                     /note="SV40 polyA" 
     rep_origin      1928..2013 
                     /note="SV40 ori" 
     misc_feature    928..936 
                     /note="3xSTOP" 
     misc_recomb     883..921 
                     /note="upstream homologous region" 
     misc_recomb     928..960 
                     /note="downstream homologous region" 
     misc_recomb     913..921 
                     /note="Kozak_Start" 
     source          1..5390 
                     /dnas_title="pcDNA3_SL" 
  
Appendix - pcDNA3 SL 
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DNA 
ORIGIN       
        1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
       61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
      121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
      181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
      241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
      301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
      361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
      421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
      481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
      541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
      601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
      661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
      721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
      781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
      841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGGATCTGTA CGACGATGAC 
      901 GATAAGGATC CGGCCACCAT GGATATCTGA TAATAGGAAT TCCTATAGTG TCACCTAAAT 
      961 GCTAGAGCTC GCTGATCAGC CTCGACTGTG CCTTCTAGTT GCCAGCCATC TGTTGTTTGC 
     1021 CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT TTCCTAATAA 
     1081 AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT CTATTCTGGG GGGTGGGGTG 
     1141 GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA GGCATGCTGG GGATGCGGTG 
     1201 GGCTCTATGG CTTCTGAGGC GGAAAGAACC AGCTGGGGCT CTAGGGGGTA TCCCCACGCG 
     1261 CCCTGTAGCG GCGCATTAAG CGCGGCGGGT GTGGTGGTTA CGCGCAGCGT GACCGCTACA 
     1321 CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT CGCCACGTTC 
     1381 GCCGGCTTTC CCCGTCAAGC TCTAAATCGG GGCATCCCTT TAGGGTTCCG ATTTAGTGCT 
     1441 TTACGGCACC TCGACCCCAA AAAACTTGAT TAGGGTGATG GTTCACGTAG TGGGCCATCG 
     1501 CCCTGATAGA CGGTTTTTCG CCCTTTGACG TTGGAGTCCA CGTTCTTTAA TAGTGGACTC 
     1561 TTGTTCCAAA CTGGAACAAC ACTCAACCCT ATCTCGGTCT ATTCTTTTGA TTTATAAGGG 
     1621 ATTTTGGGGA TTTCGGCCTA TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACGCG 
     1681 AATTAATTCT GTGGAATGTG TGTCAGTTAG GGTGTGGAAA GTCCCCAGGC TCCCCAGGCA 
     1741 GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA CCAGGTGTGG AAAGTCCCCA 
     1801 GGCTCCCCAG CAGGCAGAAG TATGCAAAGC ATGCATCTCA ATTAGTCAGC AACCATAGTC 
     1861 CCGCCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA GTTCCGCCCA TTCTCCGCCC 
     1921 CATGGCTGAC TAATTTTTTT TATTTATGCA GAGGCCGAGG CCGCCTCTGC CTCTGAGCTA 
     1981 TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA GGCCTAGGCT TTTGCAAAAA GCTCCCGGGA 
     2041 GCTTGTATAT CCATTTTCGG ATCTGATCAA GAGACAGGAT GAGGATCGTT TCGCATGATT 
     2101 GAACAAGATG GATTGCACGC AGGTTCTCCG GCCGCTTGGG TGGAGAGGCT ATTCGGCTAT 
     2161 GACTGGGCAC AACAGACAAT CGGCTGCTCT GATGCCGCCG TGTTCCGGCT GTCAGCGCAG 
     2221 GGGCGCCCGG TTCTTTTTGT CAAGACCGAC CTGTCCGGTG CCCTGAATGA ACTGCAGGAC 
     2281 GAGGCAGCGC GGCTATCGTG GCTGGCCACG ACGGGCGTTC CTTGCGCAGC TGTGCTCGAC 
     2341 GTTGTCACTG AAGCGGGAAG GGACTGGCTG CTATTGGGCG AAGTGCCGGG GCAGGATCTC 
     2401 CTGTCATCTC ACCTTGCTCC TGCCGAGAAA GTATCCATCA TGGCTGATGC AATGCGGCGG 
     2461 CTGCATACGC TTGATCCGGC TACCTGCCCA TTCGACCACC AAGCGAAACA TCGCATCGAG 
     2521 CGAGCACGTA CTCGGATGGA AGCCGGTCTT GTCGATCAGG ATGATCTGGA CGAAGAGCAT 
     2581 CAGGGGCTCG CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG CGCGCATGCC CGACGGCGAG 
     2641 GATCTCGTCG TGACCCATGG CGATGCCTGC TTGCCGAATA TCATGGTGGA AAATGGCCGC 
     2701 TTTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG ACCGCTATCA GGACATAGCG 
     2761 TTGGCTACCC GTGATATTGC TGAAGAGCTT GGCGGCGAAT GGGCTGACCG CTTCCTCGTG 
     2821 CTTTACGGTA TCGCCGCTCC CGATTCGCAG CGCATCGCCT TCTATCGCCT TCTTGACGAG 
     2881 TTCTTCTGAG CGGGACTCTG GGGTTCGAAA TGACCGACCA AGCGACGCCC AACCTGCCAT 
     2941 CACGAGATTT CGATTCCACC GCCGCCTTCT ATGAAAGGTT GGGCTTCGGA ATCGTTTTCC 
     3001 GGGACGCCGG CTGGATGATC CTCCAGCGCG GGGATCTCAT GCTGGAGTTC TTCGCCCACC 
     3061 CCAACTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA 
     3121 CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT 
     3181 CTTATCATGT CTGTATACCG TCGACCTCTA GCTAGAGCTT GGCGTAATCA TGGTCATAGC 
     3241 TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA 
     3301 TAAAGTGTAA AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 
     3361 CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC 
     3421 GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC 
     3481 TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT 
     3541 TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG 
     3601 CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG 
     3661 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT 
     3721 ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA 
     3781 CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAA TGCTCACGCT 
     3841 GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC 
     3901 CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA 
     3961 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG 
     4021 TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG 
     4081 TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT 
     4141 GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA 
     4201 CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 
     4261 AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 
     4321 CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA 
     4381 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT 
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     4441 TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT 
     4501 TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 
     4561 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 
     4621 CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA 
     4681 ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG 
     4741 GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT 
     4801 TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG 
     4861 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 
     4921 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC 
     4981 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA 
     5041 CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC 
     5101 CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 
     5161 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG 
     5221 GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA 
     5281 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA 
     5341 AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC 
// 
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6.1.5 pcDNA3 SL II 
GenBank Header 
LOCUS       pcDNA3_SL_II            6873 bp    DNA            06-APR-2016 
 
FEATURES             Location/Qualifiers 
 
     gene            3578..4372 
                     /gene="Neomycin resistance gene" 
     promoter        864..882 
                     /note="PRO bacteriophage T7" 
     promoter        complement(2426..2443) 
                     /note="PRO bacteriophage Sp6" 
     rep_origin      5059..5732 
                     /note="ORI E. coli pMB1 (ColE1 and pBR322)" 
     gene            complement(5977..6737) 
                     /gene="beta lactamase" 
     rep_origin      3217..3542 
                     /note="f1 origin" 
     polyA_signal    2445..2676 
                     /note="BGA polyA" 
     promoter        209..863 
                     /note="CMV promoter" 
     polyA_signal    4427..4799 
                     /note="SV40 polyA" 
     rep_origin      3411..3496 
                     /note="SV40 ori" 
     misc_feature    2411..2419 
                     /note="3xSTOP" 
     misc_recomb     883..921 
                     /note="upstream homologous region" 
     misc_recomb     2411..2443 
                     /note="downstream homologous region" 
     misc_recomb     913..921 
                     /note="Kozak_Start" 
     Promoter        928..982 
                     /label=LPP5 promoter 
     gene            983..2404 
                     /gene="sacB" 
     source          1..6873 
                     /dnas_title="pcDNA3_SL_II" 
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DNA 
ORIGIN       
        1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
       61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
      121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
      181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
      241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
      301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
      361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
      421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
      481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
      541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
      601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
      661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
      721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
      781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
      841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGGATCTGTA CGACGATGAC 
      901 GATAAGGATC CGGCCACCAT GGATATCAAA CTGCAGTTGA CAACATAAAA ACTTTGTGTT 
      961 ATACTTGTAA CGTAAGGAGG TAATGAACAT CAAAAAGTTT GCAAAACAAG CAACAGTATT 
     1021 AACCTTTACT ACCGCACTGC TGGCAGGAGG CGCAACTCAA GCGTTTGCGA AAGAAACGAA 
     1081 CCAAAAGCCA TATAAGGAAA CATACGGCAT TTCCCATATT ACACGCCATG ATATGCTGCA 
     1141 AATCCCTGAA CAGCAAAAAA ATGAAAAATA TCAAGTTCCT GAATTCGATT CGTCCACAAT 
     1201 TAAAAATATC TCTTCTGCAA AAGGCCTGGA CGTTTGGGAC AGCTGGCCAT TACAAAACGC 
     1261 TGACGGCACT GTCGCAAACT ATCACGGCTA CCACATCGTC TTTGCATTAG CCGGAGATCC 
     1321 TAAAAATGCG GATGACACAT CGATTTACAT GTTCTATCAA AAAGTCGGCG AAACTTCTAT 
     1381 TGACAGCTGG AAAAACGCTG GCCGCGTCTT TAAAGACAGC GACAAATTCG ATGCAAATGA 
     1441 TTCTATCCTA AAAGACCAAA CACAAGAATG GTCAGGTTCA GCCACATTTA CATCTGACGG 
     1501 AAAAATCCGT TTATTCTACA CTGATTTCTC CGGTAAACAT TACGGCAAAC AAACACTGAC 
     1561 AACTGCACAA GTTAACGTAT CAGCATCAGA CAGCTCTTTG AACATCAACG GTGTAGAGGA 
     1621 TTATAAATCA ATCTTTGACG GTGACGGAAA AACGTATCAA AATGTACAGC AGTTCATCGA 
     1681 TGAAGGCAAC TACAGCTCAG GCGACAACCA TACGCTGAGA GATCCTCACT ACGTAGAAGA 
     1741 TAAAGGCCAC AAATACTTAG TATTTGAAGC AAACACTGGA ACTGAAGATG GCTACCAAGG 
     1801 CGAAGAATCT TTATTTAACA AAGCATACTA TGGCAAAAGC ACATCATTCT TCCGTCAAGA 
     1861 AAGTCAAAAA CTTCTGCAAA GCGATAAAAA ACGCACGGCT GAGTTAGCAA ACGGCGCTCT 
     1921 CGGTATGATT GAGCTAAACG ATGATTACAC ACTGAAAAAA GTGATGAAAC CGCTGATTGC 
     1981 ATCTAACACA GTAACAGATG AAATTGAACG CGCGAACGTC TTTAAAATGA ACGGCAAATG 
     2041 GTACCTGTTC ACTGACTCCC GCGGATCAAA AATGACGATT GACGGCATTA CGTCTAACGA 
     2101 TATTTACATG CTTGGTTATG TTTCTAATTC TTTAACTGGC CCATACAAGC CGCTGAACAA 
     2161 AACTGGCCTT GTGTTAAAAA TGGATCTTGA TCCTAACGAT GTAACCTTTA CTTACTCACA 
     2221 CTTCGCTGTA CCTCAAGCGA AAGGAAACAA TGTCGTGATT ACAAGCTATA TGACAAACAG 
     2281 AGGATTCTAC GCAGACAAAC AATCAACGTT TGCGCCAAGC TTCCTGCTGA ACATCAAAGG 
     2341 CAAGAAAACA TCTGTTGTCA AAGACAGCAT CCTTGAACAA GGACAATTAA CAGTTAACAA 
     2401 ATAAGATATC TGATAATAGG AATTCCTATA GTGTCACCTA AATGCTAGAG CTCGCTGATC 
     2461 AGCCTCGACT GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC 
     2521 CTTGACCCTG GAAGGTGCCA CTCCCACTGT CCTTTCCTAA TAAAATGAGG AAATTGCATC 
     2581 GCATTGTCTG AGTAGGTGTC ATTCTATTCT GGGGGGTGGG GTGGGGCAGG ACAGCAAGGG 
     2641 GGAGGATTGG GAAGACAATA GCAGGCATGC TGGGGATGCG GTGGGCTCTA TGGCTTCTGA 
     2701 GGCGGAAAGA ACCAGCTGGG GCTCTAGGGG GTATCCCCAC GCGCCCTGTA GCGGCGCATT 
     2761 AAGCGCGGCG GGTGTGGTGG TTACGCGCAG CGTGACCGCT ACACTTGCCA GCGCCCTAGC 
     2821 GCCCGCTCCT TTCGCTTTCT TCCCTTCCTT TCTCGCCACG TTCGCCGGCT TTCCCCGTCA 
     2881 AGCTCTAAAT CGGGGCATCC CTTTAGGGTT CCGATTTAGT GCTTTACGGC ACCTCGACCC 
     2941 CAAAAAACTT GATTAGGGTG ATGGTTCACG TAGTGGGCCA TCGCCCTGAT AGACGGTTTT 
     3001 TCGCCCTTTG ACGTTGGAGT CCACGTTCTT TAATAGTGGA CTCTTGTTCC AAACTGGAAC 
     3061 AACACTCAAC CCTATCTCGG TCTATTCTTT TGATTTATAA GGGATTTTGG GGATTTCGGC 
     3121 CTATTGGTTA AAAAATGAGC TGATTTAACA AAAATTTAAC GCGAATTAAT TCTGTGGAAT 
     3181 GTGTGTCAGT TAGGGTGTGG AAAGTCCCCA GGCTCCCCAG GCAGGCAGAA GTATGCAAAG 
     3241 CATGCATCTC AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG 
     3301 AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC 
     3361 CATCCCGCCC CTAACTCCGC CCAGTTCCGC CCATTCTCCG CCCCATGGCT GACTAATTTT 
     3421 TTTTATTTAT GCAGAGGCCG AGGCCGCCTC TGCCTCTGAG CTATTCCAGA AGTAGTGAGG 
     3481 AGGCTTTTTT GGAGGCCTAG GCTTTTGCAA AAAGCTCCCG GGAGCTTGTA TATCCATTTT 
     3541 CGGATCTGAT CAAGAGACAG GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA 
     3601 CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC 
     3661 AATCGGCTGC TCTGATGCCG CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT 
     3721 TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAACTGCAG GACGAGGCAG CGCGGCTATC 
     3781 GTGGCTGGCC ACGACGGGCG TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG 
     3841 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC 
     3901 TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC 
     3961 GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT 
     4021 GGAAGCCGGT CTTGTCGATC AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC 
     4081 CGAACTGTTC GCCAGGCTCA AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA 
     4141 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTCATCGA 
     4201 CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT 
     4261 TGCTGAAGAG CTTGGCGGCG AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC 
     4321 TCCCGATTCG CAGCGCATCG CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT 
     4381 CTGGGGTTCG AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGATTCC 
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     4441 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG 
     4501 ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCC ACCCCAACTT GTTTATTGCA 
     4561 GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTTTT 
     4621 TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGTATA 
     4681 CCGTCGACCT CTAGCTAGAG CTTGGCGTAA TCATGGTCAT AGCTGTTTCC TGTGTGAAAT 
     4741 TGTTATCCGC TCACAATTCC ACACAACATA CGAGCCGGAA GCATAAAGTG TAAAGCCTGG 
     4801 GGTGCCTAAT GAGTGAGCTA ACTCACATTA ATTGCGTTGC GCTCACTGCC CGCTTTCCAG 
     4861 TCGGGAAACC TGTCGTGCCA GCTGCATTAA TGAATCGGCC AACGCGCGGG GAGAGGCGGT 
     4921 TTGCGTATTG GGCGCTCTTC CGCTTCCTCG CTCACTGACT CGCTGCGCTC GGTCGTTCGG 
     4981 CTGCGGCGAG CGGTATCAGC TCACTCAAAG GCGGTAATAC GGTTATCCAC AGAATCAGGG 
     5041 GATAACGCAG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG 
     5101 GCCGCGTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCCTG ACGAGCATCA CAAAAATCGA 
     5161 CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC GTTTCCCCCT 
     5221 GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC TTACCGGATA CCTGTCCGCC 
     5281 TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT CAATGCTCAC GCTGTAGGTA TCTCAGTTCG 
     5341 GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA GCCCGACCGC 
     5401 TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGA CTTATCGCCA 
     5461 CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT ATGTAGGCGG TGCTACAGAG 
     5521 TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGGA CAGTATTTGG TATCTGCGCT 
     5581 CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT CTTGATCCGG CAAACAAACC 
     5641 ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC AAGCAGCAGA TTACGCGCAG AAAAAAAGGA 
     5701 TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG CTCAGTGGAA CGAAAACTCA 
     5761 CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT TCACCTAGAT CCTTTTAAAT 
     5821 TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT AAACTTGGTC TGACAGTTAC 
     5881 CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTTCGTTC ATCCATAGTT 
     5941 GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG GCTTACCATC TGGCCCCAGT 
     6001 GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG ATTTATCAGC AATAAACCAG 
     6061 CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT CCTGCAACTT TATCCGCCTC CATCCAGTCT 
     6121 ATTAATTGTT GCCGGGAAGC TAGAGTAAGT AGTTCGCCAG TTAATAGTTT GCGCAACGTT 
     6181 GTTGCCATTG CTACAGGCAT CGTGGTGTCA CGCTCGTCGT TTGGTATGGC TTCATTCAGC 
     6241 TCCGGTTCCC AACGATCAAG GCGAGTTACA TGATCCCCCA TGTTGTGCAA AAAAGCGGTT 
     6301 AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG CCGCAGTGTT ATCACTCATG 
     6361 GTTATGGCAG CACTGCATAA TTCTCTTACT GTCATGCCAT CCGTAAGATG CTTTTCTGTG 
     6421 ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTA TGCGGCGACC GAGTTGCTCT 
     6481 TGCCCGGCGT CAATACGGGA TAATACCGCG CCACATAGCA GAACTTTAAA AGTGCTCATC 
     6541 ATTGGAAAAC GTTCTTCGGG GCGAAAACTC TCAAGGATCT TACCGCTGTT GAGATCCAGT 
     6601 TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT CTTTTACTTT CACCAGCGTT 
     6661 TCTGGGTGAG CAAAAACAGG AAGGCAAAAT GCCGCAAAAA AGGGAATAAG GGCGACACGG 
     6721 AAATGTTGAA TACTCATACT CTTCCTTTTT CAATATTATT GAAGCATTTA TCAGGGTTAT 
     6781 TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT AGGGGTTCCG 
     6841 CGCACATTTC CCCGAAAAGT GCCACCTGAC GTC 
// 
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6.1.6 pSinRep5 SL 
GenBank Header 
LOCUS       pSinRep5_SL            11426 bp    DNA      r     06-APR-2016 
FEATURES             Location/Qualifiers 
     misc_feature    11408..11426 
                     /note="SP6" 
     gene            60..7598 
                     /note="p270 nonstructural polyprotein" 
     promoter        7580..7603 
                     /note="PSG subgenomic promoter" 
     polyA_site      9472..9508 
                     /note="poly A" 
     gene            9702..10560 
                     /note="beta lactamase" 
     promoter        9632..9660 
                     /note="Amp promoter" 
     misc_feature    7629..7649 
                     /note="upstream homologous region" 
     misc_feature    7641..7649 
                     /note="Kozak_Start" 
     Promoter        7658..7712 
                     /label=LPP5 promoter 
     gene            7713..9134 
                     /note="sacB" 
                     /lgene=sacB 
     misc_feature    9143..9151 
                     /note="3xSTOP" 
     misc_feature    9143..9163 
                     /note="downstream homologous region" 
     source          1..11426 
                     /dnas_title="pSinRep5_SL" 
     rep_origin      10717..11336 
                     /note="pBR322" 
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DNA 
ORIGIN       
        1 ATTGACGGCG TAGTACACAC TATTGAATCA AACAGCCGAC CAATTGCACT ACCATCACAA 
       61 TGGAGAAGCC AGTAGTAAAC GTAGACGTAG ACCCCCAGAG TCCGTTTGTC GTGCAACTGC 
      121 AAAAAAGCTT CCCGCAATTT GAGGTAGTAG CACAGCAGGT CACTCCAAAT GACCATGCTA 
      181 ATGCCAGAGC ATTTTCGCAT CTGGCCAGTA AACTAATCGA GCTGGAGGTT CCTACCACAG 
      241 CGACGATCTT GGACATAGGC AGCGCACCGG CTCGTAGAAT GTTTTCCGAG CACCAGTATC 
      301 ATTGTGTCTG CCCCATGCGT AGTCCAGAAG ACCCGGACCG CATGATGAAA TACGCCAGTA 
      361 AACTGGCGGA AAAAGCGTGC AAGATTACAA ACAAGAACTT GCATGAGAAG ATTAAGGATC 
      421 TCCGGACCGT ACTTGATACG CCGGATGCTG AAACACCATC GCTCTGCTTT CACAACGATG 
      481 TTACCTGCAA CATGCGTGCC GAATATTCCG TCATGCAGGA CGTGTATATC AACGCTCCCG 
      541 GAACTATCTA TCATCAGGCT ATGAAAGGCG TGCGGACCCT GTACTGGATT GGCTTCGACA 
      601 CCACCCAGTT CATGTTCTCG GCTATGGCAG GTTCGTACCC TGCGTACAAC ACCAACTGGG 
      661 CCGACGAGAA AGTCCTTGAA GCGCGTAACA TCGGACTTTG CAGCACAAAG CTGAGTGAAG 
      721 GTAGGACAGG AAAATTGTCG ATAATGAGGA AGAAGGAGTT GAAGCCCGGG TCGCGGGTTT 
      781 ATTTCTCCGT AGGATCGACA CTTTATCCAG AACACAGAGC CAGCTTGCAG AGCTGGCATC 
      841 TTCCATCGGT GTTCCACTTG AATGGAAAGC AGTCGTACAC TTGCCGCTGT GATACAGTGG 
      901 TGAGTTGCGA AGGCTACGTA GTGAAGAAAA TCACCATCAG TCCCGGGATC ACGGGAGAAA 
      961 CCGTGGGATA CGCGGTTACA CACAATAGCG AGGGCTTCTT GCTATGCAAA GTTACTGACA 
     1021 CAGTAAAAGG AGAACGGGTA TCGTTCCCTG TGTGCACGTA CATCCCGGCC ACCATATGCG 
     1081 ATCAGATGAC TGGTATAATG GCCACGGATA TATCACCTGA CGATGCACAA AAACTTCTGG 
     1141 TTGGGCTCAA CCAGCGAATT GTCATTAACG GTAGGACTAA CAGGAACACC AACACCATGC 
     1201 AAAATTACCT TCTGCCGATC ATAGCACAAG GGTTCAGCAA ATGGGCTAAG GAGCGCAAGG 
     1261 ATGATCTTGA TAACGAGAAA ATGCTGGGTA CTAGAGAACG CAAGCTTACG TATGGCTGCT 
     1321 TGTGGGCGTT TCGCACTAAG AAAGTACATT CGTTTTATCG CCCACCTGGA ACGCAGACCT 
     1381 GCGTAAAAGT CCCAGCCTCT TTTAGCGCTT TTCCCATGTC GTCCGTATGG ACGACCTCTT 
     1441 TGCCCATGTC GCTGAGGCAG AAATTGAAAC TGGCATTGCA ACCAAAGAAG GAGGAAAAAC 
     1501 TGCTGCAGGT CTCGGAGGAA TTAGTCATGG AGGCCAAGGC TGCTTTTGAG GATGCTCAGG 
     1561 AGGAAGCCAG AGCGGAGAAG CTCCGAGAAG CACTTCCACC ATTAGTGGCA GACAAAGGCA 
     1621 TCGAGGCAGC CGCAGAAGTT GTCTGCGAAG TGGAGGGGCT CCAGGCGGAC ATCGGAGCAG 
     1681 CATTAGTTGA AACCCCGCGC GGTCACGTAA GGATAATACC TCAAGCAAAT GACCGTATGA 
     1741 TCGGACAGTA TATCGTTGTC TCGCCAAACT CTGTGCTGAA GAATGCCAAA CTCGCACCAG 
     1801 CGCACCCGCT AGCAGATCAG GTTAAGATCA TAACACACTC CGGAAGATCA GGAAGGTACG 
     1861 CGGTCGAACC ATACGACGCT AAAGTACTGA TGCCAGCAGG AGGTGCCGTA CCATGGCCAG 
     1921 AATTCCTAGC ACTGAGTGAG AGCGCCACGT TAGTGTACAA CGAAAGAGAG TTTGTGAACC 
     1981 GCAAACTATA CCACATTGCC ATGCATGGCC CCGCCAAGAA TACAGAAGAG GAGCAGTACA 
     2041 AGGTTACAAA GGCAGAGCTT GCAGAAACAG AGTACGTGTT TGACGTGGAC AAGAAGCGTT 
     2101 GCGTTAAGAA GGAAGAAGCC TCAGGTCTGG TCCTCTCGGG AGAACTGACC AACCCTCCCT 
     2161 ATCATGAGCT AGCTCTGGAG GGACTGAAGA CCCGACCTGC GGTCCCGTAC AAGGTCGAAA 
     2221 CAATAGGAGT GATAGGCACA CCGGGGTCGG GCAAGTCAGC TATTATCAAG TCAACTGTCA 
     2281 CGGCACGAGA TCTTGTTACC AGCGGAAAGA AAGAAAATTG TCGCGAAATT GAGGCCGACG 
     2341 TGCTAAGACT GAGGGGTATG CAGATTACGT CGAAGACAGT AGATTCGGTT ATGCTCAACG 
     2401 GATGCCACAA AGCCGTAGAA GTGCTGTACG TTGACGAAGC GTTCGCGTGC CACGCAGGAG 
     2461 CACTACTTGC CTTGATTGCT ATCGTCAGGC CCCGCAAGAA GGTAGTACTA TGCGGAGACC 
     2521 CCATGCAATG CGGATTCTTC AACATGATGC AACTAAAGGT ACATTTCAAT CACCCTGAAA 
     2581 AAGACATATG CACCAAGACA TTCTACAAGT ATATCTCCCG GCGTTGCACA CAGCCAGTTA 
     2641 CAGCTATTGT ATCGACACTG CATTACGATG GAAAGATGAA AACCACGAAC CCGTGCAAGA 
     2701 AGAACATTGA AATCGATATT ACAGGGGCCA CAAAGCCGAA GCCAGGGGAT ATCATCCTGA 
     2761 CATGTTTCCG CGGGTGGGTT AAGCAATTGC AAATCGACTA TCCCGGACAT GAAGTAATGA 
     2821 CAGCCGCGGC CTCACAAGGG CTAACCAGAA AAGGAGTGTA TGCCGTCCGG CAAAAAGTCA 
     2881 ATGAAAACCC ACTGTACGCG ATCACATCAG AGCATGTGAA CGTGTTGCTC ACCCGCACTG 
     2941 AGGACAGGCT AGTGTGGAAA ACCTTGCAGG GCGACCCATG GATTAAGCAG CCCACTAACA 
     3001 TACCTAAAGG AAACTTTCAG GCTACTATAG AGGACTGGGA AGCTGAACAC AAGGGAATAA 
     3061 TTGCTGCAAT AAACAGCCCC ACTCCCCGTG CCAATCCGTT CAGCTGCAAG ACCAACGTTT 
     3121 GCTGGGCGAA AGCATTGGAA CCGATACTAG CCACGGCCGG TATCGTACTT ACCGGTTGCC 
     3181 AGTGGAGCGA ACTGTTCCCA CAGTTTGCGG ATGACAAACC ACATTCGGCC ATTTACGCCT 
     3241 TAGACGTAAT TTGCATTAAG TTTTTCGGCA TGGACTTGAC AAGCGGACTG TTTTCTAAAC 
     3301 AGAGCATCCC ACTAACGTAC CATCCCGCCG ATTCAGCGAG GCCGGTAGCT CATTGGGACA 
     3361 ACAGCCCAGG AACCCGCAAG TATGGGTACG ATCACGCCAT TGCCGCCGAA CTCTCCCGTA 
     3421 GATTTCCGGT GTTCCAGCTA GCTGGGAAGG GCACACAACT TGATTTGCAG ACGGGGAGAA 
     3481 CCAGAGTTAT CTCTGCACAG CATAACCTGG TCCCGGTGAA CCGCAATCTT CCTCACGCCT 
     3541 TAGTCCCCGA GTACAAGGAG AAGCAACCCG GCCCGGTCAA AAAATTCTTG AACCAGTTCA 
     3601 AACACCACTC AGTACTTGTG GTATCAGAGG AAAAAATTGA AGCTCCCCGT AAGAGAATCG 
     3661 AATGGATCGC CCCGATTGGC ATAGCCGGTG CAGATAAGAA CTACAACCTG GCTTTCGGGT 
     3721 TTCCGCCGCA GGCACGGTAC GACCTGGTGT TCATCAACAT TGGAACTAAA TACAGAAACC 
     3781 ACCACTTTCA GCAGTGCGAA GACCATGCGG CGACCTTAAA AACCCTTTCG CGTTCGGCCC 
     3841 TGAATTGCCT TAACCCAGGA GGCACCCTCG TGGTGAAGTC CTATGGCTAC GCCGACCGCA 
     3901 ACAGTGAGGA CGTAGTCACC GCTCTTGCCA GAAAGTTTGT CAGGGTGTCT GCAGCGAGAC 
     3961 CAGATTGTGT CTCAAGCAAT ACAGAAATGT ACCTGATTTT CCGACAACTA GACAACAGCC 
     4021 GTACACGGCA ATTCACCCCG CACCATCTGA ATTGCGTGAT TTCGTCCGTG TATGAGGGTA 
     4081 CAAGAGATGG AGTTGGAGCC GCGCCGTCAT ACCGCACCAA AAGGGAGAAT ATTGCTGACT 
     4141 GTCAAGAGGA AGCAGTTGTC AACGCAGCCA ATCCGCTGGG TAGACCAGGC GAAGGAGTCT 
     4201 GCCGTGCCAT CTATAAACGT TGGCCGACCA GTTTTACCGA TTCAGCCACG GAGACAGGCA 
     4261 CCGCAAGAAT GACTGTGTGC CTAGGAAAGA AAGTGATCCA CGCGGTCGGC CCTGATTTCC 
     4321 GGAAGCACCC AGAAGCAGAA GCCTTGAAAT TGCTACAAAA CGCCTACCAT GCAGTGGCAG 
     4381 ACTTAGTAAA TGAACATAAC ATCAAGTCTG TCGCCATTCC ACTGCTATCT ACAGGCATTT 
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     4441 ACGCAGCCGG AAAAGACCGC CTTGAAGTAT CACTTAACTG CTTGACAACC GCGCTAGACA 
     4501 GAACTGACGC GGACGTAACC ATCTATTGCC TGGATAAGAA GTGGAAGGAA AGAATCGACG 
     4561 CGGCACTCCA ACTTAAGGAG TCTGTAACAG AGCTGAAGGA TGAAGATATG GAGATCGACG 
     4621 ATGAGTTAGT ATGGATTCAT CCAGACAGTT GCTTGAAGGG AAGAAAGGGA TTCAGTACTA 
     4681 CAAAAGGAAA ATTGTATTCG TACTTCGAAG GCACCAAATT CCATCAAGCA GCAAAAGACA 
     4741 TGGCGGAGAT AAAGGTCCTG TTCCCTAATG ACCAGGAAAG TAATGAACAA CTGTGTGCCT 
     4801 ACATATTGGG TGAGACCATG GAAGCAATCC GCGAAAAGTG CCCGGTCGAC CATAACCCGT 
     4861 CGTCTAGCCC GCCCAAAACG TTGCCGTGCC TTTGCATGTA TGCCATGACG CCAGAAAGGG 
     4921 TCCACAGACT TAGAAGCAAT AACGTCAAAG AAGTTACAGT ATGCTCCTCC ACCCCCCTTC 
     4981 CTAAGCACAA AATTAAGAAT GTTCAGAAGG TTCAGTGCAC GAAAGTAGTC CTGTTTAATC 
     5041 CGCACACTCC CGCATTCGTT CCCGCCCGTA AGTACATAGA AGTGCCAGAA CAGCCTACCG 
     5101 CTCCTCCTGC ACAGGCCGAG GAGGCCCCCG AAGTTGTAGC GACACCGTCA CCATCTACAG 
     5161 CTGATAACAC CTCGCTTGAT GTCACAGACA TCTCACTGGA TATGGATGAC AGTAGCGAAG 
     5221 GCTCACTTTT TTCGAGCTTT AGCGGATCGG ACAACTCTAT TACTAGTATG GACAGTTGGT 
     5281 CGTCAGGACC TAGTTCACTA GAGATAGTAG ACCGAAGGCA GGTGGTGGTG GCTGACGTTC 
     5341 ATGCCGTCCA AGAGCCTGCC CCTATTCCAC CGCCAAGGCT AAAGAAGATG GCCCGCCTGG 
     5401 CAGCGGCAAG AAAAGAGCCC ACTCCACCGG CAAGCAATAG CTCTGAGTCC CTCCACCTCT 
     5461 CTTTTGGTGG GGTATCCATG TCCCTCGGAT CAATTTTCGA CGGAGAGACG GCCCGCCAGG 
     5521 CAGCGGTACA ACCCCTGGCA ACAGGCCCCA CGGATGTGCC TATGTCTTTC GGATCGTTTT 
     5581 CCGACGGAGA GATTGATGAG CTGAGCCGCA GAGTAACTGA GTCCGAACCC GTCCTGTTTG 
     5641 GATCATTTGA ACCGGGCGAA GTGAACTCAA TTATATCGTC CCGATCAGCC GTATCTTTTC 
     5701 CACTACGCAA GCAGAGACGT AGACGCAGGA GCAGGAGGAC TGAATACTGA CTAACCGGGG 
     5761 TAGGTGGGTA CATATTTTCG ACGGACACAG GCCCTGGGCA CTTGCAAAAG AAGTCCGTTC 
     5821 TGCAGAACCA GCTTACAGAA CCGACCTTGG AGCGCAATGT CCTGGAAAGA ATTCATGCCC 
     5881 CGGTGCTCGA CACGTCGAAA GAGGAACAAC TCAAACTCAG GTACCAGATG ATGCCCACCG 
     5941 AAGCCAACAA AAGTAGGTAC CAGTCTCGTA AAGTAGAAAA TCAGAAAGCC ATAACCACTG 
     6001 AGCGACTACT GTCAGGACTA CGACTGTATA ACTCTGCCAC AGATCAGCCA GAATGCTATA 
     6061 AGATCACCTA TCCGAAACCA TTGTACTCCA GTAGCGTACC GGCGAACTAC TCCGATCCAC 
     6121 AGTTCGCTGT AGCTGTCTGT AACAACTATC TGCATGAGAA CTATCCGACA GTAGCATCTT 
     6181 ATCAGATTAC TGACGAGTAC GATGCTTACT TGGATATGGT AGACGGGACA GTCGCCTGCC 
     6241 TGGATACTGC AACCTTCTGC CCCGCTAAGC TTAGAAGTTA CCCGAAAAAA CATGAGTATA 
     6301 GAGCCCCGAA TATCCGCAGT GCGGTTCCAT CAGCGATGCA GAACACGCTA CAAAATGTGC 
     6361 TCATTGCCGC AACTAAAAGA AATTGCAACG TCACGCAGAT GCGTGAACTG CCAACACTGG 
     6421 ACTCAGCGAC ATTCAATGTC GAATGCTTTC GAAAATATGC ATGTAATGAC GAGTATTGGG 
     6481 AGGAGTTCGC TCGGAAGCCA ATTAGGATTA CCACTGAGTT TGTCACCGCA TATGTAGCTA 
     6541 GACTGAAAGG CCCTAAGGCC GCCGCACTAT TTGCAAAGAC GTATAATTTG GTCCCATTGC 
     6601 AAGAAGTGCC TATGGATAGA TTCGTCATGG ACATGAAAAG AGACGTGAAA GTTACACCAG 
     6661 GCACGAAACA CACAGAAGAA AGACCGAAAG TACAAGTGAT ACAAGCCGCA GAACCCCTGG 
     6721 CGACTGCTTA CTTATGCGGG ATTCACCGGG AATTAGTGCG TAGGCTTACG GCCGTCTTGC 
     6781 TTCCAAACAT TCACACGCTT TTTGACATGT CGGCGGAGGA TTTTGATGCA ATCATAGCAG 
     6841 AACACTTCAA GCAAGGCGAC CCGGTACTGG AGACGGATAT CGCATCATTC GACAAAAGCC 
     6901 AAGACGACGC TATGGCGTTA ACCGGTCTGA TGATCTTGGA GGACCTGGGT GTGGATCAAC 
     6961 CACTACTCGA CTTGATCGAG TGCGCCTTTG GAGAAATATC ATCCACCCAT CTACCTACGG 
     7021 GTACTCGTTT TAAATTCGGG GCGATGATGA AATCCGGAAT GTTCCTCACA CTTTTTGTCA 
     7081 ACACAGTTTT GAATGTCGTT ATCGCCAGCA GAGTACTAGA AGAGCGGCTT AAAACGTCCA 
     7141 GATGTGCAGC GTTCATTGGC GACGACAACA TCATACATGG AGTAGTATCT GACAAAGAAA 
     7201 TGGCTGAGAG GTGCGCCACC TGGCTCAACA TGGAGGTTAA GATCATCGAC GCAGTCATCG 
     7261 GTGAGAGACC ACCTTACTTC TGCGGCGGAT TTATCTTGCA AGATTCGGTT ACTTCCACAG 
     7321 CGTGCCGCGT GGCGGATCCC CTGAAAAGGC TGTTTAAGTT GGGTAAACCG CTCCCAGCCG 
     7381 ACGACGAGCA AGACGAAGAC AGAAGACGCG CTCTGCTAGA TGAAACAAAG GCGTGGTTTA 
     7441 GAGTAGGTAT AACAGGCACT TTAGCAGTGG CCGTGACGAC CCGGTATGAG GTAGACAATA 
     7501 TTACACCTGT CCTACTGGCA TTGAGAACTT TTGCCCAGAG CAAAAGAGCA TTCCAAGCCA 
     7561 TCAGAGGGGA AATAAAGCAT CTCTACGGTG GTCCTAAATA GTCAGCATAG TACATTTCAT 
     7621 CTGACTAAGA TAAGGATCCG GCCACCATGA TTTAAATAAA CTGCAGTTGA CAACATAAAA 
     7681 ACTTTGTGTT ATACTTGTAA CGTAAGGAGG TAATGAACAT CAAAAAGTTT GCAAAACAAG 
     7741 CAACAGTATT AACCTTTACT ACCGCACTGC TGGCAGGAGG CGCAACTCAA GCGTTTGCGA 
     7801 AAGAAACGAA CCAAAAGCCA TATAAGGAAA CATACGGCAT TTCCCATATT ACACGCCATG 
     7861 ATATGCTGCA AATCCCTGAA CAGCAAAAAA ATGAAAAATA TCAAGTTCCT GAATTCGATT 
     7921 CGTCCACAAT TAAAAATATC TCTTCTGCAA AAGGCCTGGA CGTTTGGGAC AGCTGGCCAT 
     7981 TACAAAACGC TGACGGCACT GTCGCAAACT ATCACGGCTA CCACATCGTC TTTGCATTAG 
     8041 CCGGAGATCC TAAAAATGCG GATGACACAT CGATTTACAT GTTCTATCAA AAAGTCGGCG 
     8101 AAACTTCTAT TGACAGCTGG AAAAACGCTG GCCGCGTCTT TAAAGACAGC GACAAATTCG 
     8161 ATGCAAATGA TTCTATCCTA AAAGACCAAA CACAAGAATG GTCAGGTTCA GCCACATTTA 
     8221 CATCTGACGG AAAAATCCGT TTATTCTACA CTGATTTCTC CGGTAAACAT TACGGCAAAC 
     8281 AAACACTGAC AACTGCACAA GTTAACGTAT CAGCATCAGA CAGCTCTTTG AACATCAACG 
     8341 GTGTAGAGGA TTATAAATCA ATCTTTGACG GTGACGGAAA AACGTATCAA AATGTACAGC 
     8401 AGTTCATCGA TGAAGGCAAC TACAGCTCAG GCGACAACCA TACGCTGAGA GATCCTCACT 
     8461 ACGTAGAAGA TAAAGGCCAC AAATACTTAG TATTTGAAGC AAACACTGGA ACTGAAGATG 
     8521 GCTACCAAGG CGAAGAATCT TTATTTAACA AAGCATACTA TGGCAAAAGC ACATCATTCT 
     8581 TCCGTCAAGA AAGTCAAAAA CTTCTGCAAA GCGATAAAAA ACGCACGGCT GAGTTAGCAA 
     8641 ACGGCGCTCT CGGTATGATT GAGCTAAACG ATGATTACAC ACTGAAAAAA GTGATGAAAC 
     8701 CGCTGATTGC ATCTAACACA GTAACAGATG AAATTGAACG CGCGAACGTC TTTAAAATGA 
     8761 ACGGCAAATG GTACCTGTTC ACTGACTCCC GCGGATCAAA AATGACGATT GACGGCATTA 
     8821 CGTCTAACGA TATTTACATG CTTGGTTATG TTTCTAATTC TTTAACTGGC CCATACAAGC 
     8881 CGCTGAACAA AACTGGCCTT GTGTTAAAAA TGGATCTTGA TCCTAACGAT GTAACCTTTA 
     8941 CTTACTCACA CTTCGCTGTA CCTCAAGCGA AAGGAAACAA TGTCGTGATT ACAAGCTATA 
     9001 TGACAAACAG AGGATTCTAC GCAGACAAAC AATCAACGTT TGCGCCAAGC TTCCTGCTGA 
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     9061 ACATCAAAGG CAAGAAAACA TCTGTTGTCA AAGACAGCAT CCTTGAACAA GGACAATTAA 
     9121 CAGTTAACAA ATAAATTTAA ATTGATAATA GGAATTCCTA TAGCAATGAT CCGACCAGCA 
     9181 AAACTCGATG TACTTCCGAG GAACTGATGT GCATAATGCA TCAGGCTGGT ACATTAGATC 
     9241 CCCGCTTACC GCGGGCAATA TAGCAACACT AAAAACTCGA TGTACTTCCG AGGAAGCGCA 
     9301 GTGCATAATG CTGCGCAGTG TTGCCACATA ACCACTATAT TAACCATTTA TCTAGCGGAC 
     9361 GCCAAAAACT CAATGTATTT CTGAGGAAGC GTGGTGCATA ATGCCACGCA GCGTCTGCAT 
     9421 AACTTTTATT ATTTCTTTTA TTAATCAACA AAATTTTGTT TTTAACATTT CAAAAAAAAA 
     9481 AAAAAAAAAA AAAAAAAAAA AAAAAAAAGG GAATTCCTCG ATTAATTAAG CGGCCGCTCG 
     9541 AGGGGAATTA ATTCTTGAAG ACGAAAGGGC CAGGTGGCAC TTTTCGGGGA AATGTGCGCG 
     9601 GAACCCCTAT TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC ATGAGACAAT 
     9661 AACCCTGATA AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT CAACATTTCC 
     9721 GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT CACCCAGAAA 
     9781 CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT TACATCGAAC 
     9841 TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT TTTCCAATGA 
     9901 TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTGTTGAC GCCGGGCAAG 
     9961 AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC TCACCAGTCA 
    10021 CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT GCCATAACCA 
    10081 TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG AAGGAGCTAA 
    10141 CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG GAACCGGAGC 
    10201 TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGCA ATGGCAACAA 
    10261 CGTTGCGCAA ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA CAATTAATAG 
    10321 ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT CCGGCTGGCT 
    10381 GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC ATTGCAGCAC 
    10441 TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG AGTCAGGCAA 
    10501 CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT AAGCATTGGT 
    10561 AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA TTTAAAACTT CATTTTTAAT 
    10621 TTAAAAGGAT CTAGGTGAAG ATCCTTTTTG ATAATCTCAT GACCAAAATC CCTTAACGTG 
    10681 AGTTTTCGTT CCACTGAGCG TCAGACCCCG TAGAAAAGAT CAAAGGATCT TCTTGAGATC 
    10741 CTTTTTTTCT GCGCGTAATC TGCTGCTTGC AAACAAAAAA ACCACCGCTA CCAGCGGTGG 
    10801 TTTGTTTGCC GGATCAAGAG CTACCAACTC TTTTTCCGAA GGTAACTGGC TTCAGCAGAG 
    10861 CGCAGATACC AAATACTGTC CTTCTAGTGT AGCCGTAGTT AGGCCACCAC TTCAAGAACT 
    10921 CTGTAGCACC GCCTACATAC CTCGCTCTGC TAATCCTGTT ACCAGTGGCT GCTGCCAGTG 
    10981 GCGATAAGTC GTGTCTTACC GGGTTGGACT CAAGACGATA GTTACCGGAT AAGGCGCAGC 
    11041 GGTCGGGCTG AACGGGGGGT TCGTGCACAC AGCCCAGCTT GGAGCGAACG ACCTACACCG 
    11101 AACTGAGATA CCTACAGCGT GAGCATTGAG AAAGCGCCAC GCTTCCCGAA GGGAGAAAGG 
    11161 CGGACAGGTA TCCGGTAAGC GGCAGGGTCG GAACAGGAGA GCGCACGAGG GAGCTTCCAG 
    11221 GGGGAAACGC CTGGTATCTT TATAGTCCTG TCGGGTTTCG CCACCTCTGA CTTGAGCGTC 
    11281 GATTTTTGTG ATGCTCGTCA GGGGGGCGGA GCCTATGGAA AAACGCCAGC AACGCGAGCT 
    11341 CGTATGGACA TATTGTCGTT AGAACGCGGC TACAATTAAT ACATAACCTT ATGTATCATA 
    11401 CACATACGAT TTAGGGGACA CTATAG 
// 
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6.2 Sensor Reference Sequences 
6.2.1 Sensor B2 
GenBank Header 
LOCUS       B2_pRSET_SL_III         2373 bp    DNA            07-APR-2016 
FEATURES             Location/Qualifiers 
     CDS             124..804 
                     /dnas_title="YPetd11" 
                     /product="YPet" 
     misc_feature    49..81 
                     /label=T7_gene10_leader 
     misc_feature    85..108 
                     /label=Xpress_EK 
     misc_feature    85..123 
                     /note="upstream homologous region" 
     misc_feature    13..42 
                     /note="10 x His" 
     gene            805..1623 
                     /note="2 x CNB-B" 
     gene            1624..2340 
                     /note="mCerulean3" 
     misc_feature    2341..2373 
                     /note="downstream homologous region" 
     source          1..2373 
                     /dnas_title="B2_pRSET_SL_III" 
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DNA 
ORIGIN       
        1 ATGCGGGGTT CTCATCATCA TCATCATCAC CATCACCATC ACCGCGGTAT GGCTAGCATG 
       61 ACTGGTGGAC AGCAAATGGG TCGGGATCTG TACGACGATG ACGATAAGGA TCCGGCCACC 
      121 ATGGTGAGCA AAGGCGAAGA GCTGTTCACC GGCGTGGTGC CCATCCTGGT GGAGCTGGAC 
      181 GGCGACGTGA ACGGCCACAA GTTCAGCGTG AGCGGCGAGG GCGAGGGCGA CGCCACCTAC 
      241 GGCAAGCTGA CCCTGAAGCT GCTGTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCCACC 
      301 CTGGTGACCA CCCTGGGCTA CGGCGTGCAG TGCTTCGCCC GGTACCCCGA CCACATGAAG 
      361 CAGCACGACT TCTTCAAGAG CGCCATGCCC GAGGGCTACG TGCAGGAGCG GACCATCTTC 
      421 TTCAAGGACG ACGGCAACTA CAAGACCCGG GCCGAGGTGA AGTTCGAGGG CGACACCCTG 
      481 GTGAACCGGA TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGCCAC 
      541 AAGCTGGAGT ACAACTACAA CAGCCACAAC GTGTACATCA CCGCCGACAA GCAGAAGAAC 
      601 GGCATCAAGG CCAACTTCAA GATCCGGCAC AACATCGAGG ACGGCGGCGT GCAGCTGGCC 
      661 GACCACTACC AGCAGAACAC CCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC 
      721 TACCTGAGCT ACCAGAGCGC CCTGTTCAAG GACCCCAACG AGAAGCGGGA CCACATGGTG 
      781 CTGCTGGAGT TCCTGACCGC CGCCCAGGCA TTTCGCAAAT TTACCAAAAG CGAACGTAGC 
      841 AAAGATCTGA TCAAAGAAGC AATCCTGGAT AACGATTTTA TGAAAAACCT GCCGGAAGAA 
      901 ATTCTGAGCA AACTGGCAGA TGTTCTGGAA GAAACCCATT ATGAAAACGG CGAATATATC 
      961 ATTCGTCAGG GTGCACGTGG TGATACCTTT TTTATCATTA GCAAAGGCAA AGTGAACGTG 
     1021 ACCCGTGAAG ATAGCCCGAA TGAAGATCCG GTTTTTCTGC GTACCCTGGG TAAAGGTGAT 
     1081 TGGTTTGGTG AAAAAGCACT GCAGGGTGAA GATGTTCGTA CCGCCAATGT TATTGCAGCA 
     1141 GAAGCAGTTA CCTGTCTGGT TATTGATCGT GATAGCTTTA AACATCTGAT TGGTGGTCTG 
     1201 GATGATGTGA GCAATAAAGC ATATATGGAA TTTCTGAAAA GCGTTCCGAC CTTTCAGAGC 
     1261 CTGCCGGAAG AAATTCTGAG CAAACTGGCA GATGTTCTGG AAGAAACCCA TTATGAAAAC 
     1321 GGCGAATATA TCATTCGTCA GGGTGCACGT GGTGATACCT TTTTTATCAT TAGCAAAGGC 
     1381 AAAGTGAACG TGACCCGTGA AGATAGCCCG AATGAAGATC CGGTTTTTCT GCGTACCCTG 
     1441 GGTAAAGGTG ATTGGTTTGG TGAAAAAGCA CTGCAGGGTG AAGATGTTCG TACCGCCAAT 
     1501 GTTATTGCAG CAGAAGCAGT TACCTGTCTG GTTATTGATC GTGATAGCTT TAAACATCTG 
     1561 ATTGGTGGTC TGGATGATGT GAGCAATAAA GCATATGAAG ATGCAGAAGC CAAAGCCAAA 
     1621 TATATGGTGA GCAAGGGCGA GGAGCTGTTC ACCGGGGTGG TGCCCATCCT GGTCGAGCTG 
     1681 GACGGCGACG TAAACGGCCA CAAGTTCAGC GTGTCCGGCG AGGGCGAGGG CGATGCCACC 
     1741 TACGGCAAGC TGACCCTGAA GTTCATCTGC ACCACCGGCA AGCTGCCCGT GCCCTGGCCC 
     1801 ACCCTCGTGA CCACCCTGAG CTGGGGCGTG CAGTGCTTCG CCCGCTACCC CGACCACATG 
     1861 AAGCAGCACG ACTTCTTCAA GTCCGCCATG CCCGAAGGCT ACGTCCAGGA GCGCACCATC 
     1921 TTCTTCAAGG ACGACGGCAA CTACAAGACC CGCGCCGAGG TGAAGTTCGA GGGCGACACC 
     1981 CTGGTGAACC GCATCGAGCT GAAGGGCATC GACTTCAAGG AGGACGGCAA CATCCTGGGG 
     2041 CACAAGCTGG AGTACAACGC CATCCACGGC AACGTCTATA TCACCGCCGA CAAGCAGAAG 
     2101 AACGGCATCA AGGCCAACTT CGGCCTCAAC TGCAACATCG AGGACGGCAG CGTGCAGCTC 
     2161 GCCGACCACT ACCAGCAGAA CACCCCCATC GGCGACGGCC CCGTGCTGCT GCCCGACAAC 
     2221 CACTACCTGA GCACCCAGTC CAAGCTGAGC AAAGACCCCA ACGAGAAGCG CGATCACATG 
     2281 GTCCTGCTGG AGTTCGTGAC CGCCGCCGGG ATCACTCTCG GCATGGACGA GCTGTACAAG 
     2341 TGATAATAGG AATTCCTATA GTGTCACCTA AAT 
// 
Protein Sequence Sensor B2 
Leader Peptide 
Donor FP 
Sensor Domain 
Acceptor FP 
 
        1 MRGSHHHHHH HHHHRGMASM TGGQQMGRDL YDDDDKDPAT MVSKGEELFT GVVPILVELD 
       61 GDVNGHKFSV SGEGEGDATY GKLTLKLLCT TGKLPVPWPT LVTTLGYGVQ CFARYPDHMK 
      121 QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH 
      181 KLEYNYNSHN VYITADKQKN GIKANFKIRH NIEDGGVQLA DHYQQNTPIG DGPVLLPDNH 
      241 YLSYQSALFK DPNEKRDHMV LLEFLTAAQA FRKFTKSERS KDLIKEAILD NDFMKNLPEE 
      301 ILSKLADVLE ETHYENGEYI IRQGARGDTF FIISKGKVNV TREDSPNEDP VFLRTLGKGD 
      361 WFGEKALQGE DVRTANVIAA EAVTCLVIDR DSFKHLIGGL DDVSNKAYME FLKSVPTFQS 
      421 LPEEILSKLA DVLEETHYEN GEYIIRQGAR GDTFFIISKG KVNVTREDSP NEDPVFLRTL 
      481 GKGDWFGEKA LQGEDVRTAN VIAAEAVTCL VIDRDSFKHL IGGLDDVSNK AYEDAEAKAK 
      541 YMVSKGEELF TGVVPILVEL DGDVNGHKFS VSGEGEGDAT YGKLTLKFIC TTGKLPVPWP 
      601 TLVTTLSWGV QCFARYPDHM KQHDFFKSAM PEGYVQERTI FFKDDGNYKT RAEVKFEGDT 
      661 LVNRIELKGI DFKEDGNILG HKLEYNAIHG NVYITADKQK NGIKANFGLN CNIEDGSVQL 
      721 ADHYQQNTPI GDGPVLLPDN HYLSTQSKLS KDPNEKRDHM VLLEFVTAAG ITLGMDELYK 
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6.2.2 Sensor B3 
GenBank Header 
LOCUS       B3_pRSET_SL_III         2373 bp    DNA            07-APR-2016 
FEATURES             Location/Qualifiers 
     gene            124..804 
                     /note="mCerulean3 d11" 
     misc_feature    49..81 
                     /label=T7_gene10_leader 
     misc_feature    85..108 
                     /label=Xpress_EK 
     misc_feature    85..123 
                     /note="upstream homologous region" 
     misc_feature    13..42 
                     /note="10 x His" 
     gene            805..1623 
                     /note="2 x CNB-B" 
     CDS             1624..2340 
                     /dnas_title="YPet" 
                     /product="YPet" 
     misc_feature    2341..2373 
                     /note="downstream homologous region" 
     source          1..2373 
                     /dnas_title="B3_pRSET_SL_III" 
  
Appendix - Sensor B3 
162 
DNA 
ORIGIN       
        1 ATGCGGGGTT CTCATCATCA TCATCATCAC CATCACCATC ACCGCGGTAT GGCTAGCATG 
       61 ACTGGTGGAC AGCAAATGGG TCGGGATCTG TACGACGATG ACGATAAGGA TCCGGCCACC 
      121 ATGGTGAGCA AGGGCGAGGA GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC 
      181 GGCGACGTAA ACGGCCACAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC 
      241 GGCAAGCTGA CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCCACC 
      301 CTCGTGACCA CCCTGAGCTG GGGCGTGCAG TGCTTCGCCC GCTACCCCGA CCACATGAAG 
      361 CAGCACGACT TCTTCAAGTC CGCCATGCCC GAAGGCTACG TCCAGGAGCG CACCATCTTC 
      421 TTCAAGGACG ACGGCAACTA CAAGACCCGC GCCGAGGTGA AGTTCGAGGG CGACACCCTG 
      481 GTGAACCGCA TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC 
      541 AAGCTGGAGT ACAACGCCAT CCACGGCAAC GTCTATATCA CCGCCGACAA GCAGAAGAAC 
      601 GGCATCAAGG CCAACTTCGG CCTCAACTGC AACATCGAGG ACGGCAGCGT GCAGCTCGCC 
      661 GACCACTACC AGCAGAACAC CCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC 
      721 TACCTGAGCA CCCAGTCCAA GCTGAGCAAA GACCCCAACG AGAAGCGCGA TCACATGGTC 
      781 CTGCTGGAGT TCGTGACCGC CGCCCAGGCA TTTCGCAAAT TTACCAAAAG CGAACGTAGC 
      841 AAAGATCTGA TCAAAGAAGC AATCCTGGAT AACGATTTTA TGAAAAACCT GCCGGAAGAA 
      901 ATTCTGAGCA AACTGGCAGA TGTTCTGGAA GAAACCCATT ATGAAAACGG CGAATATATC 
      961 ATTCGTCAGG GTGCACGTGG TGATACCTTT TTTATCATTA GCAAAGGCAA AGTGAACGTG 
     1021 ACCCGTGAAG ATAGCCCGAA TGAAGATCCG GTTTTTCTGC GTACCCTGGG TAAAGGTGAT 
     1081 TGGTTTGGTG AAAAAGCACT GCAGGGTGAA GATGTTCGTA CCGCCAATGT TATTGCAGCA 
     1141 GAAGCAGTTA CCTGTCTGGT TATTGATCGT GATAGCTTTA AACATCTGAT TGGTGGTCTG 
     1201 GATGATGTGA GCAATAAAGC ATATATGGAA TTTCTGAAAA GCGTTCCGAC CTTTCAGAGC 
     1261 CTGCCGGAAG AAATTCTGAG CAAACTGGCA GATGTTCTGG AAGAAACCCA TTATGAAAAC 
     1321 GGCGAATATA TCATTCGTCA GGGTGCACGT GGTGATACCT TTTTTATCAT TAGCAAAGGC 
     1381 AAAGTGAACG TGACCCGTGA AGATAGCCCG AATGAAGATC CGGTTTTTCT GCGTACCCTG 
     1441 GGTAAAGGTG ATTGGTTTGG TGAAAAAGCA CTGCAGGGTG AAGATGTTCG TACCGCCAAT 
     1501 GTTATTGCAG CAGAAGCAGT TACCTGTCTG GTTATTGATC GTGATAGCTT TAAACATCTG 
     1561 ATTGGTGGTC TGGATGATGT GAGCAATAAA GCATATGAAG ATGCAGAAGC CAAAGCCAAA 
     1621 TATATGGTGA GCAAAGGCGA AGAGCTGTTC ACCGGCGTGG TGCCCATCCT GGTGGAGCTG 
     1681 GACGGCGACG TGAACGGCCA CAAGTTCAGC GTGAGCGGCG AGGGCGAGGG CGACGCCACC 
     1741 TACGGCAAGC TGACCCTGAA GCTGCTGTGC ACCACCGGCA AGCTGCCCGT GCCCTGGCCC 
     1801 ACCCTGGTGA CCACCCTGGG CTACGGCGTG CAGTGCTTCG CCCGGTACCC CGACCACATG 
     1861 AAGCAGCACG ACTTCTTCAA GAGCGCCATG CCCGAGGGCT ACGTGCAGGA GCGGACCATC 
     1921 TTCTTCAAGG ACGACGGCAA CTACAAGACC CGGGCCGAGG TGAAGTTCGA GGGCGACACC 
     1981 CTGGTGAACC GGATCGAGCT GAAGGGCATC GACTTCAAGG AGGACGGCAA CATCCTGGGC 
     2041 CACAAGCTGG AGTACAACTA CAACAGCCAC AACGTGTACA TCACCGCCGA CAAGCAGAAG 
     2101 AACGGCATCA AGGCCAACTT CAAGATCCGG CACAACATCG AGGACGGCGG CGTGCAGCTG 
     2161 GCCGACCACT ACCAGCAGAA CACCCCCATC GGCGACGGCC CCGTGCTGCT GCCCGACAAC 
     2221 CACTACCTGA GCTACCAGAG CGCCCTGTTC AAGGACCCCA ACGAGAAGCG GGACCACATG 
     2281 GTGCTGCTGG AGTTCCTGAC CGCCGCCGGC ATCACCGAGG GCATGAACGA GCTCTATAAG 
     2341 TGATAATAGG AATTCCTATA GTGTCACCTA AAT 
// 
Protein Sequence Sensor B3 
Leader Peptide 
Donor FP 
Sensor Domain 
Acceptor FP 
 
        1 MRGSHHHHHH HHHHRGMASM TGGQQMGRDL YDDDDKDPAT MVSKGEELFT GVVPILVELD 
       61 GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT LVTTLSWGVQ CFARYPDHMK 
      121 QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH 
      181 KLEYNAIHGN VYITADKQKN GIKANFGLNC NIEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
      241 YLSTQSKLSK DPNEKRDHMV LLEFVTAAQA FRKFTKSERS KDLIKEAILD NDFMKNLPEE 
      301 ILSKLADVLE ETHYENGEYI IRQGARGDTF FIISKGKVNV TREDSPNEDP VFLRTLGKGD 
      361 WFGEKALQGE DVRTANVIAA EAVTCLVIDR DSFKHLIGGL DDVSNKAYME FLKSVPTFQS 
      421 LPEEILSKLA DVLEETHYEN GEYIIRQGAR GDTFFIISKG KVNVTREDSP NEDPVFLRTL 
      481 GKGDWFGEKA LQGEDVRTAN VIAAEAVTCL VIDRDSFKHL IGGLDDVSNK AYEDAEAKAK 
      541 YMVSKGEELF TGVVPILVEL DGDVNGHKFS VSGEGEGDAT YGKLTLKLLC TTGKLPVPWP 
      601 TLVTTLGYGV QCFARYPDHM KQHDFFKSAM PEGYVQERTI FFKDDGNYKT RAEVKFEGDT 
      661 LVNRIELKGI DFKEDGNILG HKLEYNYNSH NVYITADKQK NGIKANFKIR HNIEDGGVQL 
      721 ADHYQQNTPI GDGPVLLPDN HYLSYQSALF KDPNEKRDHM VLLEFLTAAG ITEGMNELYK 
  
Appendix - Sensor C1 
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6.2.3 Sensor C1 
GenBank Header 
LOCUS       C1_pRSET_SL_III         2002 bp    DNA            06-APR-2016 
FEATURES             Location/Qualifiers 
     gene            124..804 
                     /note="mCerulean3 d11" 
     misc_feature    49..81 
                     /label=T7_gene10_leader 
     misc_feature    85..108 
                     /label=Xpress_EK 
     misc_feature    85..123 
                     /note="upstream homologous region" 
     misc_feature    13..42 
                     /note="10 x His 
     misc_feature    805..1251 
                     /note="1 x CNB-B" 
     CDS             1252..1968 
                     /dnas_title="YPet" 
                     /product="YPet" 
     misc_feature    1969..2001 
                     /note="downstream homologous region" 
     source          1..2002 
                     /dnas_title="C1_pRSET_SL_III" 
  
Appendix - Sensor C1 
164 
DNA 
ORIGIN       
        1 ATGCGGGGTT CTCATCATCA TCATCATCAC CATCACCATC ACCGCGGTAT GGCTAGCATG 
       61 ACTGGTGGAC AGCAAATGGG TCGGGATCTG TACGACGATG ACGATAAGGA TCCGGCCACC 
      121 ATGGTGAGCA AGGGCGAGGA GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC 
      181 GGCGACGTAA ACGGCCACAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC 
      241 GGCAAGCTGA CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCCACC 
      301 CTCGTGACCA CCCTGAGCTG GGGCGTGCAG TGCTTCGCCC GCTACCCCGA CCACATGAAG 
      361 CAGCACGACT TCTTCAAGTC CGCCATGCCC GAAGGCTACG TCCAGGAGCG CACCATCTTC 
      421 TTCAAGGACG ACGGCAACTA CAAGACCCGC GCCGAGGTGA AGTTCGAGGG CGACACCCTG 
      481 GTGAACCGCA TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC 
      541 AAGCTGGAGT ACAACGCCAT CCACGGCAAC GTCTATATCA CCGCCGACAA GCAGAAGAAC 
      601 GGCATCAAGG CCAACTTCGG CCTCAACTGC AACATCGAGG ACGGCAGCGT GCAGCTCGCC 
      661 GACCACTACC AGCAGAACAC CCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC 
      721 TACCTGAGCA CCCAGTCCAA GCTGAGCAAA GACCCCAACG AGAAGCGCGA TCACATGGTC 
      781 CTGCTGGAGT TCGTGACCGC CGCCCAGGCA TTTCGCAAAT TTACCAAAAG CGAACGTAGC 
      841 AAAGATCTGA TCAAAGAAGC AATCCTGGAT AACGATTTTA TGAAAAACCT GCCGGAAGAA 
      901 ATTCTGAGCA AACTGGCAGA TGTTCTGGAA GAAACCCATT ATGAAAACGG CGAATATATC 
      961 ATTCGTCAGG GTGCACGTGG TGATACCTTT TTTATCATTA GCAAAGGCAA AGTGAACGTG 
     1021 ACCCGTGAAG ATAGCCCGAA TGAAGATCCG GTTTTTCTGC GTACCCTGGG TAAAGGTGAT 
     1081 TGGTTTGGTG AAAAAGCACT GCAGGGTGAA GATGTTCGTA CCGCCAATGT TATTGCAGCA 
     1141 GAAGCAGTTA CCTGTCTGGT TATTGATCGT GATAGCTTTA AACATCTGAT TGGTGGTCTG 
     1201 GATGATGTGA GCAATAAAGC ATATGAAGAT GCAGAAGCCA AAGCCAAATA TATGGTGAGC 
     1261 AAAGGCGAAG AGCTGTTCAC CGGCGTGGTG CCCATCCTGG TGGAGCTGGA CGGCGACGTG 
     1321 AACGGCCACA AGTTCAGCGT GAGCGGCGAG GGCGAGGGCG ACGCCACCTA CGGCAAGCTG 
     1381 ACCCTGAAGC TGCTGTGCAC CACCGGCAAG CTGCCCGTGC CCTGGCCCAC CCTGGTGACC 
     1441 ACCCTGGGCT ACGGCGTGCA GTGCTTCGCC CGGTACCCCG ACCACATGAA GCAGCACGAC 
     1501 TTCTTCAAGA GCGCCATGCC CGAGGGCTAC GTGCAGGAGC GGACCATCTT CTTCAAGGAC 
     1561 GACGGCAACT ACAAGACCCG GGCCGAGGTG AAGTTCGAGG GCGACACCCT GGTGAACCGG 
     1621 ATCGAGCTGA AGGGCATCGA CTTCAAGGAG GACGGCAACA TCCTGGGCCA CAAGCTGGAG 
     1681 TACAACTACA ACAGCCACAA CGTGTACATC ACCGCCGACA AGCAGAAGAA CGGCATCAAG 
     1741 GCCAACTTCA AGATCCGGCA CAACATCGAG GACGGCGGCG TGCAGCTGGC CGACCACTAC 
     1801 CAGCAGAACA CCCCCATCGG CGACGGCCCC GTGCTGCTGC CCGACAACCA CTACCTGAGC 
     1861 TACCAGAGCG CCCTGTTCAA GGACCCCAAC GAGAAGCGGG ACCACATGGT GCTGCTGGAG 
     1921 TTCCTGACCG CCGCCGGCAT CACCGAGGGC ATGAACGAGC TCTATAAGTG ATAATAGGAA 
     1981 TTCCTATAGT GTCACCTAAA TG 
// 
Protein Sequence Sensor C1 
Leader Peptide 
Donor FP 
Sensor Domain 
Acceptor FP 
 
        1 MRGSHHHHHH HHHHRGMASM TGGQQMGRDL YDDDDKDPAT MVSKGEELFT GVVPILVELD 
       61 GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT LVTTLSWGVQ CFARYPDHMK 
      121 QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH 
      181 KLEYNAIHGN VYITADKQKN GIKANFGLNC NIEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
      241 YLSTQSKLSK DPNEKRDHMV LLEFVTAAQA FRKFTKSERS KDLIKEAILD NDFMKNLPEE 
      301 ILSKLADVLE ETHYENGEYI IRQGARGDTF FIISKGKVNV TREDSPNEDP VFLRTLGKGD 
      361 WFGEKALQGE DVRTANVIAA EAVTCLVIDR DSFKHLIGGL DDVSNKAYED AEAKAKYMVS 
      421 KGEELFTGVV PILVELDGDV NGHKFSVSGE GEGDATYGKL TLKLLCTTGK LPVPWPTLVT 
      481 TLGYGVQCFA RYPDHMKQHD FFKSAMPEGY VQERTIFFKD DGNYKTRAEV KFEGDTLVNR 
      541 IELKGIDFKE DGNILGHKLE YNYNSHNVYI TADKQKNGIK ANFKIRHNIE DGGVQLADHY 
      601 QQNTPIGDGP VLLPDNHYLS YQSALFKDPN EKRDHMVLLE FLTAAGITEG MNELYK 
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6.2.4 Sensor D1 
GenBank Header 
LOCUS       D1_pRSET_SL_III         2028 bp    DNA            07-APR-2016 
FEATURES             Location/Qualifiers 
     gene            124..804 
                     /note="mCerulean3" 
     misc_feature    49..81 
                     /label=T7_gene10_leader 
     misc_feature    85..108 
                     /label=Xpress_EK 
     misc_feature    85..123 
                     /note="upstream homologous region" 
     misc_feature    13..42 
                     /note="10 x His" 
     CDS             1279..1995 
                     /dnas_title="YPet" 
                     /product="YPet" 
     misc_feature    1996..2028 
                     /note="downstream homologous region" 
     misc_feature    805..1278 
                     /note="1 x CNB-BII" 
     source          1..2028 
                     /dnas_title="D1_pRSET_SL_III" 
  
Appendix - Sensor D1 
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DNA 
ORIGIN       
        1 ATGCGGGGTT CTCATCATCA TCATCATCAC CATCACCATC ACCGCGGTAT GGCTAGCATG 
       61 ACTGGTGGAC AGCAAATGGG TCGGGATCTG TACGACGATG ACGATAAGGA TCCGGCCACC 
      121 ATGGTGAGCA AGGGCGAGGA GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC 
      181 GGCGACGTAA ACGGCCACAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC 
      241 GGCAAGCTGA CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC CTGGCCCACC 
      301 CTCGTGACCA CCCTGAGCTG GGGCGTGCAG TGCTTCGCCC GCTACCCCGA CCACATGAAG 
      361 CAGCACGACT TCTTCAAGTC CGCCATGCCC GAAGGCTACG TCCAGGAGCG CACCATCTTC 
      421 TTCAAGGACG ACGGCAACTA CAAGACCCGC GCCGAGGTGA AGTTCGAGGG CGACACCCTG 
      481 GTGAACCGCA TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC 
      541 AAGCTGGAGT ACAACGCCAT CCACGGCAAC GTCTATATCA CCGCCGACAA GCAGAAGAAC 
      601 GGCATCAAGG CCAACTTCGG CCTCAACTGC AACATCGAGG ACGGCAGCGT GCAGCTCGCC 
      661 GACCACTACC AGCAGAACAC CCCCATCGGC GACGGCCCCG TGCTGCTGCC CGACAACCAC 
      721 TACCTGAGCA CCCAGTCCAA GCTGAGCAAA GACCCCAACG AGAAGCGCGA TCACATGGTC 
      781 CTGCTGGAGT TCGTGACCGC CGCCCAGGCA TTTCGCAAAT TTACCAAAAG CGAACGTAGC 
      841 AAAGATCTGA TCAAAGAAGC AATCCTGGAT AACGATTTTA TGAAAAACCT GCCTGAAGAT 
      901 AAATTAACCA AGATCATTGA CTGCTTGGAA GTGGAATACT ATGACAAAGG AGATTACATC 
      961 ATTAGAGAGG GCGAGGAAGG AAGTACCTTT TTCATTTTGG CAAAAGGAAA GGTAAAAGTA 
     1021 ACACAGAGCA CAGAAGGCCA TGATCAACCA CAGCTGATAA AAACACTGCA GAAAGGAGAA 
     1081 TACTTTGGAG AAAAAGCTCT TATCAGTGAT GATGTCAGGT CAGCTAACAT TATTGCTGAA 
     1141 GAAAATGATG TTGCATGCCT GGTTATAGAT CGAGAAACAT TCAACCAAAC TGTCGGTACA 
     1201 TTTGAAGAGC TGCAAAAATA CCTTGAAGGA TATGTGGCAA ACCTGAACCG TGATGATGAA 
     1261 AAAAGACATG CGAAGCGGAT GGTGAGCAAA GGCGAAGAGC TGTTCACCGG CGTGGTGCCC 
     1321 ATCCTGGTGG AGCTGGACGG CGACGTGAAC GGCCACAAGT TCAGCGTGAG CGGCGAGGGC 
     1381 GAGGGCGACG CCACCTACGG CAAGCTGACC CTGAAGCTGC TGTGCACCAC CGGCAAGCTG 
     1441 CCCGTGCCCT GGCCCACCCT GGTGACCACC CTGGGCTACG GCGTGCAGTG CTTCGCCCGG 
     1501 TACCCCGACC ACATGAAGCA GCACGACTTC TTCAAGAGCG CCATGCCCGA GGGCTACGTG 
     1561 CAGGAGCGGA CCATCTTCTT CAAGGACGAC GGCAACTACA AGACCCGGGC CGAGGTGAAG 
     1621 TTCGAGGGCG ACACCCTGGT GAACCGGATC GAGCTGAAGG GCATCGACTT CAAGGAGGAC 
     1681 GGCAACATCC TGGGCCACAA GCTGGAGTAC AACTACAACA GCCACAACGT GTACATCACC 
     1741 GCCGACAAGC AGAAGAACGG CATCAAGGCC AACTTCAAGA TCCGGCACAA CATCGAGGAC 
     1801 GGCGGCGTGC AGCTGGCCGA CCACTACCAG CAGAACACCC CCATCGGCGA CGGCCCCGTG 
     1861 CTGCTGCCCG ACAACCACTA CCTGAGCTAC CAGAGCGCCC TGTTCAAGGA CCCCAACGAG 
     1921 AAGCGGGACC ACATGGTGCT GCTGGAGTTC CTGACCGCCG CCGGCATCAC CGAGGGCATG 
     1981 AACGAGCTCT ATAAGTGATA ATAGGAATTC CTATAGTGTC ACCTAAAT 
// 
Protein Sequence Sensor D1 
Leader Peptide 
Donor FP 
Sensor Domain 
Acceptor FP 
 
        1 MRGSHHHHHH HHHHRGMASM TGGQQMGRDL YDDDDKDPAT MVSKGEELFT GVVPILVELD 
       61 GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT LVTTLSWGVQ CFARYPDHMK 
      121 QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH 
      181 KLEYNAIHGN VYITADKQKN GIKANFGLNC NIEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
      241 YLSTQSKLSK DPNEKRDHMV LLEFVTAAQA FRKFTKSERS KDLIKEAILD NDFMKNLPED 
      301 KLTKIIDCLE VEYYDKGDYI IREGEEGSTF FILAKGKVKV TQSTEGHDQP QLIKTLQKGE 
      361 YFGEKALISD DVRSANIIAE ENDVACLVID RETFNQTVGT FEELQKYLEG YVANLNRDDE 
      421 KRHAKRMVSK GEELFTGVVP ILVELDGDVN GHKFSVSGEG EGDATYGKLT LKLLCTTGKL 
      481 PVPWPTLVTT LGYGVQCFAR YPDHMKQHDF FKSAMPEGYV QERTIFFKDD GNYKTRAEVK 
      541 FEGDTLVNRI ELKGIDFKED GNILGHKLEY NYNSHNVYIT ADKQKNGIKA NFKIRHNIED 
      601 GGVQLADHYQ QNTPIGDGPV LLPDNHYLSY QSALFKDPNE KRDHMVLLEF LTAAGITEGM 
      661 NELYK 
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6.2.5 Sensor Tomato 1 x CNB-B Ultramarine 
GenBank Header 
LOCUS       Tomato_1xCNB-B_U        1965 bp    DNA            07-APR-2016 
FEATURES             Location/Qualifiers 
     misc_feature    49..81 
                     /label=T7_gene10_leader 
     misc_feature    85..123 
                     /note="upstream homologous region" 
     misc_feature    13..42 
                     /note="10 x His" 
     misc_feature    124..822 
                     /note="Tomato" 
     misc_feature    823..1272 
                     /note="" 
     misc_feature    1933..1965 
                     /note="downstream homologous region" 
     misc_feature    823..1269 
                     /note="1 x CNB-B" 
     gene            1270..1932 
                     /note="Ultramarine" 
     source          1..1965 
                     /dnas_title="Tomato_1xCNB-B_Ultramarine" 
  
Appendix - Sensor Tomato 1 x CNB-B Ultramarine 
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DNA 
ORIGIN       
        1 ATGCGGGGTT CTCATCATCA TCATCATCAC CATCACCATC ACCGCGGTAT GGCTAGCATG 
       61 ACTGGTGGAC AGCAAATGGG TCGGGATCTG TACGACGATG ACGATAAGGA TCCGGCCACC 
      121 ATGGTGAGCA AGGGCGAGGA GGTCATCAAA GAGTTCATGC GCTTCAAGGT GCGCATGGAG 
      181 GGCTCCATGA ACGGCCACGA GTTCGAGATC GAGGGCGAGG GCGAGGGCCG CCCCTACGAG 
      241 GGCACCCAGA CCGCCAAGCT GAAGGTGACC AAGGGCGGCC CCCTGCCCTT CGCCTGGGAC 
      301 ATCCTGTCCC CCCAGTTCAT GTACGGCTCC AAGGCGTACG TGAAGCACCC CGCCGACATC 
      361 CCCGATTACA AGAAGCTGTC CTTCCCCGAG GGCTTCAAGT GGGAGCGCGT GATGAACTTC 
      421 GAGGACGGCG GTCTGGTGAC CGTGACCCAG GACTCCTCCC TGCAGGACGG CACGCTGATC 
      481 TACAAGGTGA AGATGCGCGG CACCAACTTC CCCCCCGACG GCCCCGTAAT GCAGAAGAAG 
      541 ACCATGGGCT GGGAGGCCTC CACCGAGCGC CTGTACCCCC GCGACGGCGT GCTGAAGGGC 
      601 GAGATCCACC AGGCCCTGAA GCTGAAGGAC GGCGGCCACT ACCTGGTGGA GTTCAAGACC 
      661 ATCTACATGG CCAAGAAGCC CGTGCAACTG CCCGGCTACT ACTACGTGGA CACCAAGCTG 
      721 GACATCACCT CCCACAACGA GGACTACACC ATCGTGGAAC AGTACGAGCG CTCCGAGGGC 
      781 CGCCACCACC TGTTCCTGTA CGGCATGGAC GAGCTGTACA AGCAGGCATT TCGCAAATTT 
      841 ACCAAAAGCG AACGTAGCAA AGATCTGATC AAAGAAGCAA TCCTGGATAA CGATTTTATG 
      901 AAAAACCTGC CGGAAGAAAT TCTGAGCAAA CTGGCAGATG TTCTGGAAGA AACCCATTAT 
      961 GAAAACGGCG AATATATCAT TCGTCAGGGT GCACGTGGTG ATACCTTTTT TATCATTAGC 
     1021 AAAGGCAAAG TGAACGTGAC CCGTGAAGAT AGCCCGAATG AAGATCCGGT TTTTCTGCGT 
     1081 ACCCTGGGTA AAGGTGATTG GTTTGGTGAA AAAGCACTGC AGGGTGAAGA TGTTCGTACC 
     1141 GCCAATGTTA TTGCAGCAGA AGCAGTTACC TGTCTGGTTA TTGATCGTGA TAGCTTTAAA 
     1201 CATCTGATTG GTGGTCTGGA TGATGTGAGC AATAAAGCAT ATGAAGATGC AGAAGCCAAA 
     1261 GCCAAATATA TGTCTGTTAT CGCCACCCAG ATGACCTACA AAGTTTACAT GTCTGGCACC 
     1321 GTGAACGGCC ACTACTTTGA AGTGGAAGGC GACGGCAAAG GCCGCCCTTA CGAAGGCGAA 
     1381 CAGACCGCCA AACTGACCGT GACCAAAGGC GGCCCTCTGC CTTTCGCCTG GGACATCCTG 
     1441 TCTCCTCAGT GCCAGTACGG CTCTATCCCT TTCACCAAAT ACCCTGAAGA CATCCCTGAC 
     1501 TACGTGAAAC AGTCTTTCCC TGAAGGCTTC ACCTGGGAAC GCATCATGAA CTTTGAAGAC 
     1561 GGCGCCGTGT GCACCGTGTC TAACGACTCT TCTATCCAGG GCAACTGCTT CACCTACCAC 
     1621 GTGAAATTCC GCGGCACCAA CTTCCCTCCT AACGGCCCTG TGATGCAGAA AAAAACCCAG 
     1681 GGCTGGGAAC CTAACTCTGA ACGCCTGTTC GCCCGCGGCG GCATGTTGAT CGGCAACAAC 
     1741 CGCATGGCCC TGAAACTGGA AGGCGGCGGC CACTACCTGT GCGAATTTAA AACCACCTAC 
     1801 AAAGCCAAAA AACCTGTGAA AATGCCTGGC TACCACTACG TGGACCGCAA ACTGGACGTG 
     1861 ACCAACCACA ACAAAGACTA CACCTCTGTG GAACAGTGCG AAATCTCTAT CGCCCGCAAA 
     1921 CCTGTGGTGG CCTGATAATA GGAATTCCTA TAGTGTCACC TAAAT 
// 
Protein Sequence Sensor Tomato 1 x CNB-B Ultramarine 
Leader Peptide 
Donor FP 
Sensor Domain 
Acceptor CP 
 
        1 MRGSHHHHHH HHHHRGMASM TGGQQMGRDL YDDDDKDPAT MVSKGEEVIK EFMRFKVRME 
       61 GSMNGHEFEI EGEGEGRPYE GTQTAKLKVT KGGPLPFAWD ILSPQFMYGS KAYVKHPADI 
      121 PDYKKLSFPE GFKWERVMNF EDGGLVTVTQ DSSLQDGTLI YKVKMRGTNF PPDGPVMQKK 
      181 TMGWEASTER LYPRDGVLKG EIHQALKLKD GGHYLVEFKT IYMAKKPVQL PGYYYVDTKL 
      241 DITSHNEDYT IVEQYERSEG RHHLFLYGMD ELYKQAFRKF TKSERSKDLI KEAILDNDFM 
      301 KNLPEEILSK LADVLEETHY ENGEYIIRQG ARGDTFFIIS KGKVNVTRED SPNEDPVFLR 
      361 TLGKGDWFGE KALQGEDVRT ANVIAAEAVT CLVIDRDSFK HLIGGLDDVS NKAYEDAEAK 
      421 AKYMSVIATQ MTYKVYMSGT VNGHYFEVEG DGKGRPYEGE QTAKLTVTKG GPLPFAWDIL 
      481 SPQCQYGSIP FTKYPEDIPD YVKQSFPEGF TWERIMNFED GAVCTVSNDS SIQGNCFTYH 
      541 VKFRGTNFPP NGPVMQKKTQ GWEPNSERLF ARGGMLIGNN RMALKLEGGG HYLCEFKTTY 
      601 KAKKPVKMPG YHYVDRKLDV TNHNKDYTSV EQCEISIARK PVVA 
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